Other Sites:
Robert J. Robbins is a biologist, an educator, a science administrator, a publisher, an information technologist, and an IT leader and manager who specializes in advancing biomedical knowledge and supporting education through the application of information technology. More About: RJR | OUR TEAM | OUR SERVICES | THIS WEBSITE
RJR: Recommended Bibliography 19 Nov 2026 at 01:56 Created:
Microbiome
It has long been known that every multicellular organism coexists with large prokaryotic ecosystems — microbiomes — that completely cover its surfaces, external and internal. Recent studies have shown that these associated microbiomes are not mere contamination, but instead have profound effects upon the function and fitness of the multicellular organism. We now know that all MCEs are actually functional composites, holobionts, composed of more prokaryotic cells than eukaryotic cells and expressing more prokaryotic genes than eukaryotic genes. A full understanding of the biology of "individual" eukaryotes will now depend on an understanding of their associated microbiomes.
Created with PubMed® Query: microbiome[tiab] NOT pmcbook NOT ispreviousversion
Citations The Papers (from PubMed®)
RevDate: 2026-11-18
Infant RSV immunity study (IRIS): protocol for a prospective birth cohort in Vancouver, Canada examining how age at respiratory syncytial virus exposure affects how infants respond to the virus immunologically.
BMJ open, 16(11):e127619.
INTRODUCTION: Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness in infants. Age at first infection is strongly associated with disease severity. Infants exposed to RSV at a younger age may not produce an immune response against RSV that is as protective as infection at a later age, and early life infection may influence the risk of recurrent or persistent wheezing, or subsequent asthma. However, how immune development at the time of exposure shapes RSV-specific immunity and long-term respiratory health remains unclear.
METHODS AND ANALYSIS: The Infant RSV Immunity Study (IRIS) is a prospective birth cohort of 300 healthy infants in British Columbia, Canada, followed to age 3 years. The primary objective is to determine how age at exposure influences RSV-specific immunity and respiratory outcomes. Infants are enrolled in April–June or September–November so that they enter the peak RSV season at either more than 6 months or less than 6 months of age. Symptom-triggered oropharyngeal nasal swabs and post-season RSV serology will identify RSV infections. Birth, pre-season dried blood spot and post-season blood samples will assess RSV-specific antibody, neutralisation, functional antibody and T-cell responses. Clinical outcomes include medically attended respiratory illness, RSV hospitalisation, daily wheezing and inhaler use, and asthma risk at age 3 assessed using the Childhood Asthma Risk Tool. A subgroup of infants will undergo infection-timed blood samples ⁓2 weeks into their first RSV infection. Maternal RSV vaccination and antibody status will be examined as determinants of infant responses. A microbiome upper-airway sample will be collected from the infant at 2 weeks, pre-season and post-season, and around PCR-confirmed RSV infection. In addition, serial stool samples will be collected at 2 weeks, 3, 6, 9 and 12 months of age. Analyses will distinguish developmental, seasonal and infection-associated influences on microbiome and immune development trajectories and test associations with antiviral responses, disease severity and recurrent wheezing post-RSV infection. Infants’ diet will be assessed by serial questionnaires, as another determinant of microbiome development.
ETHICS AND DISSEMINATION: The study was approved by the University of British Columbia Children’s and Women’s Research Ethics Board (H25-02623). Findings will be disseminated through publications, scientific meetings and participant communication.
TRIAL REGISTRATION NUMBER: NCT07653347.
Additional Links: PMID-43020492
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43020492,
year = {2026},
author = {Watts, AW and O'Malley, C and Majdoubi, A and Golzan, SA and Dang, X and Makhanko-Tang, C and Viñeta Paramo, M and Sadarangani, M and Goldfarb, DM and Lunken, G and Sabr, Y and Bone, JN and Lee, AHY and Beristain, AG and Turvey, SE and Abu-Raya, B and Lavoie, PM},
title = {Infant RSV immunity study (IRIS): protocol for a prospective birth cohort in Vancouver, Canada examining how age at respiratory syncytial virus exposure affects how infants respond to the virus immunologically.},
journal = {BMJ open},
volume = {16},
number = {11},
pages = {e127619},
pmid = {43020492},
issn = {2044-6055},
abstract = {INTRODUCTION: Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness in infants. Age at first infection is strongly associated with disease severity. Infants exposed to RSV at a younger age may not produce an immune response against RSV that is as protective as infection at a later age, and early life infection may influence the risk of recurrent or persistent wheezing, or subsequent asthma. However, how immune development at the time of exposure shapes RSV-specific immunity and long-term respiratory health remains unclear.
METHODS AND ANALYSIS: The Infant RSV Immunity Study (IRIS) is a prospective birth cohort of 300 healthy infants in British Columbia, Canada, followed to age 3 years. The primary objective is to determine how age at exposure influences RSV-specific immunity and respiratory outcomes. Infants are enrolled in April–June or September–November so that they enter the peak RSV season at either more than 6 months or less than 6 months of age. Symptom-triggered oropharyngeal nasal swabs and post-season RSV serology will identify RSV infections. Birth, pre-season dried blood spot and post-season blood samples will assess RSV-specific antibody, neutralisation, functional antibody and T-cell responses. Clinical outcomes include medically attended respiratory illness, RSV hospitalisation, daily wheezing and inhaler use, and asthma risk at age 3 assessed using the Childhood Asthma Risk Tool. A subgroup of infants will undergo infection-timed blood samples ⁓2 weeks into their first RSV infection. Maternal RSV vaccination and antibody status will be examined as determinants of infant responses. A microbiome upper-airway sample will be collected from the infant at 2 weeks, pre-season and post-season, and around PCR-confirmed RSV infection. In addition, serial stool samples will be collected at 2 weeks, 3, 6, 9 and 12 months of age. Analyses will distinguish developmental, seasonal and infection-associated influences on microbiome and immune development trajectories and test associations with antiviral responses, disease severity and recurrent wheezing post-RSV infection. Infants’ diet will be assessed by serial questionnaires, as another determinant of microbiome development.
ETHICS AND DISSEMINATION: The study was approved by the University of British Columbia Children’s and Women’s Research Ethics Board (H25-02623). Findings will be disseminated through publications, scientific meetings and participant communication.
TRIAL REGISTRATION NUMBER: NCT07653347.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-17
Targeting Energy Metabolism and Tryptophan Pathways in Alzheimer's Disease for Developing Therapeutic Strategies.
Molecular neurobiology, 63(1):.
Alzheimer's disease (AD) is the primary cause of dementia worldwide and carries a high socioeconomic burden. However, despite the fact that such pathological features as amyloid-beta plaques and neurofibrillary tangles are considered hallmark traits of AD, therapeutic approaches targeting these pathological features have shown limited clinical efficacy to date. Recent scientific discoveries have drawn attention to the importance of metabolic processes preceding neurodegeneration. Reduced glucose utilization and impaired oxidative phosphorylation (OXPHOS) are associated with bioenergetic deficits that may increase neuronal vulnerability to damage. In addition, neuroinflammation is associated with altered tryptophan metabolism through the kynurenine pathway and may favor the production of potentially neurotoxic metabolites. Despite these separate aspects of AD, the interaction between impaired bioenergetics and altered tryptophan metabolism in the brain has not been sufficiently studied. This gap complicates the development of multi-targeted treatment strategies. The purpose of this narrative review is to examine how gut dysbiosis, immune activation, mitochondrial oxidative phosphorylation (OXPHOS) impairment, redox imbalance, and tryptophan-kynurenine pathway dysregulation interact and may contribute to AD development and progression, including associated neuropsychiatric symptoms. We examine whether NAD[+] depletion and rerouting of tryptophan metabolism may act as key nodes linking mitochondrial respiratory failure with the generation of neurotoxic kynurenine metabolites, excitotoxic glutamatergic signaling, loss of neurotrophic support, and synaptic dysfunction, and to analyze existing and emerging therapeutic strategies that target these interconnected pathways. In addition, this review highlights potentially promising interventions, such as NAD[+] precursor supplementation, central nervous system insulin delivery, and modification of gut microbiome. Here we propose that the energy-tryptophan metabolic axis is a promising but underexplored area of AD research. Targeting these convergent bioenergetic and metabolomic pathways may support precision intervention strategies that could extend beyond conventional amyloid-centric paradigms to address broader neurodegenerative and neuropsychiatric syndromes.
Additional Links: PMID-43043577
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43043577,
year = {2026},
author = {Joshi, D and Uniyal, S and Singh, SK and Kollur, SP and Singh, P},
title = {Targeting Energy Metabolism and Tryptophan Pathways in Alzheimer's Disease for Developing Therapeutic Strategies.},
journal = {Molecular neurobiology},
volume = {63},
number = {1},
pages = {},
pmid = {43043577},
issn = {1559-1182},
mesh = {Humans ; *Alzheimer Disease/metabolism/therapy/drug therapy ; *Energy Metabolism/physiology/drug effects ; *Tryptophan/metabolism ; Animals ; *Signal Transduction ; Mitochondria/metabolism ; Kynurenine/metabolism ; },
abstract = {Alzheimer's disease (AD) is the primary cause of dementia worldwide and carries a high socioeconomic burden. However, despite the fact that such pathological features as amyloid-beta plaques and neurofibrillary tangles are considered hallmark traits of AD, therapeutic approaches targeting these pathological features have shown limited clinical efficacy to date. Recent scientific discoveries have drawn attention to the importance of metabolic processes preceding neurodegeneration. Reduced glucose utilization and impaired oxidative phosphorylation (OXPHOS) are associated with bioenergetic deficits that may increase neuronal vulnerability to damage. In addition, neuroinflammation is associated with altered tryptophan metabolism through the kynurenine pathway and may favor the production of potentially neurotoxic metabolites. Despite these separate aspects of AD, the interaction between impaired bioenergetics and altered tryptophan metabolism in the brain has not been sufficiently studied. This gap complicates the development of multi-targeted treatment strategies. The purpose of this narrative review is to examine how gut dysbiosis, immune activation, mitochondrial oxidative phosphorylation (OXPHOS) impairment, redox imbalance, and tryptophan-kynurenine pathway dysregulation interact and may contribute to AD development and progression, including associated neuropsychiatric symptoms. We examine whether NAD[+] depletion and rerouting of tryptophan metabolism may act as key nodes linking mitochondrial respiratory failure with the generation of neurotoxic kynurenine metabolites, excitotoxic glutamatergic signaling, loss of neurotrophic support, and synaptic dysfunction, and to analyze existing and emerging therapeutic strategies that target these interconnected pathways. In addition, this review highlights potentially promising interventions, such as NAD[+] precursor supplementation, central nervous system insulin delivery, and modification of gut microbiome. Here we propose that the energy-tryptophan metabolic axis is a promising but underexplored area of AD research. Targeting these convergent bioenergetic and metabolomic pathways may support precision intervention strategies that could extend beyond conventional amyloid-centric paradigms to address broader neurodegenerative and neuropsychiatric syndromes.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Alzheimer Disease/metabolism/therapy/drug therapy
*Energy Metabolism/physiology/drug effects
*Tryptophan/metabolism
Animals
*Signal Transduction
Mitochondria/metabolism
Kynurenine/metabolism
RevDate: 2026-11-17
Investigation of Korean women's facial skin microbiome and the effects of aging.
Genes & genomics [Epub ahead of print].
BACKGROUND: The human skin microbiome alters with aging, yet the dynamic shift in how the microbial ecosystem responds to external hygiene habits versus intrinsic aging factors across life stages remains poorly understood.
OBJECTIVE: To investigate age-specific changes in the facial microbial community of Korean women and identify the ecological 'tipping point' where microbial composition and responses to daily cleansing habits fundamentally shift.
METHODS: We performed 16 S rRNA V3-V4 amplicon sequencing on facial swab samples from 94 Korean women across five decades (20-60 s). Taxonomic, alpha/beta-diversity, and predictive functional (PICRUSt2) analyses were integrated with clinical exposome metadata to evaluate age-stratified microbiome-host interactions.
RESULTS: While species richness remained stable, beta-diversity exhibited a strong trending toward structural divergence (p = 0.057) between the 40 and 50 s groups, indicating a mid-life ecological tipping point. In the 50 s, the core resident Staphylococcus collapsed drastically (from 23.33% in the 40 s to 3.87%), signaling the onset of microbial dysbiosis. Concurrently, the microbiome-derived 'Carotenoid biosynthesis' antioxidant pathway significantly deteriorated. Spearman correlation networks demonstrated that while local facial cleansing habits tightly regulated the microbiome in the pre-tipping group (20-40 s), this external regulatory efficacy completely decoupled in the post-tipping group (50-60 s), compelling surviving core taxa to rely on intra-microbial symbiotic networks.
CONCLUSION: Facial skin aging involves a discontinuous ecological tipping point during the 50 s characterized by structural dysbiosis, functional antioxidant depletion, and the collapse of external hygiene efficacy. Age-specific dermatological strategies for older demographics must transition from simple surface cleansing to customized interventions restoring microbial balance.
Additional Links: PMID-43043618
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43043618,
year = {2026},
author = {Kim, D and Oh, Y and Kim, J and Jeong, J and Mun, S and Jo, H and Lee, DG and Lee, JH and Han, K},
title = {Investigation of Korean women's facial skin microbiome and the effects of aging.},
journal = {Genes & genomics},
volume = {},
number = {},
pages = {},
pmid = {43043618},
issn = {2092-9293},
abstract = {BACKGROUND: The human skin microbiome alters with aging, yet the dynamic shift in how the microbial ecosystem responds to external hygiene habits versus intrinsic aging factors across life stages remains poorly understood.
OBJECTIVE: To investigate age-specific changes in the facial microbial community of Korean women and identify the ecological 'tipping point' where microbial composition and responses to daily cleansing habits fundamentally shift.
METHODS: We performed 16 S rRNA V3-V4 amplicon sequencing on facial swab samples from 94 Korean women across five decades (20-60 s). Taxonomic, alpha/beta-diversity, and predictive functional (PICRUSt2) analyses were integrated with clinical exposome metadata to evaluate age-stratified microbiome-host interactions.
RESULTS: While species richness remained stable, beta-diversity exhibited a strong trending toward structural divergence (p = 0.057) between the 40 and 50 s groups, indicating a mid-life ecological tipping point. In the 50 s, the core resident Staphylococcus collapsed drastically (from 23.33% in the 40 s to 3.87%), signaling the onset of microbial dysbiosis. Concurrently, the microbiome-derived 'Carotenoid biosynthesis' antioxidant pathway significantly deteriorated. Spearman correlation networks demonstrated that while local facial cleansing habits tightly regulated the microbiome in the pre-tipping group (20-40 s), this external regulatory efficacy completely decoupled in the post-tipping group (50-60 s), compelling surviving core taxa to rely on intra-microbial symbiotic networks.
CONCLUSION: Facial skin aging involves a discontinuous ecological tipping point during the 50 s characterized by structural dysbiosis, functional antioxidant depletion, and the collapse of external hygiene efficacy. Age-specific dermatological strategies for older demographics must transition from simple surface cleansing to customized interventions restoring microbial balance.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-17
Dysbiosis in the Aerobic Microbiota of E-Cigarette Users: Evidence From Salivary Microcosm Biofilm.
Clinical and experimental dental research, 12(6):.
OBJECTIVES: Tobacco and nicotine are known to alter the oral microbiome, thereby promoting dysbiosis. The impact of new nicotine forms, such as electronic cigarettes (e-cigs), on oral dysbiosis remains unclear. This study aimed to evaluate the microbial biofilm composition and carbohydrate presence in e-cig users' saliva.
MATERIAL AND METH: Fifty participants with healthy oral mucosa were divided into two groups: E-cig group (EG)-25 regular and exclusive e-cig users; Control group (CG)-25 non-smokers, matched for sex and age. Unstimulated saliva and flavoring samples were collected. The salivary biofilm's biomass and metabolic activity were assessed, along with non-selective counts of general microorganisms, yeasts, Streptococcus mutans group streptococci, and lactobacilli in the microcosm biofilms. Total carbohydrate content in saliva was quantified using the phenol-sulfuric acid method.
RESULTS: The biomass average and the metabolic activity showed an increase in EG. The counts of non-selective microorganisms, yeasts, and mutans group streptococci were higher in EG compared with those in CG. Conversely, EG showed a reduction in lactobacilli counts in all samples. No differences were found in total carbohydrate content in saliva between EG and CG. However, significant carbohydrate presence was noted in the flavoring, particularly in fruit/sweet flavors.
CONCLUSIONS: The e-cig use promotes dysbiosis in the aerobic microbiota through a significant increase in biofilm formation and in the counts of S. mutans and oral yeast. Significant concentrations of glucose were detected in e-cig liquids, especially in sweet flavors.
Additional Links: PMID-43043900
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43043900,
year = {2026},
author = {Carvalho, BFDC and Garcia, MT and do Carmo, PHF and de Carvalho Faria, N and de Souza Silva, FA and Junqueira, JC and Almeida, JD},
title = {Dysbiosis in the Aerobic Microbiota of E-Cigarette Users: Evidence From Salivary Microcosm Biofilm.},
journal = {Clinical and experimental dental research},
volume = {12},
number = {6},
pages = {},
pmid = {43043900},
issn = {2057-4347},
support = {#2020/10362-0//São Paulo Research Foundation (FAPESP)/ ; #2020/10322-9//São Paulo Research Foundation (FAPESP)/ ; #2024/05449-0//São Paulo Research Foundation (FAPESP)/ ; 001//Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/ ; },
mesh = {Humans ; *Biofilms/growth & development/drug effects ; *Saliva/microbiology/chemistry ; *Dysbiosis/microbiology/etiology ; Female ; Adult ; Male ; *Microbiota/drug effects ; *Electronic Nicotine Delivery Systems ; Young Adult ; },
abstract = {OBJECTIVES: Tobacco and nicotine are known to alter the oral microbiome, thereby promoting dysbiosis. The impact of new nicotine forms, such as electronic cigarettes (e-cigs), on oral dysbiosis remains unclear. This study aimed to evaluate the microbial biofilm composition and carbohydrate presence in e-cig users' saliva.
MATERIAL AND METH: Fifty participants with healthy oral mucosa were divided into two groups: E-cig group (EG)-25 regular and exclusive e-cig users; Control group (CG)-25 non-smokers, matched for sex and age. Unstimulated saliva and flavoring samples were collected. The salivary biofilm's biomass and metabolic activity were assessed, along with non-selective counts of general microorganisms, yeasts, Streptococcus mutans group streptococci, and lactobacilli in the microcosm biofilms. Total carbohydrate content in saliva was quantified using the phenol-sulfuric acid method.
RESULTS: The biomass average and the metabolic activity showed an increase in EG. The counts of non-selective microorganisms, yeasts, and mutans group streptococci were higher in EG compared with those in CG. Conversely, EG showed a reduction in lactobacilli counts in all samples. No differences were found in total carbohydrate content in saliva between EG and CG. However, significant carbohydrate presence was noted in the flavoring, particularly in fruit/sweet flavors.
CONCLUSIONS: The e-cig use promotes dysbiosis in the aerobic microbiota through a significant increase in biofilm formation and in the counts of S. mutans and oral yeast. Significant concentrations of glucose were detected in e-cig liquids, especially in sweet flavors.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Biofilms/growth & development/drug effects
*Saliva/microbiology/chemistry
*Dysbiosis/microbiology/etiology
Female
Adult
Male
*Microbiota/drug effects
*Electronic Nicotine Delivery Systems
Young Adult
RevDate: 2026-11-17
The 32nd Annual Prostate Cancer Foundation Scientific Retreat Report.
The Prostate [Epub ahead of print].
BACKGROUND: The 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat took place in Carlsbad, CA on October 23-25, 2025.
METHODS: The Annual PCF Scientific Retreat is a global forum for presenting the newest basic, translational, and clinical discoveries in prostate cancer, alongside work from related fields. Presentations highlight discoveries with strong potential to advance prostate cancer understanding, change clinical practice, and improve patient outcomes.
RESULTS: The 2025 PCF Retreat featured research and special lectures from many disciplines, including: (i) next-generation theranostics; (ii) emerging immunotherapy approaches in prostate cancer; (iii) understanding and drugging the epigenome; (iv) clinical trial updates; (v) artificial intelligence (AI) and machine learning; (vi) circulating biomarkers; (vii) harnessing the host microbiome in cancer; (viii) exercise interventions for patients with prostate cancer; (ix) CYP17A1-independent androgen biosynthesis as a mechanism of persistent androgen production; (x) Prostate Cancer Working Group 4 recommendations for trial design and response assessment; (xi) tissue-guided optimization of combination therapy; (xii) PCF Women in Science Lifetime Achievement Award lecture; and (xiii) bridging biomedical research and drug development.
CONCLUSIONS: The 2025 PCF Scientific Retreat illustrated how advances across diverse fields, including theranostics, immunotherapy, epigenetics, AI, and liquid biopsy, are converging to reshape how prostate cancer is understood, monitored, and treated. Recurring themes included tumor heterogeneity and lineage plasticity as determinants of treatment response, the need for predictive biomarkers to guide increasingly intensive and combination therapies, and the movement of effective therapies into earlier disease settings. This report reflects the state of the science as of October 2025.
Additional Links: PMID-43043976
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43043976,
year = {2026},
author = {Miyahira, AK and Koo, PJ},
title = {The 32nd Annual Prostate Cancer Foundation Scientific Retreat Report.},
journal = {The Prostate},
volume = {},
number = {},
pages = {},
doi = {10.1002/pros.70276},
pmid = {43043976},
issn = {1097-0045},
support = {//PCF/ ; },
abstract = {BACKGROUND: The 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat took place in Carlsbad, CA on October 23-25, 2025.
METHODS: The Annual PCF Scientific Retreat is a global forum for presenting the newest basic, translational, and clinical discoveries in prostate cancer, alongside work from related fields. Presentations highlight discoveries with strong potential to advance prostate cancer understanding, change clinical practice, and improve patient outcomes.
RESULTS: The 2025 PCF Retreat featured research and special lectures from many disciplines, including: (i) next-generation theranostics; (ii) emerging immunotherapy approaches in prostate cancer; (iii) understanding and drugging the epigenome; (iv) clinical trial updates; (v) artificial intelligence (AI) and machine learning; (vi) circulating biomarkers; (vii) harnessing the host microbiome in cancer; (viii) exercise interventions for patients with prostate cancer; (ix) CYP17A1-independent androgen biosynthesis as a mechanism of persistent androgen production; (x) Prostate Cancer Working Group 4 recommendations for trial design and response assessment; (xi) tissue-guided optimization of combination therapy; (xii) PCF Women in Science Lifetime Achievement Award lecture; and (xiii) bridging biomedical research and drug development.
CONCLUSIONS: The 2025 PCF Scientific Retreat illustrated how advances across diverse fields, including theranostics, immunotherapy, epigenetics, AI, and liquid biopsy, are converging to reshape how prostate cancer is understood, monitored, and treated. Recurring themes included tumor heterogeneity and lineage plasticity as determinants of treatment response, the need for predictive biomarkers to guide increasingly intensive and combination therapies, and the movement of effective therapies into earlier disease settings. This report reflects the state of the science as of October 2025.},
}
RevDate: 2026-11-17
Inhibitors of Gut Bacterial l-Dopa Decarboxylation with Reduced Susceptibility to Host Metabolism.
ACS chemical biology pii:5472025 [Epub ahead of print].
Microorganisms in the human gut influence the efficacy and metabolism of host-targeted small molecule therapeutics, including the frontline Parkinson's disease drug levodopa (l-dopa). Previous work has identified a mechanism-based inhibitor of gut bacterial decarboxylases that degrade l-dopa, α-fluoromethyltyrosine (AFMT). However, early experiments with AFMT in rodent models suggested undesirable in vivo metabolism by host tyrosine hydroxylase, producing α-fluoromethyldopa, a metabolite likely to worsen Parkinson's phenotypes and prevent application as an l-dopa cotreatment. Here, we demonstrate oxidation of AFMT to α-fluoromethyldopa in vitro by recombinant human tyrosine hydroxylase. We then develop AFMT analogues that retain activity against bacterial decarboxylases but have reduced susceptibility to host hydroxylation. Suitable arenes for inhibitor design were identified using assays with commercially available noncanonical amino acids, which revealed aryl difluorination as a promising modification. Difluoroaryl AFMT derivatives are less prone to degradation by tyrosine hydroxylase in vitro yet still inhibit l-dopa metabolism by bacterial decarboxylases. This work exemplifies how substrate reactivity can streamline design of mechanism-based enzyme inhibitors, as well as how constraints posed by the host can be incorporated during development of microbiome-targeted therapeutics. The compounds reported here are promising starting points for future studies in animal models and further exploration of gut bacterial effects on l-dopa treatment efficacy.
Additional Links: PMID-43044065
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044065,
year = {2026},
author = {Narayan, R and Le, CC and Khurana, JK and Nieto, V and Olson, CA and Turnbaugh, PJ and Balskus, EP},
title = {Inhibitors of Gut Bacterial l-Dopa Decarboxylation with Reduced Susceptibility to Host Metabolism.},
journal = {ACS chemical biology},
volume = {},
number = {},
pages = {},
doi = {10.1021/acschembio.6c00480},
pmid = {43044065},
issn = {1554-8937},
abstract = {Microorganisms in the human gut influence the efficacy and metabolism of host-targeted small molecule therapeutics, including the frontline Parkinson's disease drug levodopa (l-dopa). Previous work has identified a mechanism-based inhibitor of gut bacterial decarboxylases that degrade l-dopa, α-fluoromethyltyrosine (AFMT). However, early experiments with AFMT in rodent models suggested undesirable in vivo metabolism by host tyrosine hydroxylase, producing α-fluoromethyldopa, a metabolite likely to worsen Parkinson's phenotypes and prevent application as an l-dopa cotreatment. Here, we demonstrate oxidation of AFMT to α-fluoromethyldopa in vitro by recombinant human tyrosine hydroxylase. We then develop AFMT analogues that retain activity against bacterial decarboxylases but have reduced susceptibility to host hydroxylation. Suitable arenes for inhibitor design were identified using assays with commercially available noncanonical amino acids, which revealed aryl difluorination as a promising modification. Difluoroaryl AFMT derivatives are less prone to degradation by tyrosine hydroxylase in vitro yet still inhibit l-dopa metabolism by bacterial decarboxylases. This work exemplifies how substrate reactivity can streamline design of mechanism-based enzyme inhibitors, as well as how constraints posed by the host can be incorporated during development of microbiome-targeted therapeutics. The compounds reported here are promising starting points for future studies in animal models and further exploration of gut bacterial effects on l-dopa treatment efficacy.},
}
RevDate: 2026-11-17
Learning from nature: What non-native halophilic and halotolerant bacteria reveal about root immunity under salt stress.
Microbiological research, 316:128827 pii:S0944-5013(26)00391-5 [Epub ahead of print].
Soil salinity is increasingly recognised as one of the main limits to crop production worldwide, yet attempts to use halophilic and halotolerant plant growth-promoting bacteria in saline agriculture have produced mixed and often disappointing results, particularly when strains are moved onto non-native host plants. In this review, the literature is brought together to examine how such non-native halophilic and halotolerant bacteria behave at the root-soil interface under salt stress, and which molecular, physiological, and ecological factors determine whether they are rejected by, or can pass through, plant defence barriers. The article first summarises how salinity reshapes root immune organisation, from root system architecture and cell-wall properties to redox homeostasis and ABA-SA-JA signalling, and how these changes open and close specific spatial and temporal windows for microbial entry, recognition and persistence. Plant immune responses to native and non‑native halophilic bacteria are compared, revealing that differences in MAMP perception, PTI dynamics, and host-microbe feedback determine host preference and colonisation in saline rhizospheres. These findings are summarised in a mechanistic model describing six main bacterial tactics that modulate recognition, signalling, oxidative stress, hormonal balance, and cell‑wall-apoplast properties to evade or adjust host immunity. Looking across different plant-bacteria pairs and experimental setups, the review discusses why promising halophilic inoculants so often fail when transferred to new hosts, which trait combinations are repeatedly associated with successful non-native colonisation, and where the major gaps remain in in planta and systems-level evidence. Together, these points are used to argue that future microbiome-based strategies for salt-affected soils need to be designed around plant immune architecture, salinity-induced physiological states and ecological fit, rather than relying only on generic stress-alleviating traits.
Additional Links: PMID-43044247
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044247,
year = {2026},
author = {Ahmadi, F},
title = {Learning from nature: What non-native halophilic and halotolerant bacteria reveal about root immunity under salt stress.},
journal = {Microbiological research},
volume = {316},
number = {},
pages = {128827},
doi = {10.1016/j.micres.2026.128827},
pmid = {43044247},
issn = {1618-0623},
abstract = {Soil salinity is increasingly recognised as one of the main limits to crop production worldwide, yet attempts to use halophilic and halotolerant plant growth-promoting bacteria in saline agriculture have produced mixed and often disappointing results, particularly when strains are moved onto non-native host plants. In this review, the literature is brought together to examine how such non-native halophilic and halotolerant bacteria behave at the root-soil interface under salt stress, and which molecular, physiological, and ecological factors determine whether they are rejected by, or can pass through, plant defence barriers. The article first summarises how salinity reshapes root immune organisation, from root system architecture and cell-wall properties to redox homeostasis and ABA-SA-JA signalling, and how these changes open and close specific spatial and temporal windows for microbial entry, recognition and persistence. Plant immune responses to native and non‑native halophilic bacteria are compared, revealing that differences in MAMP perception, PTI dynamics, and host-microbe feedback determine host preference and colonisation in saline rhizospheres. These findings are summarised in a mechanistic model describing six main bacterial tactics that modulate recognition, signalling, oxidative stress, hormonal balance, and cell‑wall-apoplast properties to evade or adjust host immunity. Looking across different plant-bacteria pairs and experimental setups, the review discusses why promising halophilic inoculants so often fail when transferred to new hosts, which trait combinations are repeatedly associated with successful non-native colonisation, and where the major gaps remain in in planta and systems-level evidence. Together, these points are used to argue that future microbiome-based strategies for salt-affected soils need to be designed around plant immune architecture, salinity-induced physiological states and ecological fit, rather than relying only on generic stress-alleviating traits.},
}
RevDate: 2026-11-17
The endometrial microbiome and reproductive outcomes following assisted reproductive technologies: A systematic review.
Journal of reproductive immunology, 178:105169 pii:S0165-0378(26)00338-4 [Epub ahead of print].
The endometrial microbiome has emerged as a potential determinant of endometrial receptivity and reproductive outcomes following assisted reproductive technologies (ART), although its clinical significance remains uncertain. This systematic review evaluated the association between endometrial microbiome composition and reproductive outcomes after ART and critically appraised the evidence supporting microbiome-guided diagnostic and therapeutic strategies. The review was registered in PROSPERO (CRD420261405558) and reported in accordance with the PRISMA 2020 statement. PubMed/MEDLINE, Embase, Scopus, Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to March 2026. Twelve studies involving more than 2200 women undergoing ART met the inclusion criteria. Across the included studies, Lactobacillus-enriched endometrial microbial profiles were associated with more favorable reproductive outcomes in some cohorts; however, findings were inconsistent across studies and individual endpoints, including implantation, clinical pregnancy, ongoing pregnancy, and live birth. Associations involving non-Lactobacillus microbial profiles were also heterogeneous and should be interpreted in the context of study-specific microbial definitions and patient populations. Preliminary non-randomized studies have reported favorable reproductive outcomes following microbiome-guided management in selected populations, but these findings do not establish treatment efficacy. However, substantial heterogeneity in study populations, microbiome assessment methods, definitions of dysbiosis, and outcome reporting limits the certainty and clinical applicability of the available evidence. Overall, current evidence supports a biologically plausible association between endometrial microbiome composition and reproductive outcomes following ART, but well-designed prospective studies using standardized methodologies are needed to determine whether endometrial microbial signatures can serve as clinically actionable biomarkers and therapeutic targets.
Additional Links: PMID-43044308
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044308,
year = {2026},
author = {Mihoci, AM and Socolov, D and Dumitrescu, RD and Nemescu, D and Mihoci, EC and Voicu, I and Scripcariu, IS and Socolov, RV},
title = {The endometrial microbiome and reproductive outcomes following assisted reproductive technologies: A systematic review.},
journal = {Journal of reproductive immunology},
volume = {178},
number = {},
pages = {105169},
doi = {10.1016/j.jri.2026.105169},
pmid = {43044308},
issn = {1872-7603},
abstract = {The endometrial microbiome has emerged as a potential determinant of endometrial receptivity and reproductive outcomes following assisted reproductive technologies (ART), although its clinical significance remains uncertain. This systematic review evaluated the association between endometrial microbiome composition and reproductive outcomes after ART and critically appraised the evidence supporting microbiome-guided diagnostic and therapeutic strategies. The review was registered in PROSPERO (CRD420261405558) and reported in accordance with the PRISMA 2020 statement. PubMed/MEDLINE, Embase, Scopus, Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to March 2026. Twelve studies involving more than 2200 women undergoing ART met the inclusion criteria. Across the included studies, Lactobacillus-enriched endometrial microbial profiles were associated with more favorable reproductive outcomes in some cohorts; however, findings were inconsistent across studies and individual endpoints, including implantation, clinical pregnancy, ongoing pregnancy, and live birth. Associations involving non-Lactobacillus microbial profiles were also heterogeneous and should be interpreted in the context of study-specific microbial definitions and patient populations. Preliminary non-randomized studies have reported favorable reproductive outcomes following microbiome-guided management in selected populations, but these findings do not establish treatment efficacy. However, substantial heterogeneity in study populations, microbiome assessment methods, definitions of dysbiosis, and outcome reporting limits the certainty and clinical applicability of the available evidence. Overall, current evidence supports a biologically plausible association between endometrial microbiome composition and reproductive outcomes following ART, but well-designed prospective studies using standardized methodologies are needed to determine whether endometrial microbial signatures can serve as clinically actionable biomarkers and therapeutic targets.},
}
RevDate: 2026-11-17
From plastic fragments to secondary microplastics: Long-term polymer aging and microbial functional responses at the sediment-water interface.
Journal of environmental management, 420:131357 pii:S0301-4797(26)02817-3 [Epub ahead of print].
Biodegradable plastics (BPs) are widely considered alternatives to conventional plastics, yet whether biodegradability reduces ecological impacts remains uncertain. Here, a 12-month sediment-water microcosm experiment was conducted to compare the aging behavior, microplastic (MP) generation, and microbial responses of polypropylene (PP), polylactic acid (PLA), poly(butylene adipate-co-terephthalate) (PBAT), and PLA/PBAT blends in urban river sediments. BPs exhibited accelerated oxidation, hydrolysis, and fragmentation compared with PP, with PLA/PBAT showing the greatest mass loss (9.74%) and releasing the highest MP abundance in sediments (217 particles g[-1]) and overlying water (14 particles mL[-1]). Metagenomic analyses revealed that biodegradable MPs reshaped microbial community assembly, interaction networks, and functional potentials by altering sediment carbon availability and environmental conditions. Notably, BPs enhanced microbial carbon acquisition, metabolic activity, and environmental sensing, while selectively restructuring virulence-associated gene profiles. The PLA/PBAT blend showed the strongest coupling among polymer degradation, microbial functional traits, and environmental filtering. These findings demonstrate that enhanced biodegradability does not necessarily translate into reduced ecological disturbance and highlight the need to integrate polymer aging dynamics, secondary MP generation, and microbially mediated responses into environmental risk assessments of biodegradable plastics.
Additional Links: PMID-43044499
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044499,
year = {2026},
author = {Chen, J and Zhang, R and Zhang, Z and Tao, X and Ma, Y and Yin, J and Wang, K and Wang, J and Qiu, H and Sun, Y},
title = {From plastic fragments to secondary microplastics: Long-term polymer aging and microbial functional responses at the sediment-water interface.},
journal = {Journal of environmental management},
volume = {420},
number = {},
pages = {131357},
doi = {10.1016/j.jenvman.2026.131357},
pmid = {43044499},
issn = {1095-8630},
abstract = {Biodegradable plastics (BPs) are widely considered alternatives to conventional plastics, yet whether biodegradability reduces ecological impacts remains uncertain. Here, a 12-month sediment-water microcosm experiment was conducted to compare the aging behavior, microplastic (MP) generation, and microbial responses of polypropylene (PP), polylactic acid (PLA), poly(butylene adipate-co-terephthalate) (PBAT), and PLA/PBAT blends in urban river sediments. BPs exhibited accelerated oxidation, hydrolysis, and fragmentation compared with PP, with PLA/PBAT showing the greatest mass loss (9.74%) and releasing the highest MP abundance in sediments (217 particles g[-1]) and overlying water (14 particles mL[-1]). Metagenomic analyses revealed that biodegradable MPs reshaped microbial community assembly, interaction networks, and functional potentials by altering sediment carbon availability and environmental conditions. Notably, BPs enhanced microbial carbon acquisition, metabolic activity, and environmental sensing, while selectively restructuring virulence-associated gene profiles. The PLA/PBAT blend showed the strongest coupling among polymer degradation, microbial functional traits, and environmental filtering. These findings demonstrate that enhanced biodegradability does not necessarily translate into reduced ecological disturbance and highlight the need to integrate polymer aging dynamics, secondary MP generation, and microbially mediated responses into environmental risk assessments of biodegradable plastics.},
}
RevDate: 2026-11-17
Beyond cytokines in inflammatory bowel disease: targeting the epithelial microbiome-mitochondria-immune axis to restore metabolic homeostasis.
Inflammatory bowel diseases pii:9080960 [Epub ahead of print].
Inflammatory bowel disease is a chronic inflammatory disease characterized by mucosal immunity dysregulation, epithelial barrier dysfunction, and gut microbiome dysbiosis. While cytokine-targeted therapies have improved clinical outcomes, many patients remain refractory or relapse, emphasizing the need for additional therapeutic approaches. Recent evidence suggests that mitochondrial metabolism in the intestinal epithelium regulates mucosal homeostasis, immune cell recruitment, and susceptibility to inflammation. However, it remains controversial whether mitochondrial dysfunction is a cause or a consequence of intestinal inflammation. Epithelial energetic deficiency and barrier dysfunction are associated with impaired oxidative phosphorylation, defective short-chain fatty acid utilization, redox imbalance, and faulty mitochondrial quality control. Indeed, impaired mitophagy promotes mitochondrial DNA (mtDNA) release through voltage-dependent anion channel 1 (VDAC1) oligomerization and mitochondrial permeability transition pore opening. Extracellular mtDNA acts as a damage-associated molecular pattern, activating cyclic GMP-AMP synthase-stimulator of interferon genes, toll-like receptor 9, and NLR family pyrin domain-containing 3 inflammasome pathways that amplify mucosal inflammation. These metabolic changes alter luminal oxygen and microbiome composition, whereas microbial metabolites, particularly tryptophan-derived indoles and kynurenines, modulate epithelial mitochondrial function through aryl hydrocarbon receptor signaling. These findings support a bidirectional microbiome-mitochondria-immune axis that potentiates intestinal inflammation. In this review, we summarize the current evidence of how epithelial mitochondrial dysfunction associates with intestinal inflammation. We discuss how mitochondrial metabolism interfaces with microbial ecology and immune regulation to shape disease pathogenesis. We also discuss therapeutic strategies targeting this axis: mitochondrial-targeted antioxidants (eg, MitoQ), VDAC1 inhibitors, bile-acid derivatives (eg, tauroursodeoxycholic acid), and metabolite-based therapies to restore microbial tryptophan metabolism. These approaches target mitochondrial bioenergetics and microbial metabolic cross-talk with the potential to restore microbiome-immune homeostasis, preserve barrier integrity, and complement conventional immune-directed therapies.
Additional Links: PMID-43044573
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044573,
year = {2026},
author = {Torossian, T and Choufany, E and Bazzi, S and Chahine, A and Hadchity, G and Khachab, M and Bahr, GM and Echtay, KS},
title = {Beyond cytokines in inflammatory bowel disease: targeting the epithelial microbiome-mitochondria-immune axis to restore metabolic homeostasis.},
journal = {Inflammatory bowel diseases},
volume = {},
number = {},
pages = {},
doi = {10.1093/ibd/izag237},
pmid = {43044573},
issn = {1536-4844},
abstract = {Inflammatory bowel disease is a chronic inflammatory disease characterized by mucosal immunity dysregulation, epithelial barrier dysfunction, and gut microbiome dysbiosis. While cytokine-targeted therapies have improved clinical outcomes, many patients remain refractory or relapse, emphasizing the need for additional therapeutic approaches. Recent evidence suggests that mitochondrial metabolism in the intestinal epithelium regulates mucosal homeostasis, immune cell recruitment, and susceptibility to inflammation. However, it remains controversial whether mitochondrial dysfunction is a cause or a consequence of intestinal inflammation. Epithelial energetic deficiency and barrier dysfunction are associated with impaired oxidative phosphorylation, defective short-chain fatty acid utilization, redox imbalance, and faulty mitochondrial quality control. Indeed, impaired mitophagy promotes mitochondrial DNA (mtDNA) release through voltage-dependent anion channel 1 (VDAC1) oligomerization and mitochondrial permeability transition pore opening. Extracellular mtDNA acts as a damage-associated molecular pattern, activating cyclic GMP-AMP synthase-stimulator of interferon genes, toll-like receptor 9, and NLR family pyrin domain-containing 3 inflammasome pathways that amplify mucosal inflammation. These metabolic changes alter luminal oxygen and microbiome composition, whereas microbial metabolites, particularly tryptophan-derived indoles and kynurenines, modulate epithelial mitochondrial function through aryl hydrocarbon receptor signaling. These findings support a bidirectional microbiome-mitochondria-immune axis that potentiates intestinal inflammation. In this review, we summarize the current evidence of how epithelial mitochondrial dysfunction associates with intestinal inflammation. We discuss how mitochondrial metabolism interfaces with microbial ecology and immune regulation to shape disease pathogenesis. We also discuss therapeutic strategies targeting this axis: mitochondrial-targeted antioxidants (eg, MitoQ), VDAC1 inhibitors, bile-acid derivatives (eg, tauroursodeoxycholic acid), and metabolite-based therapies to restore microbial tryptophan metabolism. These approaches target mitochondrial bioenergetics and microbial metabolic cross-talk with the potential to restore microbiome-immune homeostasis, preserve barrier integrity, and complement conventional immune-directed therapies.},
}
RevDate: 2026-11-17
Spatial Transcriptomic Analysis Suggests Inflammatory Heterogeneity and Stromal-Epithelial Transcriptional Differences in Peri-Implantitis Tissues.
Journal of clinical periodontology [Epub ahead of print].
AIM: To explore spatial inflammatory heterogeneity and associated stromal-epithelial transcriptional differences in peri-implantitis tissues using high-resolution spatial transcriptomics.
MATERIALS AND METHODS: This exploratory study applied Visium HD spatial transcriptomics to five peri-implantitis lesions and four tooth-associated healthy gingival reference tissues. Spatial barcodes were annotated by histology, marker expression and module scoring. BANKSY, GASTON, differential expression, Gene Ontology, public scRNA-seq reanalysis, CellChat and multiplex immunofluorescence were used to assess inflammatory niches, stromal and epithelial gradients, epithelial gene sets and inferred signalling.
RESULTS: Peri-implantitis lesions showed descriptively greater immune-cell enrichment in an unmatched comparison with tooth-associated gingival reference tissue. Fibroblasts in inflammation-enriched niches differed from stromal-region fibroblasts and COL11A1-positive fibroblasts localised near immune-rich areas. GASTON identified graded expression patterns along the epithelial-stromal interface and epithelial regions. An 11-gene epithelial-inflammation-associated set showed region-associated expression differences, with supportive expression trends in public epithelial scRNA-seq data. CellChat suggested descriptively increased epithelial outgoing signalling involving WNT5A, MIF and ANXA1.
CONCLUSIONS: This study spatially describes host responses in peri-implantitis, including regional inflammatory heterogeneity, fibroblast-state variation and epithelial transcriptional differences. The epithelial-inflammation-associated gene set requires further validation. Interpretation should account for the small sample size, tooth-associated gingival reference tissue, absence of microbiome profiling and barcode-level Visium HD data.
Additional Links: PMID-43044580
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044580,
year = {2026},
author = {Wang, P and Yang, J and Li, S and Cheng, X and Zhao, C and Shen, Z and Zhang, Y},
title = {Spatial Transcriptomic Analysis Suggests Inflammatory Heterogeneity and Stromal-Epithelial Transcriptional Differences in Peri-Implantitis Tissues.},
journal = {Journal of clinical periodontology},
volume = {},
number = {},
pages = {},
doi = {10.1111/jcpe.70231},
pmid = {43044580},
issn = {1600-051X},
support = {82571059//National Natural Science Foundation of China/ ; 2024QNRC001//Young Elite Scientist Sponsorship Program by CAST/ ; 2025A1515012861//Guangdong Basic and Applied Basic Research Foundation/ ; A2024026//Medical Science and Technology Research Fund Project of Guangdong Province/ ; },
abstract = {AIM: To explore spatial inflammatory heterogeneity and associated stromal-epithelial transcriptional differences in peri-implantitis tissues using high-resolution spatial transcriptomics.
MATERIALS AND METHODS: This exploratory study applied Visium HD spatial transcriptomics to five peri-implantitis lesions and four tooth-associated healthy gingival reference tissues. Spatial barcodes were annotated by histology, marker expression and module scoring. BANKSY, GASTON, differential expression, Gene Ontology, public scRNA-seq reanalysis, CellChat and multiplex immunofluorescence were used to assess inflammatory niches, stromal and epithelial gradients, epithelial gene sets and inferred signalling.
RESULTS: Peri-implantitis lesions showed descriptively greater immune-cell enrichment in an unmatched comparison with tooth-associated gingival reference tissue. Fibroblasts in inflammation-enriched niches differed from stromal-region fibroblasts and COL11A1-positive fibroblasts localised near immune-rich areas. GASTON identified graded expression patterns along the epithelial-stromal interface and epithelial regions. An 11-gene epithelial-inflammation-associated set showed region-associated expression differences, with supportive expression trends in public epithelial scRNA-seq data. CellChat suggested descriptively increased epithelial outgoing signalling involving WNT5A, MIF and ANXA1.
CONCLUSIONS: This study spatially describes host responses in peri-implantitis, including regional inflammatory heterogeneity, fibroblast-state variation and epithelial transcriptional differences. The epithelial-inflammation-associated gene set requires further validation. Interpretation should account for the small sample size, tooth-associated gingival reference tissue, absence of microbiome profiling and barcode-level Visium HD data.},
}
RevDate: 2026-11-17
Molecular basis for the efficiency of an Akkermansia muciniphila α-1,2-fucosidase on conjugated H and Lewis epitopes.
Structure (London, England : 1993) pii:S0969-2126(26)00329-1 [Epub ahead of print].
H and Lewis antigens are ABO blood group precursors and modulators of microbe-host interactions. Enzymatic removal of 1,2-fucosyl units in these antigens is pivotal for glycoengineering applications, e.g., within transfusion medicine. How α-1,2-fucosidases recognize multiple H and Le antigens remains unexplored, which we investigate in AmGH95B, an α-1,2-fucosidase from the gut symbiont Akkermansia muciniphila. Substrate binding was shown to trigger a conformational switch to the catalytically competent enzyme state via loop rearrangements. We also identified structural features underpinning the recognition of H and Lewis antigens with diverse fucosylation and mainchain linkages by the same binding subsites, including a previously undescribed secondary fucosyl binding site. Mutagenesis revealed that the glycan context of conjugated substrates is sensed by the enzyme, which has not been previously shown in α-fucosidases. This study unravels an unprecedented recognition across 4-5 saccharide units by an α-1,2-fucosidase and provides a framework for tailoring α-1,2-fucosidases for biomedical applications.
Additional Links: PMID-43044581
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044581,
year = {2026},
author = {Jensen, M and Corbella, M and Stenfelt, L and Olsson, ML and Morth, JP and Rovira, C and Abou Hachem, M},
title = {Molecular basis for the efficiency of an Akkermansia muciniphila α-1,2-fucosidase on conjugated H and Lewis epitopes.},
journal = {Structure (London, England : 1993)},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.str.2026.10.011},
pmid = {43044581},
issn = {1878-4186},
abstract = {H and Lewis antigens are ABO blood group precursors and modulators of microbe-host interactions. Enzymatic removal of 1,2-fucosyl units in these antigens is pivotal for glycoengineering applications, e.g., within transfusion medicine. How α-1,2-fucosidases recognize multiple H and Le antigens remains unexplored, which we investigate in AmGH95B, an α-1,2-fucosidase from the gut symbiont Akkermansia muciniphila. Substrate binding was shown to trigger a conformational switch to the catalytically competent enzyme state via loop rearrangements. We also identified structural features underpinning the recognition of H and Lewis antigens with diverse fucosylation and mainchain linkages by the same binding subsites, including a previously undescribed secondary fucosyl binding site. Mutagenesis revealed that the glycan context of conjugated substrates is sensed by the enzyme, which has not been previously shown in α-fucosidases. This study unravels an unprecedented recognition across 4-5 saccharide units by an α-1,2-fucosidase and provides a framework for tailoring α-1,2-fucosidases for biomedical applications.},
}
RevDate: 2026-11-17
Diet-microbiome interaction shapes stress susceptibility via a gut-brain neurometabolic circuit.
Cell metabolism pii:S1550-4131(26)00451-1 [Epub ahead of print].
Dietary patterns shape mood and behavior, yet the microbial signals and neurosensory mechanisms underlying these effects remain unclear. Here, we identify a microbiota-mediated gut-brain circuit that dynamically regulates stress susceptibility during high-fat diet (HFD) exposure. Short- and long-term HFD differentially alter L-pipecolic acid (L-PipA), a metabolite produced by bacterial pyrroline-5-carboxylate reductase and sensed by oxytocinergic neurons in the paraventricular hypothalamus (PVH). Supplementation with L-PipA, either through its native producer Alistipes dispar or a bioengineered bacterial strain, promotes stress resilience, an effect mechanistically linked to ferritin heavy chain 1 (FTH1)-associated oxytocin secretion and a neural circuit linking PVH oxytocinergic neurons to lateral septal γ-aminobutyric acid (GABAergic) neurons. In humans, circulating L-PipA levels are reduced in patients with depression but increased in healthy volunteers following a 5-day HFD intervention. Together, these findings reveal a diet-microbiome-neural circuit axis regulating stress-related behaviors and suggest a potential strategy for enhancing stress resilience.
Additional Links: PMID-43044587
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044587,
year = {2026},
author = {Zhang, Y and Nie, R and Chen, Z and Li, X and Li, Z and Hou, Y and Li, C and Kang, G and Shan, Y and Xu, Y and Zhang, T and Li, J and Yu, S and Zhang, X and Lian, Z and Chen, J and Zhou, X and Yuan, Y and Fu, Y and Xu, X and Zhang, X and Hao, H and Zheng, X},
title = {Diet-microbiome interaction shapes stress susceptibility via a gut-brain neurometabolic circuit.},
journal = {Cell metabolism},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.cmet.2026.10.014},
pmid = {43044587},
issn = {1932-7420},
abstract = {Dietary patterns shape mood and behavior, yet the microbial signals and neurosensory mechanisms underlying these effects remain unclear. Here, we identify a microbiota-mediated gut-brain circuit that dynamically regulates stress susceptibility during high-fat diet (HFD) exposure. Short- and long-term HFD differentially alter L-pipecolic acid (L-PipA), a metabolite produced by bacterial pyrroline-5-carboxylate reductase and sensed by oxytocinergic neurons in the paraventricular hypothalamus (PVH). Supplementation with L-PipA, either through its native producer Alistipes dispar or a bioengineered bacterial strain, promotes stress resilience, an effect mechanistically linked to ferritin heavy chain 1 (FTH1)-associated oxytocin secretion and a neural circuit linking PVH oxytocinergic neurons to lateral septal γ-aminobutyric acid (GABAergic) neurons. In humans, circulating L-PipA levels are reduced in patients with depression but increased in healthy volunteers following a 5-day HFD intervention. Together, these findings reveal a diet-microbiome-neural circuit axis regulating stress-related behaviors and suggest a potential strategy for enhancing stress resilience.},
}
RevDate: 2026-11-17
Inflammation at the Crossroads of UV Radiation and Pollution: The Molecular Synergy Behind Accelerated Skin Aging.
Toxicology letters pii:S0378-4274(26)02463-X [Epub ahead of print].
The skin exposome which is the cumulative sum of environmental exposures and their biological imprint from conception to death remains an underexplored driver of premature skin aging, despite the skin's unique accessibility as a model organ. Ultraviolet (UV) radiation and polycyclic aromatic hydrocarbons (PAHs), notably benzo[a]pyrene (BaP), are two of the most pervasive and co-occurring extrinsic stressors acting directly on the skin surface. While each independently disrupts redox homeostasis, genomic integrity, and immune function, their combined exposure produces a supra-additive, non-linear interaction now termed "oxinflammation" whose magnitude depends critically on UV dose, pollutant concentration, and exposure duration, ranging from adaptive responses at low, acute exposures to persistent, maladaptive inflammatory activation under chronic, cumulative co-exposure. Building on this dose- and time-dependent framework, and extending beyond prior reviews that have treated UV and air pollution as parallel or additive threats to skin aging, this review centers on the immuno-inflammatory circuitry underlying their synergy particularly crosstalk between the aryl hydrocarbon receptor (AhR), mitogen-activated protein kinase (MAPK), and NF-κB pathways and its role in driving chronic low-grade inflammation ("inflammaging"), cellular senescence, and senescence-associated secretory phenotype (SASP) accumulation. We further examine PAH-driven immunomodulation and skin microbiome disruption as emerging, underappreciated contributors to this inflammatory circuit. Recent proteomic, metabolomic, and epigenetic evidence is synthesized to describe how this interplay impairs autophagy and DNA repair, degrades collagen through matrix metalloproteinase and cathepsin activation, and compromises epidermal barrier integrity, collectively accelerating extrinsic skin aging and contributing to the elevated carcinogenic risk associated with cumulative UV-pollutant co-exposure. We critically evaluate emerging therapeutic strategies including Nrf2 activators, mitochondria-targeted antioxidants, AhR antagonists, NAD+-restoring compounds, barrier-repair technologies, and microbiome-modulating interventions together with their translational limitations, such as poor cutaneous bioavailability of key candidate molecules. Finally, we outline future research priorities, emphasizing systematic dose-response characterization, multi-omics integration, advanced 3D and human-on-chip skin models, and personalized exposome analytics as necessary steps toward precision prevention of environmentally induced skin aging and its downstream oncological consequences.
Additional Links: PMID-43044695
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044695,
year = {2026},
author = {Nasrallah, A and El Mir, J and Fayyad-Kazan, M and Rachidi, W},
title = {Inflammation at the Crossroads of UV Radiation and Pollution: The Molecular Synergy Behind Accelerated Skin Aging.},
journal = {Toxicology letters},
volume = {},
number = {},
pages = {113234},
doi = {10.1016/j.toxlet.2026.113234},
pmid = {43044695},
issn = {1879-3169},
abstract = {The skin exposome which is the cumulative sum of environmental exposures and their biological imprint from conception to death remains an underexplored driver of premature skin aging, despite the skin's unique accessibility as a model organ. Ultraviolet (UV) radiation and polycyclic aromatic hydrocarbons (PAHs), notably benzo[a]pyrene (BaP), are two of the most pervasive and co-occurring extrinsic stressors acting directly on the skin surface. While each independently disrupts redox homeostasis, genomic integrity, and immune function, their combined exposure produces a supra-additive, non-linear interaction now termed "oxinflammation" whose magnitude depends critically on UV dose, pollutant concentration, and exposure duration, ranging from adaptive responses at low, acute exposures to persistent, maladaptive inflammatory activation under chronic, cumulative co-exposure. Building on this dose- and time-dependent framework, and extending beyond prior reviews that have treated UV and air pollution as parallel or additive threats to skin aging, this review centers on the immuno-inflammatory circuitry underlying their synergy particularly crosstalk between the aryl hydrocarbon receptor (AhR), mitogen-activated protein kinase (MAPK), and NF-κB pathways and its role in driving chronic low-grade inflammation ("inflammaging"), cellular senescence, and senescence-associated secretory phenotype (SASP) accumulation. We further examine PAH-driven immunomodulation and skin microbiome disruption as emerging, underappreciated contributors to this inflammatory circuit. Recent proteomic, metabolomic, and epigenetic evidence is synthesized to describe how this interplay impairs autophagy and DNA repair, degrades collagen through matrix metalloproteinase and cathepsin activation, and compromises epidermal barrier integrity, collectively accelerating extrinsic skin aging and contributing to the elevated carcinogenic risk associated with cumulative UV-pollutant co-exposure. We critically evaluate emerging therapeutic strategies including Nrf2 activators, mitochondria-targeted antioxidants, AhR antagonists, NAD+-restoring compounds, barrier-repair technologies, and microbiome-modulating interventions together with their translational limitations, such as poor cutaneous bioavailability of key candidate molecules. Finally, we outline future research priorities, emphasizing systematic dose-response characterization, multi-omics integration, advanced 3D and human-on-chip skin models, and personalized exposome analytics as necessary steps toward precision prevention of environmentally induced skin aging and its downstream oncological consequences.},
}
RevDate: 2026-11-17
Podophyllotoxin-induced mammary gland injury via the gut-mammary gland axis mediated by gut microbiota-derived metabolite PAG and aberrant EGFR signaling in SD rats based on the toxicological evidence chain (TEC) concept.
Chemico-biological interactions pii:S0009-2797(26)00541-7 [Epub ahead of print].
Podophyllotoxin is a lignan isolated from Dysosma versipellis with well-established antitumor activity. In this study, we applied an upgraded toxicological evidence chain 2.0 framework to characterize podophyllotoxin-induced mammary toxicity in female rats and to probe the distal regulatory mechanism operating through the gut-mammary axis. Repeated oral exposure provoked acute toxic signs in the animals, and histomorphometric analysis revealed a significant loss of collagen fibers in mammary tissue. 16S rRNA sequencing showed reduced gut microbial diversity, marked expansion of the opportunistic pathogen Escherichia_710834, and concurrent depletion of short-chain fatty acid producers such as Ligilactobacillus. Raman spectroscopy combined with targeted metabolomics uncovered 53 differentially abundant metabolites. Among these, four microbial-derived compounds-p-cresol, phenylacetylglycine, skatole, and trimethylamine N-oxide-correlated positively with Escherichia_710834 abundance. Further screening prioritized phenylacetylglycine and the epidermal growth factor receptor as the most credible ligand-receptor pair. Microscale thermophoresis confirmed a strong direct interaction, and qPCR revealed upregulated expression of downstream genes linked to proliferation and inflammation. Together, our findings define a complete causal pathway: podophyllotoxin perturbs the gut microbiome, driving excess production of phenylacetylglycine, which enters the circulation, engages mammary epidermal growth factor receptor, and aberrantly activates transcriptional responses that ultimately culminate in mammary tissue damage.
Additional Links: PMID-43044719
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044719,
year = {2026},
author = {Yan, L and Xurui, W and Zhangtian, T and Bingjie, X and Xin, L and Yulu, L and Lu, S and Bin, Z and Ding, LI and Yanan, B and Chuanxin, L and Zilong, C},
title = {Podophyllotoxin-induced mammary gland injury via the gut-mammary gland axis mediated by gut microbiota-derived metabolite PAG and aberrant EGFR signaling in SD rats based on the toxicological evidence chain (TEC) concept.},
journal = {Chemico-biological interactions},
volume = {},
number = {},
pages = {112433},
doi = {10.1016/j.cbi.2026.112433},
pmid = {43044719},
issn = {1872-7786},
abstract = {Podophyllotoxin is a lignan isolated from Dysosma versipellis with well-established antitumor activity. In this study, we applied an upgraded toxicological evidence chain 2.0 framework to characterize podophyllotoxin-induced mammary toxicity in female rats and to probe the distal regulatory mechanism operating through the gut-mammary axis. Repeated oral exposure provoked acute toxic signs in the animals, and histomorphometric analysis revealed a significant loss of collagen fibers in mammary tissue. 16S rRNA sequencing showed reduced gut microbial diversity, marked expansion of the opportunistic pathogen Escherichia_710834, and concurrent depletion of short-chain fatty acid producers such as Ligilactobacillus. Raman spectroscopy combined with targeted metabolomics uncovered 53 differentially abundant metabolites. Among these, four microbial-derived compounds-p-cresol, phenylacetylglycine, skatole, and trimethylamine N-oxide-correlated positively with Escherichia_710834 abundance. Further screening prioritized phenylacetylglycine and the epidermal growth factor receptor as the most credible ligand-receptor pair. Microscale thermophoresis confirmed a strong direct interaction, and qPCR revealed upregulated expression of downstream genes linked to proliferation and inflammation. Together, our findings define a complete causal pathway: podophyllotoxin perturbs the gut microbiome, driving excess production of phenylacetylglycine, which enters the circulation, engages mammary epidermal growth factor receptor, and aberrantly activates transcriptional responses that ultimately culminate in mammary tissue damage.},
}
RevDate: 2026-11-17
Combined metagenomic and metabolomic characterization of rhizosphere responses to GLDA-assisted cadmium phytoextraction by Artemisia argyi.
Environmental research pii:S0013-9351(26)02526-0 [Epub ahead of print].
Biodegradable chelator-assisted phytoextraction is widely proposed for cadmium (Cd)-contaminated farmland. In this study, we investigated the effects of the tetrasodium N,N-bis(carboxymethyl)-L-glutamic acid (GLDA) on Cd uptake by Artemisia argyi, and how rhizosphere functional gene abundances and metabolites co-vary across a GLDA dose gradient (0-5.00 mmol·kg[-1]; G0-G4) in a 65-day pot experiment. GLDA addition increased the exchangeable Cd fraction (8.8%-14.5%) and DTPA-extractable Cd (10.7%-18.6%), raising total plant Cd accumulation by 22%-36% and soil Cd removal rate from 4.87% (G0) to 5.93%-6.63% (G1-G4). GLDA selectively enhanced Cd accumulation in stems (11.11 to 25.17 mg·kg[-1]) without increasing Cd in the roots or leaves. Antioxidant enzyme activities (SOD, CAT, APX, GR) and glutathione content were higher under GLDA addition, but oxidative stress was not alleviated. GLDA addition was accompanied by a distinct restructuring of the rhizosphere microbiome and metabolome. Metagenomics showed enrichment of plant growth-promoting rhizobacteria (Bradyrhizobium, Paraburkholderia, Pandoraea, Ramlibacter, and Burkholderia), and higher relative abundances of genes for assimilatory sulfate/nitrate reduction, the glyoxylate cycle, glutathione synthesis, and Cd resistance. Soil metabolomics showed a contraction of the soluble oligosaccharide pool, suggesting reduced availability of soluble sugars in the rhizosphere. These biological shifts co-occurred with the chemical mobilization of Cd, representing a concurrent rhizosphere response during phytoextraction. Overall, these findings suggest that GLDA-assisted phytoextraction by A. argyi is a highly efficient remediation approach and simultaneously promotes a beneficial rhizosphere microbiome, providing a practical solution for Cd-contaminated soils.
Additional Links: PMID-43044740
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044740,
year = {2026},
author = {Gu, Y and Fu, S and Wu, H and Zhou, J and Chen, G and Liu, Q and Li, M and Sheng, H and Deng, Y},
title = {Combined metagenomic and metabolomic characterization of rhizosphere responses to GLDA-assisted cadmium phytoextraction by Artemisia argyi.},
journal = {Environmental research},
volume = {},
number = {},
pages = {126189},
doi = {10.1016/j.envres.2026.126189},
pmid = {43044740},
issn = {1096-0953},
abstract = {Biodegradable chelator-assisted phytoextraction is widely proposed for cadmium (Cd)-contaminated farmland. In this study, we investigated the effects of the tetrasodium N,N-bis(carboxymethyl)-L-glutamic acid (GLDA) on Cd uptake by Artemisia argyi, and how rhizosphere functional gene abundances and metabolites co-vary across a GLDA dose gradient (0-5.00 mmol·kg[-1]; G0-G4) in a 65-day pot experiment. GLDA addition increased the exchangeable Cd fraction (8.8%-14.5%) and DTPA-extractable Cd (10.7%-18.6%), raising total plant Cd accumulation by 22%-36% and soil Cd removal rate from 4.87% (G0) to 5.93%-6.63% (G1-G4). GLDA selectively enhanced Cd accumulation in stems (11.11 to 25.17 mg·kg[-1]) without increasing Cd in the roots or leaves. Antioxidant enzyme activities (SOD, CAT, APX, GR) and glutathione content were higher under GLDA addition, but oxidative stress was not alleviated. GLDA addition was accompanied by a distinct restructuring of the rhizosphere microbiome and metabolome. Metagenomics showed enrichment of plant growth-promoting rhizobacteria (Bradyrhizobium, Paraburkholderia, Pandoraea, Ramlibacter, and Burkholderia), and higher relative abundances of genes for assimilatory sulfate/nitrate reduction, the glyoxylate cycle, glutathione synthesis, and Cd resistance. Soil metabolomics showed a contraction of the soluble oligosaccharide pool, suggesting reduced availability of soluble sugars in the rhizosphere. These biological shifts co-occurred with the chemical mobilization of Cd, representing a concurrent rhizosphere response during phytoextraction. Overall, these findings suggest that GLDA-assisted phytoextraction by A. argyi is a highly efficient remediation approach and simultaneously promotes a beneficial rhizosphere microbiome, providing a practical solution for Cd-contaminated soils.},
}
RevDate: 2026-11-17
Molecular Landscape of Inflammatory Bowel Disease: From Molecular Mechanisms to Emerging Pharmacological Strategies.
European journal of pharmacology pii:S0014-2999(26)01060-5 [Epub ahead of print].
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract, broadly classified into ulcerative colitis and Crohn's disease, that affects millions of people worldwide. Despite significant advances in therapeutic options, including biologics, small-molecule drugs, and microbiota-targeted therapies, the aetiology of IBD remains incompletely understood. There is currently no curative treatment, and many patients experience suboptimal responses or severe treatment-related adverse effects. Increasing evidence suggests that IBD results from a complex interplay of genetic susceptibility, impaired epithelial barrier integrity, dysregulation of innate and adaptive immune responses and altered host-microbiome interactions. These disruptions trigger key inflammatory pathways and receptors, such as TNF receptors and IL-23R signalling, which sustain intestinal inflammation and contribute to disease severity and therapeutic resistance. This review summarises current understanding of IBD pathogenesis and highlights both established and emerging molecular targets. It also critically evaluates recent advances in drug discovery and targeted delivery strategies. By integrating mechanistic insights with translational approaches, this review aims to support the development of more effective, mechanism-driven, and personalised therapies for IBD.
Additional Links: PMID-43044750
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044750,
year = {2026},
author = {Ripa, JD and Yeshi, K and Field, M and Smithson, J and Wangchuk, P},
title = {Molecular Landscape of Inflammatory Bowel Disease: From Molecular Mechanisms to Emerging Pharmacological Strategies.},
journal = {European journal of pharmacology},
volume = {},
number = {},
pages = {179578},
doi = {10.1016/j.ejphar.2026.179578},
pmid = {43044750},
issn = {1879-0712},
abstract = {Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract, broadly classified into ulcerative colitis and Crohn's disease, that affects millions of people worldwide. Despite significant advances in therapeutic options, including biologics, small-molecule drugs, and microbiota-targeted therapies, the aetiology of IBD remains incompletely understood. There is currently no curative treatment, and many patients experience suboptimal responses or severe treatment-related adverse effects. Increasing evidence suggests that IBD results from a complex interplay of genetic susceptibility, impaired epithelial barrier integrity, dysregulation of innate and adaptive immune responses and altered host-microbiome interactions. These disruptions trigger key inflammatory pathways and receptors, such as TNF receptors and IL-23R signalling, which sustain intestinal inflammation and contribute to disease severity and therapeutic resistance. This review summarises current understanding of IBD pathogenesis and highlights both established and emerging molecular targets. It also critically evaluates recent advances in drug discovery and targeted delivery strategies. By integrating mechanistic insights with translational approaches, this review aims to support the development of more effective, mechanism-driven, and personalised therapies for IBD.},
}
RevDate: 2026-11-17
Immune Mechanisms of Oral Tolerance in the Prevention of IgE-Mediated Food Allergy.
The Journal of allergy and clinical immunology pii:S0091-6749(26)00814-6 [Epub ahead of print].
IgE-mediated food allergy develops when the immune response to dietary antigens is diverted from active tolerance towards a pathogenic type 2 immune response. Oral tolerance is the default, antigen-specific suppression of immune responses to ingested proteins. Early introduction trials, most notably the LEAP study, have demonstrated that oral exposure to food antigens during the first year of life can prevent food allergy and generate durable tolerance. Mechanistic advances have revealed that oral tolerance is governed by the coordinated activity of multiple overlapping immune layers. These include transcellular antigen transport through goblet cell-associated antigen passages (GAPs), tolerogenic antigen presentation by specialized RORγt+ antigen presenting cells (APCs) and classical dendritic cells (cDCs), induction and maintenance of heterogeneous regulatory T cell programs, and germinal center regulation of IgE and IgG responses. These cellular programs are further modulated by genetic determinants including HLA class II alleles, filaggrin variants, and microbial metabolites such as butyrate and indole derivatives and non-allergic dietary components. Infections can break tolerance by displacing or reprogramming tolerogenic APCs. Once food allergy has been established, regulatory pathways generated by oral allergen exposure are not sufficient to establish tolerance. These findings support a model in which tolerance and allergy represent competing, self-reinforcing immune states stabilized by redundant regulatory circuits. This review synthesizes the current understanding of these multilayered mechanisms and discusses their implications for prevention and treatment of food allergy.
Additional Links: PMID-43044855
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044855,
year = {2026},
author = {Chhiba, KD and Berin, MC},
title = {Immune Mechanisms of Oral Tolerance in the Prevention of IgE-Mediated Food Allergy.},
journal = {The Journal of allergy and clinical immunology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.jaci.2026.10.029},
pmid = {43044855},
issn = {1097-6825},
abstract = {IgE-mediated food allergy develops when the immune response to dietary antigens is diverted from active tolerance towards a pathogenic type 2 immune response. Oral tolerance is the default, antigen-specific suppression of immune responses to ingested proteins. Early introduction trials, most notably the LEAP study, have demonstrated that oral exposure to food antigens during the first year of life can prevent food allergy and generate durable tolerance. Mechanistic advances have revealed that oral tolerance is governed by the coordinated activity of multiple overlapping immune layers. These include transcellular antigen transport through goblet cell-associated antigen passages (GAPs), tolerogenic antigen presentation by specialized RORγt+ antigen presenting cells (APCs) and classical dendritic cells (cDCs), induction and maintenance of heterogeneous regulatory T cell programs, and germinal center regulation of IgE and IgG responses. These cellular programs are further modulated by genetic determinants including HLA class II alleles, filaggrin variants, and microbial metabolites such as butyrate and indole derivatives and non-allergic dietary components. Infections can break tolerance by displacing or reprogramming tolerogenic APCs. Once food allergy has been established, regulatory pathways generated by oral allergen exposure are not sufficient to establish tolerance. These findings support a model in which tolerance and allergy represent competing, self-reinforcing immune states stabilized by redundant regulatory circuits. This review synthesizes the current understanding of these multilayered mechanisms and discusses their implications for prevention and treatment of food allergy.},
}
RevDate: 2026-11-17
Molecular basis of behavioral and cognitive changes induced by neurotropic viruses.
Brain, behavior, and immunity pii:S0889-1591(26)01021-4 [Epub ahead of print].
Neurotropic viruses induce behavioral and cognitive alterations through diverse molecular and cellular mechanisms that extend beyond simple neuronal damage. Comparative analysis of rabies virus (RABV), pseudorabies virus (PRV), Borna disease virus (BoDV-1), SARS-CoV-2, Nipah virus (NiV), West Nile virus (WNV) and Herpes Simplex virus 1 (HSV-1) reveals distinct pathogenic strategies targeting specific neural circuits. While neuroinflammation characterized by microglial activation, astrocytic responses, and pro-inflammatory cytokine production contributes significantly to synaptic and network dysfunction in WNV and NiV infections, other mechanisms predominate in different pathogens. RABV selectively disrupts cholinergic, serotonergic, and glutamate/GABAergic pathways while preserving neuronal integrity to facilitate transmission, whereas BoDV-1 and SARS-CoV-2 induce dopaminergic and serotonergic dysfunctions through persistent immune activation and endothelial damage. Additionally, systemic factors such as the gut-brain axis and microbiome alterations, particularly evident in SARS-CoV-2 infection, modulate neurotransmitter metabolism and neuroimmune responses. Considering the lack of even diffuse neuronal loss observed during infection, behavioral changes may arise more from selective, circuit-dependent vulnerabilities, involving specific disruptions to emotion, cognition, and motor control networks. To provide a clear review of the knowledge regarding how targeted neuronal population alterations translate into behavioral phenotypes, we here integrate molecular, cellular, and systems-level insights across these seven neurotropic viruses used as models, with the aim of identifying common pathways linking infection to behavioral changes and cognitive dysfunction. Understanding these discrete mechanisms ranging from acute synaptic manipulation to long-lasting neuroimmune dysregulation is essential for developing therapeutic strategies that address both the infectious agent and the specific neural networks mediating acute disturbances and long-term neurological sequelae.
Additional Links: PMID-43044888
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044888,
year = {2026},
author = {Coleon, A and Ronco, I and Raber, J and O'Niel, A and Herden, C and Horvat, B and Bourhy, H and de Melo, GD},
title = {Molecular basis of behavioral and cognitive changes induced by neurotropic viruses.},
journal = {Brain, behavior, and immunity},
volume = {},
number = {},
pages = {107273},
doi = {10.1016/j.bbi.2026.107273},
pmid = {43044888},
issn = {1090-2139},
abstract = {Neurotropic viruses induce behavioral and cognitive alterations through diverse molecular and cellular mechanisms that extend beyond simple neuronal damage. Comparative analysis of rabies virus (RABV), pseudorabies virus (PRV), Borna disease virus (BoDV-1), SARS-CoV-2, Nipah virus (NiV), West Nile virus (WNV) and Herpes Simplex virus 1 (HSV-1) reveals distinct pathogenic strategies targeting specific neural circuits. While neuroinflammation characterized by microglial activation, astrocytic responses, and pro-inflammatory cytokine production contributes significantly to synaptic and network dysfunction in WNV and NiV infections, other mechanisms predominate in different pathogens. RABV selectively disrupts cholinergic, serotonergic, and glutamate/GABAergic pathways while preserving neuronal integrity to facilitate transmission, whereas BoDV-1 and SARS-CoV-2 induce dopaminergic and serotonergic dysfunctions through persistent immune activation and endothelial damage. Additionally, systemic factors such as the gut-brain axis and microbiome alterations, particularly evident in SARS-CoV-2 infection, modulate neurotransmitter metabolism and neuroimmune responses. Considering the lack of even diffuse neuronal loss observed during infection, behavioral changes may arise more from selective, circuit-dependent vulnerabilities, involving specific disruptions to emotion, cognition, and motor control networks. To provide a clear review of the knowledge regarding how targeted neuronal population alterations translate into behavioral phenotypes, we here integrate molecular, cellular, and systems-level insights across these seven neurotropic viruses used as models, with the aim of identifying common pathways linking infection to behavioral changes and cognitive dysfunction. Understanding these discrete mechanisms ranging from acute synaptic manipulation to long-lasting neuroimmune dysregulation is essential for developing therapeutic strategies that address both the infectious agent and the specific neural networks mediating acute disturbances and long-term neurological sequelae.},
}
RevDate: 2026-11-17
Microplastics And Nanoplastics In Soils: Inconsistent Evidence And Unresolved Toxicological Risks For Terrestrial Invertebrates.
Environmental toxicology and pharmacology pii:S1382-6689(26)00312-1 [Epub ahead of print].
Microplastics (MPs) and nanoplastics (NPs) accumulate in soils, but their risks to terrestrial invertebrates supporting soil formation, nutrient cycling, and pollination remain uncertain. We critically examine exposure and toxicity evidence for earthworms, fruit flies, bees, and tenebrionid beetles. Across taxa, oxidative stress, intestinal and epithelial injury, and microbiome disruption recur, whereas reproductive, immune, and behavioral effects are less consistent and often observed at high concentrations. Proposed mechanisms include mitochondrial and lysosomal dysfunction and altered antioxidant defenses, although causal links to organism-level outcomes remain limited. Comparisons are constrained by incomplete particle characterization, reliance on pristine particles, unrealistic exposures, and heterogeneous protocols. Insects can biofragment, depolymerize, and partially mineralize plastics, but the extent and ecological relevance of biodegradation remain contested, and fragmentation may generate smaller plastic particles. Progress requires environmentally relevant experiments using characterized, weathered particles, mechanistic endpoints linked to ecologically meaningful outcomes, and tiered risk assessment.
Additional Links: PMID-43044948
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044948,
year = {2026},
author = {Fontes, BLM and Aguiar, JD and da Costa, ALC and do Almo Guimarães, G and Costa, APF and Martins, KC and da Fonseca, RN and Cavalcanti-Neto, MP and Pinheiro, CR},
title = {Microplastics And Nanoplastics In Soils: Inconsistent Evidence And Unresolved Toxicological Risks For Terrestrial Invertebrates.},
journal = {Environmental toxicology and pharmacology},
volume = {},
number = {},
pages = {105234},
doi = {10.1016/j.etap.2026.105234},
pmid = {43044948},
issn = {1872-7077},
abstract = {Microplastics (MPs) and nanoplastics (NPs) accumulate in soils, but their risks to terrestrial invertebrates supporting soil formation, nutrient cycling, and pollination remain uncertain. We critically examine exposure and toxicity evidence for earthworms, fruit flies, bees, and tenebrionid beetles. Across taxa, oxidative stress, intestinal and epithelial injury, and microbiome disruption recur, whereas reproductive, immune, and behavioral effects are less consistent and often observed at high concentrations. Proposed mechanisms include mitochondrial and lysosomal dysfunction and altered antioxidant defenses, although causal links to organism-level outcomes remain limited. Comparisons are constrained by incomplete particle characterization, reliance on pristine particles, unrealistic exposures, and heterogeneous protocols. Insects can biofragment, depolymerize, and partially mineralize plastics, but the extent and ecological relevance of biodegradation remain contested, and fragmentation may generate smaller plastic particles. Progress requires environmentally relevant experiments using characterized, weathered particles, mechanistic endpoints linked to ecologically meaningful outcomes, and tiered risk assessment.},
}
RevDate: 2026-11-17
Species-specific bacteriophage-mediated engineering of an artificial microbiome composed of Bacteroides and Phocaeicola species.
New biotechnology pii:S1871-6784(26)00139-1 [Epub ahead of print].
Members of the Bacteroides and Phocaeicola genera have been involved in various health- and disease-related states, but their in situ functions have not been clearly elucidated yet. Targeted removal of specific bacterial species using bacteriophages is expected to facilitate in situ functional analysis of gut bacteria. However, the feasibility of species-specific removal in microbiomes including Bacteroides and Phocaeicola species has not been demonstrated, in part due to the limited availability of isolated phages infecting these taxa. We newly isolated two lytic phages infecting Bacteroides uniformis or Bacteroides caccae and evaluated their applicability for species-specific microbiome engineering using an artificial microbiome composed of five Bacteroides and two Phocaeicola species formerly classified as Bacteroides. Adding the B. uniformis phage selectively suppressed the growth of B. uniformis, resulting in 1.16 × 10[5] CFU-equivalent/mL in the presence of the phage compared with 6.01 × 10[7] CFU-equivalent/mL in the absence of the phage, without affecting the growth of nontarget species. In contrast, adding the B. caccae phage decreased the abundance of B. caccae and also significantly increased the bacterial abundance of the nontarget species Bacteroides finegoldii. This growth enhancement was likely mediated, at least in part, by cellular components released upon lysis of B. caccae. The results indicate that species-specific bacteriophage-mediated microbiome engineering is feasible within a defined Bacteroides/Phocaeicola community and can be a basis for subsequent functional analyses and for exploring interspecies growth interactions.
Additional Links: PMID-43044962
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044962,
year = {2026},
author = {Tanaka, T and Ueki, R and Fukuda, R and Kawakami, S and Okuno, Y and Honda, K and Iwaki, H and Okano, K},
title = {Species-specific bacteriophage-mediated engineering of an artificial microbiome composed of Bacteroides and Phocaeicola species.},
journal = {New biotechnology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.nbt.2026.11.012},
pmid = {43044962},
issn = {1876-4347},
abstract = {Members of the Bacteroides and Phocaeicola genera have been involved in various health- and disease-related states, but their in situ functions have not been clearly elucidated yet. Targeted removal of specific bacterial species using bacteriophages is expected to facilitate in situ functional analysis of gut bacteria. However, the feasibility of species-specific removal in microbiomes including Bacteroides and Phocaeicola species has not been demonstrated, in part due to the limited availability of isolated phages infecting these taxa. We newly isolated two lytic phages infecting Bacteroides uniformis or Bacteroides caccae and evaluated their applicability for species-specific microbiome engineering using an artificial microbiome composed of five Bacteroides and two Phocaeicola species formerly classified as Bacteroides. Adding the B. uniformis phage selectively suppressed the growth of B. uniformis, resulting in 1.16 × 10[5] CFU-equivalent/mL in the presence of the phage compared with 6.01 × 10[7] CFU-equivalent/mL in the absence of the phage, without affecting the growth of nontarget species. In contrast, adding the B. caccae phage decreased the abundance of B. caccae and also significantly increased the bacterial abundance of the nontarget species Bacteroides finegoldii. This growth enhancement was likely mediated, at least in part, by cellular components released upon lysis of B. caccae. The results indicate that species-specific bacteriophage-mediated microbiome engineering is feasible within a defined Bacteroides/Phocaeicola community and can be a basis for subsequent functional analyses and for exploring interspecies growth interactions.},
}
RevDate: 2026-11-17
Biomarkers and molecular determinants of T-cell engager response, resistance and toxicity.
Biochemical pharmacology pii:S0006-2952(26)00996-2 [Epub ahead of print].
T-cell engagers redirect endogenous T cells against malignant cells and have produced clinically meaningful responses across haematological malignancies and selected solid tumours. Responses vary, while cytokine release syndrome, neurotoxicity, infection and on-target, off-tumour injury constrain treatment. Target positivity alone is therefore insufficient for selecting patients, molecules or dosing strategies. This Review synthesises evidence across five interacting domains: host immune reserve and T-cell fitness; engager molecular design and pharmacology; tumour antigen ecology and genomic vulnerability; the tumour immune ecosystem; and toxicity risk. Productive engagement requires functionally competent T cells, adequate active exposure at the tumour site, accessible and persistent antigen, tissue trafficking and calibrated T-cell activation. Candidate host markers include circulating lymphocyte and T-cell subsets, differentiation and exhaustion states, systemic inflammation, prior immunotherapy and microbiome-metabolic features. Molecular format, pharmacokinetics, activation threshold and synapse geometry influence the balance between cytotoxicity and systemic inflammation. Antigen density, coverage, accessibility, heterogeneity and treatment-induced loss shape sensitivity and resistance, whereas suppressive immune cells, stroma and metabolic constraints restrict tissue activity. Circulating tumour DNA, measurable residual disease and soluble antigen can support longitudinal response assessment. Baseline inflammation, cytokine kinetics and normal immune-lineage depletion may inform safety monitoring, but risk factors, pharmacodynamic changes, early-warning signals and manifestations of established toxicity serve different purposes. Most reported markers remain prognostic, pharmacodynamic or useful for resistance classification rather than validated predictors of treatment benefit. Clinical translation requires standardised assays, context-specific thresholds, external validation and prospective trials showing that biomarker-guided decisions improve patient outcomes.
Additional Links: PMID-43044994
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43044994,
year = {2026},
author = {Li, W and Wu, Y and Cheng, M and Wu, S and Liu, M and Zou, L},
title = {Biomarkers and molecular determinants of T-cell engager response, resistance and toxicity.},
journal = {Biochemical pharmacology},
volume = {},
number = {},
pages = {118653},
doi = {10.1016/j.bcp.2026.118653},
pmid = {43044994},
issn = {1873-2968},
abstract = {T-cell engagers redirect endogenous T cells against malignant cells and have produced clinically meaningful responses across haematological malignancies and selected solid tumours. Responses vary, while cytokine release syndrome, neurotoxicity, infection and on-target, off-tumour injury constrain treatment. Target positivity alone is therefore insufficient for selecting patients, molecules or dosing strategies. This Review synthesises evidence across five interacting domains: host immune reserve and T-cell fitness; engager molecular design and pharmacology; tumour antigen ecology and genomic vulnerability; the tumour immune ecosystem; and toxicity risk. Productive engagement requires functionally competent T cells, adequate active exposure at the tumour site, accessible and persistent antigen, tissue trafficking and calibrated T-cell activation. Candidate host markers include circulating lymphocyte and T-cell subsets, differentiation and exhaustion states, systemic inflammation, prior immunotherapy and microbiome-metabolic features. Molecular format, pharmacokinetics, activation threshold and synapse geometry influence the balance between cytotoxicity and systemic inflammation. Antigen density, coverage, accessibility, heterogeneity and treatment-induced loss shape sensitivity and resistance, whereas suppressive immune cells, stroma and metabolic constraints restrict tissue activity. Circulating tumour DNA, measurable residual disease and soluble antigen can support longitudinal response assessment. Baseline inflammation, cytokine kinetics and normal immune-lineage depletion may inform safety monitoring, but risk factors, pharmacodynamic changes, early-warning signals and manifestations of established toxicity serve different purposes. Most reported markers remain prognostic, pharmacodynamic or useful for resistance classification rather than validated predictors of treatment benefit. Clinical translation requires standardised assays, context-specific thresholds, external validation and prospective trials showing that biomarker-guided decisions improve patient outcomes.},
}
RevDate: 2026-11-17
Bidirectional interplay of the gut microbiota and herbal medicine in Alzheimer's disease: mechanisms and therapeutic prospects.
Journal of ethnopharmacology pii:S0378-8741(26)01474-1 [Epub ahead of print].
Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which alterations in the gut microbiota and microbiota-gut-brain axis (MGBA) may contribute to disease-related pathological processes. Herbal medicines have long been used for memory impairment and age-related cognitive disorders and contain bioactive constituents with diverse molecular targets. Increasing evidence suggests that herbal interventions can modulate the gut microbiota, while gut microorganisms can biotransform selected herbal constituents and influence their absorption and biological activity. These reciprocal interactions provide a mechanistic basis for investigating herbal medicine in AD.
AIM OF THE REVIEW: This review summarizes the bidirectional interactions between herbal medicine and the gut microbiota in AD, focusing on microbial composition and metabolites, intestinal barrier function, herbal biotransformation and bioavailability, signaling pathways, and multi-omics approaches.
MATERIALS AND METHODS: A structured narrative literature review was conducted using PubMed, Web of Science, and ScienceDirect for studies published from January 2010 to June 2026. Google Scholar searches and reference-list screening supplemented the database searches. Human, animal, and in vitro studies concerning AD, gut microbiota, herbal interventions, microbial metabolites, biotransformation, and bioavailability were included according to predefined eligibility criteria.
RESULTS: Herbal formulas, extracts, and compounds have been reported to alter gut microbial composition and metabolite profiles, improve intestinal barrier integrity, and influence inflammatory, oxidative, amyloid-β (Aβ)-related, and synaptic pathways relevant to AD. Conversely, the gut microbiota can biotransform selected herbal constituents, thereby altering their absorption and pharmacological properties. Integrated microbiome-metabolome studies also link microbial taxa, metabolites, and host signaling pathways, but most findings remain preclinical or correlational.
CONCLUSIONS: The bidirectional interaction between herbal medicine and the gut microbiota may be relevant to AD treatment. However, current evidence is largely preclinical and clinical validation remains limited. Future studies should clarify microbiota-dependent biotransformation and pharmacokinetics, standardize herbal formulas and dosing, establish causal microbe-metabolite-host relationships, assess long-term safety and herb-drug interactions, and conduct rigorous clinical trials before translation into AD management.
Additional Links: PMID-43045019
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045019,
year = {2026},
author = {Liu, DY and Zhang, F and Ding, K and Zhang, LM and Sun, YW and He, J and Yan, Y and Zhang, WK and Xu, JK},
title = {Bidirectional interplay of the gut microbiota and herbal medicine in Alzheimer's disease: mechanisms and therapeutic prospects.},
journal = {Journal of ethnopharmacology},
volume = {},
number = {},
pages = {122619},
doi = {10.1016/j.jep.2026.122619},
pmid = {43045019},
issn = {1872-7573},
abstract = {Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which alterations in the gut microbiota and microbiota-gut-brain axis (MGBA) may contribute to disease-related pathological processes. Herbal medicines have long been used for memory impairment and age-related cognitive disorders and contain bioactive constituents with diverse molecular targets. Increasing evidence suggests that herbal interventions can modulate the gut microbiota, while gut microorganisms can biotransform selected herbal constituents and influence their absorption and biological activity. These reciprocal interactions provide a mechanistic basis for investigating herbal medicine in AD.
AIM OF THE REVIEW: This review summarizes the bidirectional interactions between herbal medicine and the gut microbiota in AD, focusing on microbial composition and metabolites, intestinal barrier function, herbal biotransformation and bioavailability, signaling pathways, and multi-omics approaches.
MATERIALS AND METHODS: A structured narrative literature review was conducted using PubMed, Web of Science, and ScienceDirect for studies published from January 2010 to June 2026. Google Scholar searches and reference-list screening supplemented the database searches. Human, animal, and in vitro studies concerning AD, gut microbiota, herbal interventions, microbial metabolites, biotransformation, and bioavailability were included according to predefined eligibility criteria.
RESULTS: Herbal formulas, extracts, and compounds have been reported to alter gut microbial composition and metabolite profiles, improve intestinal barrier integrity, and influence inflammatory, oxidative, amyloid-β (Aβ)-related, and synaptic pathways relevant to AD. Conversely, the gut microbiota can biotransform selected herbal constituents, thereby altering their absorption and pharmacological properties. Integrated microbiome-metabolome studies also link microbial taxa, metabolites, and host signaling pathways, but most findings remain preclinical or correlational.
CONCLUSIONS: The bidirectional interaction between herbal medicine and the gut microbiota may be relevant to AD treatment. However, current evidence is largely preclinical and clinical validation remains limited. Future studies should clarify microbiota-dependent biotransformation and pharmacokinetics, standardize herbal formulas and dosing, establish causal microbe-metabolite-host relationships, assess long-term safety and herb-drug interactions, and conduct rigorous clinical trials before translation into AD management.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-17
[Exploring research value and application prospects of intestinal organoids in prevention and treatment of cardiovascular diseases with TCM based on theory of "gut-heart axis"].
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 51(20):5740-5748.
Cardiovascular diseases(CVD) cause a major burden on global health, and their occurrence and development are closely related to gut microbiome dysbiosis and intestinal barrier dysfunction. The theory of "gut-heart axis" reveals the complex bidirectional regulatory network between the gut and the cardiovascular system, providing new avenues for the prevention and treatment of CVD. TCM has unique advantages in preventing and treating CVD due to its multi-target and holistic regulatory effects, whereas the molecular mechanisms through which TCM acts via the "gut-heart axis" require further elucidation. Intestinal organoids, as three-dimensional in vitro models that highly simulate the structure and function of the intestine in vivo, provide a crucial platform for mechanism research. According to the theory of "gut-heart axis" and the technical advantages of intestinal organoids, this article systematically explores how to utilize intestinal organoids to delve into the material basis and pathways of TCM interventions for CVD from multiple dimensions, including intestinal barrier integrity, immune regulation, metabolites, and neuroendocrine mechanisms, aiming to promote the modern development of TCM research and provide new strategies and ideas for the prevention and treatment of CVD.
Additional Links: PMID-43045115
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045115,
year = {2026},
author = {Wu, XP and Wang, JA and Liu, ZY and Huang, LL},
title = {[Exploring research value and application prospects of intestinal organoids in prevention and treatment of cardiovascular diseases with TCM based on theory of "gut-heart axis"].},
journal = {Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica},
volume = {51},
number = {20},
pages = {5740-5748},
doi = {10.19540/j.cnki.cjcmm.20260618.361},
pmid = {43045115},
issn = {1001-5302},
mesh = {*Cardiovascular Diseases/drug therapy/prevention & control/physiopathology/microbiology/metabolism ; Humans ; Animals ; *Organoids/drug effects/metabolism ; *Intestines/drug effects/microbiology ; *Heart/drug effects/physiopathology ; Medicine, Chinese Traditional ; *Drugs, Chinese Herbal/administration & dosage ; Intestinal Barrier Function ; },
abstract = {Cardiovascular diseases(CVD) cause a major burden on global health, and their occurrence and development are closely related to gut microbiome dysbiosis and intestinal barrier dysfunction. The theory of "gut-heart axis" reveals the complex bidirectional regulatory network between the gut and the cardiovascular system, providing new avenues for the prevention and treatment of CVD. TCM has unique advantages in preventing and treating CVD due to its multi-target and holistic regulatory effects, whereas the molecular mechanisms through which TCM acts via the "gut-heart axis" require further elucidation. Intestinal organoids, as three-dimensional in vitro models that highly simulate the structure and function of the intestine in vivo, provide a crucial platform for mechanism research. According to the theory of "gut-heart axis" and the technical advantages of intestinal organoids, this article systematically explores how to utilize intestinal organoids to delve into the material basis and pathways of TCM interventions for CVD from multiple dimensions, including intestinal barrier integrity, immune regulation, metabolites, and neuroendocrine mechanisms, aiming to promote the modern development of TCM research and provide new strategies and ideas for the prevention and treatment of CVD.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Cardiovascular Diseases/drug therapy/prevention & control/physiopathology/microbiology/metabolism
Humans
Animals
*Organoids/drug effects/metabolism
*Intestines/drug effects/microbiology
*Heart/drug effects/physiopathology
Medicine, Chinese Traditional
*Drugs, Chinese Herbal/administration & dosage
Intestinal Barrier Function
RevDate: 2026-11-17
CmpDate: 2026-11-17
Diagnosis and Management of Hepatic Encephalopathy.
Clinics in liver disease, 31(1):45-57.
Hepatic encephalopathy (HE) is a neuropsychiatric complication of acute and chronic liver disease driven by hyperammonemia, systemic inflammation, and portosystemic shunting within the gut-liver-brain axis. Astrocyte dysfunction mediates cerebral swelling in acute liver failure and metabolic disturbances in cirrhosis-associated HE. Diagnosis is clinical, as serum ammonia correlates poorly with severity. Management encompasses identification of precipitating factors, lactulose and rifaximin therapy, nutritional optimization, and shunt-directed interventions in refractory cases. Emerging microbiome-based therapies show promise. HE significantly increases hospitalization, mortality, and caregiver burden, underscoring the need for coordinated multidisciplinary care.
Additional Links: PMID-43045309
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045309,
year = {2027},
author = {Dawod, SM and Victor, DW},
title = {Diagnosis and Management of Hepatic Encephalopathy.},
journal = {Clinics in liver disease},
volume = {31},
number = {1},
pages = {45-57},
doi = {10.1016/j.cld.2026.08.009},
pmid = {43045309},
issn = {1557-8224},
mesh = {Humans ; *Hepatic Encephalopathy/diagnosis/therapy/etiology ; Lactulose/therapeutic use ; Rifaximin/therapeutic use ; Gastrointestinal Agents/therapeutic use ; Rifamycins/therapeutic use ; Hyperammonemia ; Liver Cirrhosis/complications ; Ammonia/blood ; },
abstract = {Hepatic encephalopathy (HE) is a neuropsychiatric complication of acute and chronic liver disease driven by hyperammonemia, systemic inflammation, and portosystemic shunting within the gut-liver-brain axis. Astrocyte dysfunction mediates cerebral swelling in acute liver failure and metabolic disturbances in cirrhosis-associated HE. Diagnosis is clinical, as serum ammonia correlates poorly with severity. Management encompasses identification of precipitating factors, lactulose and rifaximin therapy, nutritional optimization, and shunt-directed interventions in refractory cases. Emerging microbiome-based therapies show promise. HE significantly increases hospitalization, mortality, and caregiver burden, underscoring the need for coordinated multidisciplinary care.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Hepatic Encephalopathy/diagnosis/therapy/etiology
Lactulose/therapeutic use
Rifaximin/therapeutic use
Gastrointestinal Agents/therapeutic use
Rifamycins/therapeutic use
Hyperammonemia
Liver Cirrhosis/complications
Ammonia/blood
RevDate: 2026-11-17
CmpDate: 2026-11-18
From Self-Provisioning Agriculture to Store-Bought Foods: How Adaptive Choices Shape Gut Microbiome Maturation and Metabolic Vulnerability in Rural Maya Populations From Yucatan, Mexico.
American journal of human biology : the official journal of the Human Biology Council, 38(11):.
OBJECTIVES: Determine how increased reliance on store-bought foods alters gut microbiota composition, maturation, and ecological vulnerability in the first 36 months of life in Maya agriculturalists.
METHODS: Shotgun metagenomic data from stool samples of 23 rural Maya mothers, their infants and children under 36 months from households classified by their dependence on cash generating activities as traditional or "transformed" were collected. Microbial community structure was examined using Bray-Curtis clustering, permutational analysis of variance (PERMANOVA), and ecological network modeling. A contemporaneous 24-h food portions study was collected, and nutrient intake was correlated with microbial taxa.
RESULTS: Children from "transformed" households clustered with infants and showed reduced microbial diversity, simplified interaction networks, and higher relative abundances of Bacteroides, Bifidobacterium, and Streptococcus. In contrast, children from traditional households clustered with adults and exhibited higher diversity and enrichment of fiber-adapted taxa, including Clostridium, Prevotella, Faecalibacterium, and Ruminococcus. Network analyses indicated less-integrated, weakly regulated microbial communities in "transformed" children and infants, whereas traditional children and adults displayed denser, competitively structured networks. Diet-microbiome correlations were stronger and more directional in "transformed" children and infants, with positive associations with carbohydrate and fiber intake and widespread negative associations with saturated fat, whereas in traditional children and adults, associations were fewer and weaker.
CONCLUSIONS: Early-life exposure to market-based diets disrupts microbiome maturation, maintaining developmentally immature and diet-sensitive ecosystems beyond infancy. This instability may increase developmental mismatch and metabolic vulnerability in children from nutritionally transitioning populations.
Additional Links: PMID-43045516
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045516,
year = {2026},
author = {Gurri, FD and Peña-Ramírez, YJ and Ruiz-García, W and Labrin-Sotomayor, NY and Vallejo-Nieto, MI and Aelion, CM},
title = {From Self-Provisioning Agriculture to Store-Bought Foods: How Adaptive Choices Shape Gut Microbiome Maturation and Metabolic Vulnerability in Rural Maya Populations From Yucatan, Mexico.},
journal = {American journal of human biology : the official journal of the Human Biology Council},
volume = {38},
number = {11},
pages = {},
doi = {10.1002/ajhb.70361},
pmid = {43045516},
issn = {1520-6300},
support = {CB-CONAHCYT-240697//CONAHCYT/ ; //University of Massachusetts Amherst/ ; },
mesh = {Humans ; Mexico ; Infant ; *Gastrointestinal Microbiome ; Rural Population/statistics & numerical data ; Child, Preschool ; *Agriculture ; Female ; *Diet ; *Food Supply ; },
abstract = {OBJECTIVES: Determine how increased reliance on store-bought foods alters gut microbiota composition, maturation, and ecological vulnerability in the first 36 months of life in Maya agriculturalists.
METHODS: Shotgun metagenomic data from stool samples of 23 rural Maya mothers, their infants and children under 36 months from households classified by their dependence on cash generating activities as traditional or "transformed" were collected. Microbial community structure was examined using Bray-Curtis clustering, permutational analysis of variance (PERMANOVA), and ecological network modeling. A contemporaneous 24-h food portions study was collected, and nutrient intake was correlated with microbial taxa.
RESULTS: Children from "transformed" households clustered with infants and showed reduced microbial diversity, simplified interaction networks, and higher relative abundances of Bacteroides, Bifidobacterium, and Streptococcus. In contrast, children from traditional households clustered with adults and exhibited higher diversity and enrichment of fiber-adapted taxa, including Clostridium, Prevotella, Faecalibacterium, and Ruminococcus. Network analyses indicated less-integrated, weakly regulated microbial communities in "transformed" children and infants, whereas traditional children and adults displayed denser, competitively structured networks. Diet-microbiome correlations were stronger and more directional in "transformed" children and infants, with positive associations with carbohydrate and fiber intake and widespread negative associations with saturated fat, whereas in traditional children and adults, associations were fewer and weaker.
CONCLUSIONS: Early-life exposure to market-based diets disrupts microbiome maturation, maintaining developmentally immature and diet-sensitive ecosystems beyond infancy. This instability may increase developmental mismatch and metabolic vulnerability in children from nutritionally transitioning populations.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Mexico
Infant
*Gastrointestinal Microbiome
Rural Population/statistics & numerical data
Child, Preschool
*Agriculture
Female
*Diet
*Food Supply
RevDate: 2026-11-17
Plant autonomy in a function-rich microbial world.
Trends in microbiology pii:S0966-842X(26)00311-2 [Epub ahead of print].
Plants evolved in environments where microbes already performed key ecological functions. We hypothesize that persistent access to reliable microbial functions may have shaped plant autonomy, favoring reduced investment in costly autonomous processes. We distinguish this from plant-microbe coevolution and propose predictions testable with comparative genomics, crop wild relatives, and experimental evolution.
Additional Links: PMID-43045550
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045550,
year = {2026},
author = {Pylro, VS and Del Bem, LEV and Morais, DK},
title = {Plant autonomy in a function-rich microbial world.},
journal = {Trends in microbiology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.tim.2026.10.013},
pmid = {43045550},
issn = {1878-4380},
abstract = {Plants evolved in environments where microbes already performed key ecological functions. We hypothesize that persistent access to reliable microbial functions may have shaped plant autonomy, favoring reduced investment in costly autonomous processes. We distinguish this from plant-microbe coevolution and propose predictions testable with comparative genomics, crop wild relatives, and experimental evolution.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-18
Herbivory-triggered assemblage of sunflower rhizosphere microbiome enhances herbivore tolerance through plant-soil feedback.
NPJ biofilms and microbiomes, 12(1):.
Rhizosphere microbial communities are key drivers of plant immunity and stress responses, and plants recruit beneficial microorganisms under stress. Herbivorous insects pose a major agricultural challenge, yet how leaf herbivory influences root-associated microbiomes and whether these changes generate plant-soil feedbacks that alter plant defense phenotypes remain poorly understood. With a two-phase greenhouse bioassay, we investigated how leaf herbivory with Spodoptera exigua affects sunflower rhizosphere microbiome (Conditioning Phase) and whether herbivory-induced microbial shifts modulate plant defense traits via plant-soil feedback (Feedback Phase). Herbivory triggered significant changes in bacterial community structure and dynamics, as well as in microbiome functional profile, whereas effects on fungal community were weaker. Several bacterial taxa and functional groups were enriched, co-occurrence networks became more complex, and community assembly showed increased stochasticity. Herbivore-driven microbial legacies increased plant nutrient content and photosynthetic pigments via plant-soil feedback. After subsequent infestation, resistance-related traits and herbivore performance were unaffected, but tolerance-related traits were significantly altered. Plants grown with a herbivory-conditioned microbiome were smaller but exhibited reduced biomass loss after attack, indicating enhanced compensatory growth. Overall, herbivory reshaped the sunflower rhizosphere microbiome and generated a soil legacy that enhances plant tolerance, highlighting the role of microbiome-mediated plant-soil feedbacks in plant adaptation to herbivory.
Additional Links: PMID-43045719
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045719,
year = {2026},
author = {Rodríguez-Blanco, PM and Zitlalpopoca-Hernández, G and González-Holgado, MG and Fernández, I and Ossowicki, A and Carrión, VJ and Carro, L and Martínez-Medina, A},
title = {Herbivory-triggered assemblage of sunflower rhizosphere microbiome enhances herbivore tolerance through plant-soil feedback.},
journal = {NPJ biofilms and microbiomes},
volume = {12},
number = {1},
pages = {},
pmid = {43045719},
issn = {2055-5008},
support = {PRE2022-101400//Ministerio de Ciencia e Innovación/ ; PID2021-128318OA-I00//Ministerio de Ciencia e Innovación/ ; ERC-2023-COG: 101124883 MIMIR/ERC_/European Research Council/International ; },
mesh = {*Helianthus/microbiology/physiology ; *Rhizosphere ; Animals ; *Soil Microbiology ; *Herbivory ; *Microbiota ; Spodoptera/physiology ; Plant Roots/microbiology ; Bacteria/classification/genetics/isolation & purification ; Fungi/classification/genetics ; Plant Leaves ; },
abstract = {Rhizosphere microbial communities are key drivers of plant immunity and stress responses, and plants recruit beneficial microorganisms under stress. Herbivorous insects pose a major agricultural challenge, yet how leaf herbivory influences root-associated microbiomes and whether these changes generate plant-soil feedbacks that alter plant defense phenotypes remain poorly understood. With a two-phase greenhouse bioassay, we investigated how leaf herbivory with Spodoptera exigua affects sunflower rhizosphere microbiome (Conditioning Phase) and whether herbivory-induced microbial shifts modulate plant defense traits via plant-soil feedback (Feedback Phase). Herbivory triggered significant changes in bacterial community structure and dynamics, as well as in microbiome functional profile, whereas effects on fungal community were weaker. Several bacterial taxa and functional groups were enriched, co-occurrence networks became more complex, and community assembly showed increased stochasticity. Herbivore-driven microbial legacies increased plant nutrient content and photosynthetic pigments via plant-soil feedback. After subsequent infestation, resistance-related traits and herbivore performance were unaffected, but tolerance-related traits were significantly altered. Plants grown with a herbivory-conditioned microbiome were smaller but exhibited reduced biomass loss after attack, indicating enhanced compensatory growth. Overall, herbivory reshaped the sunflower rhizosphere microbiome and generated a soil legacy that enhances plant tolerance, highlighting the role of microbiome-mediated plant-soil feedbacks in plant adaptation to herbivory.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Helianthus/microbiology/physiology
*Rhizosphere
Animals
*Soil Microbiology
*Herbivory
*Microbiota
Spodoptera/physiology
Plant Roots/microbiology
Bacteria/classification/genetics/isolation & purification
Fungi/classification/genetics
Plant Leaves
RevDate: 2026-11-17
CmpDate: 2026-11-18
Oral Lactiplantibacillus plantarum accelerates nucleotide excision repair and suppresses UVB-induced checkpoint immunosuppression.
NPJ biofilms and microbiomes, 12(1):.
Ultraviolet B (UVB) exposure initiates skin carcinogenesis by generating persistent DNA photolesions and immunosuppressive microenvironment. Whether a defined probiotic can reinforce genome maintenance while counteracting UVB-driven inflammatory-checkpoint programs remains unclear. Here we show that oral administration of Lactiplantibacillus plantarum TH-B59 accelerates cyclobutane pyrimidine dimers (CPDs) resolution and dampens γ-H2AX accumulation in UVB-irradiated BALB/c skin. TH-B59 restores the expression of nucleotide excision repair-related genes (Xpc, Ercc4, Xpa, and Ercc5) and attenuates UVB-induced PI3K/AKT signaling. In parallel, TH-B59 suppresses UVB-induced NF-κB/COX-2/PGE2 activation, reduces PD-L1 induction, and enhances IL-12 transcription, consistent with a shift toward immune surveillance. Fecal microbiota profiling identifies UVB-associated dysbiosis and a TH-B59-linked microbiome reconfiguration, with integrative correlation/network analyses connecting L. plantarum abundance to increased NER gene expression and reduced inflammatory mediators across gut and skin. Whole-genome sequencing supports TH-B59 as a bacteriocin-encoding, stress-tolerant strain lacking transferable antibiotic resistance and virulence determinants. Collectively, TH-B59 couples photolesion clearance with inflammatory-checkpoint remodeling to mitigate early UVB programs that drive photocarcinogenesis.
Additional Links: PMID-43045753
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045753,
year = {2026},
author = {Zheng, Q and Thi Minh Nguyen, T and Gwak, YS and Lee, SY and Kim, JW and Yi, GS and Choi, JW and Chun, SH and Choi, YR and Bae, CI and Jeong, J and Choi, J and Kim, MJ and Park, SJ and Yi, TH},
title = {Oral Lactiplantibacillus plantarum accelerates nucleotide excision repair and suppresses UVB-induced checkpoint immunosuppression.},
journal = {NPJ biofilms and microbiomes},
volume = {12},
number = {1},
pages = {},
pmid = {43045753},
issn = {2055-5008},
mesh = {Animals ; *Excision Repair ; *Ultraviolet Rays/adverse effects ; *Lactiplantibacillus plantarum/physiology ; Pyrimidine Dimers/metabolism ; Mice, Inbred BALB C ; Skin/radiation effects/immunology ; Mice ; Administration, Oral ; Signal Transduction ; Interleukin-12/genetics/metabolism ; DNA-Binding Proteins/genetics ; NF-kappa B/metabolism ; B7-H1 Antigen/genetics ; Female ; Cyclooxygenase 2/metabolism/genetics ; *DNA Repair ; Xeroderma Pigmentosum Group A Protein/genetics ; Immune Tolerance ; },
abstract = {Ultraviolet B (UVB) exposure initiates skin carcinogenesis by generating persistent DNA photolesions and immunosuppressive microenvironment. Whether a defined probiotic can reinforce genome maintenance while counteracting UVB-driven inflammatory-checkpoint programs remains unclear. Here we show that oral administration of Lactiplantibacillus plantarum TH-B59 accelerates cyclobutane pyrimidine dimers (CPDs) resolution and dampens γ-H2AX accumulation in UVB-irradiated BALB/c skin. TH-B59 restores the expression of nucleotide excision repair-related genes (Xpc, Ercc4, Xpa, and Ercc5) and attenuates UVB-induced PI3K/AKT signaling. In parallel, TH-B59 suppresses UVB-induced NF-κB/COX-2/PGE2 activation, reduces PD-L1 induction, and enhances IL-12 transcription, consistent with a shift toward immune surveillance. Fecal microbiota profiling identifies UVB-associated dysbiosis and a TH-B59-linked microbiome reconfiguration, with integrative correlation/network analyses connecting L. plantarum abundance to increased NER gene expression and reduced inflammatory mediators across gut and skin. Whole-genome sequencing supports TH-B59 as a bacteriocin-encoding, stress-tolerant strain lacking transferable antibiotic resistance and virulence determinants. Collectively, TH-B59 couples photolesion clearance with inflammatory-checkpoint remodeling to mitigate early UVB programs that drive photocarcinogenesis.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Excision Repair
*Ultraviolet Rays/adverse effects
*Lactiplantibacillus plantarum/physiology
Pyrimidine Dimers/metabolism
Mice, Inbred BALB C
Skin/radiation effects/immunology
Mice
Administration, Oral
Signal Transduction
Interleukin-12/genetics/metabolism
DNA-Binding Proteins/genetics
NF-kappa B/metabolism
B7-H1 Antigen/genetics
Female
Cyclooxygenase 2/metabolism/genetics
*DNA Repair
Xeroderma Pigmentosum Group A Protein/genetics
Immune Tolerance
RevDate: 2026-11-17
CmpDate: 2026-11-18
Tissue-specific metabolomics in experimental HFpEF reveals hepatic remodelling modulated by SGLT2 inhibition.
Cellular and molecular life sciences : CMLS, 83(1):.
BACKGROUND: Recent favourable clinical trials of sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like-peptide-1 (GLP-1) agonists have substantially changed the management landscape for heart failure with preserved ejection fraction (HFpEF) patients. However, the organ-level metabolic mechanisms underpinning these benefits remain incompletely understood and it is unclear how these therapies reshape inter-organ metabolic crosstalk in HFpEF. In many patients, the HFpEF phenotype appears to result from an intersection between abnormal cardiovascular physiology together with metabolic and inflammatory changes.
METHODS: Experimental HFpEF was induced in 18-month-old female C57BL/6J mice with a high-fat diet for 12 weeks, an angiotensin II infusion beginning at week 6, with age-matched controls, to establish a cardiometabolic phenotype. Treatment with the SGLT2 inhibitor Dapagliflozin (Dapa) was administered for 6 weeks, concurrently with AngII administration. In addition to comprehensive cardiovascular and inflammatory phenotyping, we conducted metabolomic profiling of the heart, liver and plasma and performed 16S rRNA sequencing to characterise alterations in the gut microbiome.
RESULTS: Characteristic cardiometabolic and inflammatory profiles were observed in experimental HFpEF, including obesity, hypertension, diastolic dysfunction, hepatic steatosis, and gut dysbiosis. Despite no detectable improvement in echocardiographic function at endpoint, Dapa induced distinct hepatic remodelling, with increased citraconate, restoration of succinate, modulation of branched-chain amino acid and ketone pathways and reduced oxidative stress markers. Aromatic amino acid metabolism and gut-derived metabolites were broadly disrupted across heart, liver, and plasma.
CONCLUSION: HFpEF is defined by complex, tissue-specific metabolic derangements. SGLT2 inhibition primarily remodeled the hepatic metabolome, positioning the liver as a central hub of cardio-renal-liver crosstalk. These findings suggest that extra-cardiac metabolic pathways, particularly liver-centered mechanisms, may contribute to the therapeutic benefits of SGLT2 inhibitors in HFpEF and provide new insights into inter-organ metabolic regulation.
Additional Links: PMID-43045850
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045850,
year = {2026},
author = {Kiyar, M and Magaye, R and Bailey, S and Wang, X and Nuon, R and Kiriazis, H and Grigolon, K and Donner, DG and Snelson, M and Antonacci, S and Harper, RL and Marques, FZ and O'Sullivan, JF and Wang, BH and Kaye, DM},
title = {Tissue-specific metabolomics in experimental HFpEF reveals hepatic remodelling modulated by SGLT2 inhibition.},
journal = {Cellular and molecular life sciences : CMLS},
volume = {83},
number = {1},
pages = {},
pmid = {43045850},
issn = {1420-9071},
mesh = {Animals ; Female ; *Liver/metabolism/drug effects/pathology ; *Sodium-Glucose Transporter 2 Inhibitors/pharmacology ; *Metabolomics/methods ; *Benzhydryl Compounds/pharmacology ; *Heart Failure/metabolism/drug therapy/pathology/physiopathology ; Mice, Inbred C57BL ; *Glucosides/pharmacology ; Mice ; Stroke Volume/drug effects ; Metabolome/drug effects ; Sodium-Glucose Transporter 2/metabolism ; Myocardium/metabolism ; Angiotensin II ; Disease Models, Animal ; },
abstract = {BACKGROUND: Recent favourable clinical trials of sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like-peptide-1 (GLP-1) agonists have substantially changed the management landscape for heart failure with preserved ejection fraction (HFpEF) patients. However, the organ-level metabolic mechanisms underpinning these benefits remain incompletely understood and it is unclear how these therapies reshape inter-organ metabolic crosstalk in HFpEF. In many patients, the HFpEF phenotype appears to result from an intersection between abnormal cardiovascular physiology together with metabolic and inflammatory changes.
METHODS: Experimental HFpEF was induced in 18-month-old female C57BL/6J mice with a high-fat diet for 12 weeks, an angiotensin II infusion beginning at week 6, with age-matched controls, to establish a cardiometabolic phenotype. Treatment with the SGLT2 inhibitor Dapagliflozin (Dapa) was administered for 6 weeks, concurrently with AngII administration. In addition to comprehensive cardiovascular and inflammatory phenotyping, we conducted metabolomic profiling of the heart, liver and plasma and performed 16S rRNA sequencing to characterise alterations in the gut microbiome.
RESULTS: Characteristic cardiometabolic and inflammatory profiles were observed in experimental HFpEF, including obesity, hypertension, diastolic dysfunction, hepatic steatosis, and gut dysbiosis. Despite no detectable improvement in echocardiographic function at endpoint, Dapa induced distinct hepatic remodelling, with increased citraconate, restoration of succinate, modulation of branched-chain amino acid and ketone pathways and reduced oxidative stress markers. Aromatic amino acid metabolism and gut-derived metabolites were broadly disrupted across heart, liver, and plasma.
CONCLUSION: HFpEF is defined by complex, tissue-specific metabolic derangements. SGLT2 inhibition primarily remodeled the hepatic metabolome, positioning the liver as a central hub of cardio-renal-liver crosstalk. These findings suggest that extra-cardiac metabolic pathways, particularly liver-centered mechanisms, may contribute to the therapeutic benefits of SGLT2 inhibitors in HFpEF and provide new insights into inter-organ metabolic regulation.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
Female
*Liver/metabolism/drug effects/pathology
*Sodium-Glucose Transporter 2 Inhibitors/pharmacology
*Metabolomics/methods
*Benzhydryl Compounds/pharmacology
*Heart Failure/metabolism/drug therapy/pathology/physiopathology
Mice, Inbred C57BL
*Glucosides/pharmacology
Mice
Stroke Volume/drug effects
Metabolome/drug effects
Sodium-Glucose Transporter 2/metabolism
Myocardium/metabolism
Angiotensin II
Disease Models, Animal
RevDate: 2026-11-17
CmpDate: 2026-11-18
The Human Microbiome, Dysbiosis, and Microbiome-Based Therapies.
Advances in experimental medicine and biology, 1513:1-30.
The human microbiome is a home to a broad spectrum of microorganisms that coexist with the host and are essential for sustaining good health by regulating energy metabolism, immune system and barrier functions. Basic physiological functions are maintained via a homeostatic microbiome while a dysbiotic microbiome is attributed to a wide range of disorders including metabolic, gastrointestinal, neurological, immunological disorders and certain types of cancer. Therefore, host-microbe interaction has become an important area of modern biomedical research.This chapter covers the framework and advancement of the human microbiome, major contributing factors in driving microbial communities and the mechanistic pathways by which microbes regulate host health. Dysbiosis-linked diseases and the developing prospect of microbiome-based therapeutic interventions are primarily emphasized in the chapter. From conventional methods like dietary modifications, prebiotics, probiotics, synbiotics and postbiotics to advanced personalized therapeutic strategies involving faecal microbiota transplantation, engineered microbial consortia and live biotherapeutics products for precise management of dysbiotic microbiomes are notably addressed.The importance of integrating conventional treatment methods with modern microbiome-based therapies is significantly highlighted in the chapter. These approaches work in a complementary manner to mitigate dysbiotic conditions, restore the microbial homeostasis, and reduce dysbiosis-related diseases. Target-specific microbiome-based therapy and microbiome-derived therapeutics are progressively developing contributing to evolutionize personalized and mechanism-specific treatment approaches and these strategies provide an intriguing pathway towards improving preventive and curative measures for overall well-being of host health.
Additional Links: PMID-43045918
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045918,
year = {2026},
author = {Dhar, S and Paul, S and Ahmed, T and Nath, D and Olakojo, TA and Azeez, OI and Oridupa, OA},
title = {The Human Microbiome, Dysbiosis, and Microbiome-Based Therapies.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {1-30},
pmid = {43045918},
issn = {0065-2598},
mesh = {Humans ; *Dysbiosis/microbiology/therapy ; Probiotics/therapeutic use ; Prebiotics/administration & dosage ; *Microbiota/physiology ; Fecal Microbiota Transplantation ; *Gastrointestinal Microbiome/physiology ; Host Microbial Interactions ; Animals ; },
abstract = {The human microbiome is a home to a broad spectrum of microorganisms that coexist with the host and are essential for sustaining good health by regulating energy metabolism, immune system and barrier functions. Basic physiological functions are maintained via a homeostatic microbiome while a dysbiotic microbiome is attributed to a wide range of disorders including metabolic, gastrointestinal, neurological, immunological disorders and certain types of cancer. Therefore, host-microbe interaction has become an important area of modern biomedical research.This chapter covers the framework and advancement of the human microbiome, major contributing factors in driving microbial communities and the mechanistic pathways by which microbes regulate host health. Dysbiosis-linked diseases and the developing prospect of microbiome-based therapeutic interventions are primarily emphasized in the chapter. From conventional methods like dietary modifications, prebiotics, probiotics, synbiotics and postbiotics to advanced personalized therapeutic strategies involving faecal microbiota transplantation, engineered microbial consortia and live biotherapeutics products for precise management of dysbiotic microbiomes are notably addressed.The importance of integrating conventional treatment methods with modern microbiome-based therapies is significantly highlighted in the chapter. These approaches work in a complementary manner to mitigate dysbiotic conditions, restore the microbial homeostasis, and reduce dysbiosis-related diseases. Target-specific microbiome-based therapy and microbiome-derived therapeutics are progressively developing contributing to evolutionize personalized and mechanism-specific treatment approaches and these strategies provide an intriguing pathway towards improving preventive and curative measures for overall well-being of host health.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Dysbiosis/microbiology/therapy
Probiotics/therapeutic use
Prebiotics/administration & dosage
*Microbiota/physiology
Fecal Microbiota Transplantation
*Gastrointestinal Microbiome/physiology
Host Microbial Interactions
Animals
RevDate: 2026-11-18
CmpDate: 2026-11-18
Probiotics, Prebiotics, Synbiotics and the Gut-Brain Axis in Precision Health.
Advances in experimental medicine and biology, 1513:41-89.
The gastrointestinal system synthesizes a considerable proportion of the body's neurotransmitters and neuromodulators and is consequently increasingly acknowledged as the "second brain." Advances in high-throughput sequencing technology following the Human Genome Project have considerably expanded understanding of the gut microbiome, igniting increasing interest in microbiota-based medicinal approaches. Probiotics, defined as live microorganisms offering health benefits when provided in suitable doses, have proven potential in the management of chronic inflammatory and immune-mediated illnesses through immunomodulatory and barrier-protective pathways. The therapeutic efficacy of probiotics is strain-specific and influenced by dosage, host physiology, and environmental factors; consequently, strain selection prioritizes functional attributes such as gastrointestinal survivability, adhesion to intestinal epithelium, modulation of resident microbiota, and antimicrobial activity. Despite promising clinical and preclinical evidence, comprehensive elucidation of the systemic effects of probiotics and identification of novel symbiotic strains remain critical research priorities, underscoring the need for interdisciplinary collaboration between pharmacologists and microbiologists.Another highly integral aspect of nutrition and medical research involves prebiotics. Prebiotics are defined as selectively fermentable substances that promote the activity and number of beneficial microbes in the gastrointestinal region. Oligosaccharides and inulin are examples that add to the betterment of metabolic homeostasis and immune system functioning. The rising consumer education and innovation have led to large-scale expansion in the prebiotics industry, which strengthens the connection between microbiology, nutrition, and health economics.Synbiotics that combine both probiotics and prebiotics represent a cutting-edge strategy that can enhance the resistance and stability of gut microbiota, especially in the gut-brain axis (GBA) microbiota network. New multiomics approaches have revealed the intricate relationships that exist between the microbiota and the host that modulate neuropathological, metabolic, and immunological outcomes. There is a great variation in the microbial populations and corresponding metabolic products among different human subjects that clearly reveals the need to develop microbiota-targeting therapies.
Additional Links: PMID-43045920
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045920,
year = {2026},
author = {Sikarwar, MS and Siddiqui, Z and Rathi, VK},
title = {Probiotics, Prebiotics, Synbiotics and the Gut-Brain Axis in Precision Health.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {41-89},
pmid = {43045920},
issn = {0065-2598},
mesh = {Humans ; *Probiotics/therapeutic use/administration & dosage ; *Prebiotics/administration & dosage ; *Synbiotics/administration & dosage ; *Gastrointestinal Microbiome/physiology ; Animals ; *Precision Medicine/methods ; *Brain/physiology ; *Brain-Gut Axis/physiology ; *Gastrointestinal Tract/microbiology ; },
abstract = {The gastrointestinal system synthesizes a considerable proportion of the body's neurotransmitters and neuromodulators and is consequently increasingly acknowledged as the "second brain." Advances in high-throughput sequencing technology following the Human Genome Project have considerably expanded understanding of the gut microbiome, igniting increasing interest in microbiota-based medicinal approaches. Probiotics, defined as live microorganisms offering health benefits when provided in suitable doses, have proven potential in the management of chronic inflammatory and immune-mediated illnesses through immunomodulatory and barrier-protective pathways. The therapeutic efficacy of probiotics is strain-specific and influenced by dosage, host physiology, and environmental factors; consequently, strain selection prioritizes functional attributes such as gastrointestinal survivability, adhesion to intestinal epithelium, modulation of resident microbiota, and antimicrobial activity. Despite promising clinical and preclinical evidence, comprehensive elucidation of the systemic effects of probiotics and identification of novel symbiotic strains remain critical research priorities, underscoring the need for interdisciplinary collaboration between pharmacologists and microbiologists.Another highly integral aspect of nutrition and medical research involves prebiotics. Prebiotics are defined as selectively fermentable substances that promote the activity and number of beneficial microbes in the gastrointestinal region. Oligosaccharides and inulin are examples that add to the betterment of metabolic homeostasis and immune system functioning. The rising consumer education and innovation have led to large-scale expansion in the prebiotics industry, which strengthens the connection between microbiology, nutrition, and health economics.Synbiotics that combine both probiotics and prebiotics represent a cutting-edge strategy that can enhance the resistance and stability of gut microbiota, especially in the gut-brain axis (GBA) microbiota network. New multiomics approaches have revealed the intricate relationships that exist between the microbiota and the host that modulate neuropathological, metabolic, and immunological outcomes. There is a great variation in the microbial populations and corresponding metabolic products among different human subjects that clearly reveals the need to develop microbiota-targeting therapies.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Probiotics/therapeutic use/administration & dosage
*Prebiotics/administration & dosage
*Synbiotics/administration & dosage
*Gastrointestinal Microbiome/physiology
Animals
*Precision Medicine/methods
*Brain/physiology
*Brain-Gut Axis/physiology
*Gastrointestinal Tract/microbiology
RevDate: 2026-11-17
CmpDate: 2026-11-18
Microbiome Modulation in Cancer Prevention, Personalized Nutrition, and Precision Medicine.
Advances in experimental medicine and biology, 1513:91-119.
Human microbiome which is a dynamic ecosystem of trillions of microorganisms is important in health and disease, especially in the establishment of cancer in ways such as through inflammation, generation of genotoxins, and immune modulation. This report aims to discuss the concept of microbiome modulation as a preventive and curative approach to cancer along with personalized nutrition and precision medicine. Dysbiosis is also associated with several types of cancers, such as colorectal, breast, and pancreatic whereby pathobionts, such as Fusobacterium nucleatum contribute to tumorigenesis, and beneficial taxa induce protective metabolites such as short-chain fatty acids. Eubiosis is restored through modulation methods such as probiotics, prebiotics, synbiotics, fecal microbiota transplantation, selective antibiotics, and dietary interventions and increase the efficacy of immunotherapy and decrease immunotherapy resistance. Anticancer properties of natural products, including curcumin, resveratrol, and berberine, can be summed up by their capacity to moderate microbiota in terms of achieving anti-inflammatory phenotypes. Gut microbes metabolically modify the food substances to produce bioactive metabolite, which affects the host immunity and epigenetics. Precision nutrition is a system that directs individuals to make diets based on multiomics data, microbiomics included, thereby predicting reactions and avoiding chronic diseases. Genome-scale reconstructions of metabolic models and machine learning computational models mimic these interactions to make personalized predictions. The problems are variability of microbiomes, standardization of data, ethical issues, and causality. In sum, this synthesis provides evidence that the microbiome can help make oncology a treatment centered on reaction to health issues but prevention based on individual needs and subjected to artificial intelligence personalization to allow administering the highest quality health to all the patients.
Additional Links: PMID-43045921
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045921,
year = {2026},
author = {Arora, M and Gaurav, A and Chaudhary, A and Laskar, TT},
title = {Microbiome Modulation in Cancer Prevention, Personalized Nutrition, and Precision Medicine.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {91-119},
pmid = {43045921},
issn = {0065-2598},
mesh = {Humans ; *Precision Medicine/methods ; *Neoplasms/prevention & control/microbiology ; *Gastrointestinal Microbiome/drug effects ; Probiotics/therapeutic use ; Prebiotics/administration & dosage ; Dysbiosis/microbiology ; Animals ; Multiomics ; Nutritional Status ; },
abstract = {Human microbiome which is a dynamic ecosystem of trillions of microorganisms is important in health and disease, especially in the establishment of cancer in ways such as through inflammation, generation of genotoxins, and immune modulation. This report aims to discuss the concept of microbiome modulation as a preventive and curative approach to cancer along with personalized nutrition and precision medicine. Dysbiosis is also associated with several types of cancers, such as colorectal, breast, and pancreatic whereby pathobionts, such as Fusobacterium nucleatum contribute to tumorigenesis, and beneficial taxa induce protective metabolites such as short-chain fatty acids. Eubiosis is restored through modulation methods such as probiotics, prebiotics, synbiotics, fecal microbiota transplantation, selective antibiotics, and dietary interventions and increase the efficacy of immunotherapy and decrease immunotherapy resistance. Anticancer properties of natural products, including curcumin, resveratrol, and berberine, can be summed up by their capacity to moderate microbiota in terms of achieving anti-inflammatory phenotypes. Gut microbes metabolically modify the food substances to produce bioactive metabolite, which affects the host immunity and epigenetics. Precision nutrition is a system that directs individuals to make diets based on multiomics data, microbiomics included, thereby predicting reactions and avoiding chronic diseases. Genome-scale reconstructions of metabolic models and machine learning computational models mimic these interactions to make personalized predictions. The problems are variability of microbiomes, standardization of data, ethical issues, and causality. In sum, this synthesis provides evidence that the microbiome can help make oncology a treatment centered on reaction to health issues but prevention based on individual needs and subjected to artificial intelligence personalization to allow administering the highest quality health to all the patients.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Precision Medicine/methods
*Neoplasms/prevention & control/microbiology
*Gastrointestinal Microbiome/drug effects
Probiotics/therapeutic use
Prebiotics/administration & dosage
Dysbiosis/microbiology
Animals
Multiomics
Nutritional Status
RevDate: 2026-11-18
CmpDate: 2026-11-18
Overview of In Silico Methods in Microbiome Studies.
Advances in experimental medicine and biology, 1513:121-131.
The recent advances in in-silico platforms have paved a way in rapid evolving of bioinformatics-based microbiome platforms such as multiomics techniques like amplicon sequencing or metagenomic, metatranscriptomics datasets. Advances in silico approach in such platforms have created vast datasets which provide effective relevant biological interpretations. This chapter provides a comprehensive overview of various computational software or packages applied for microbiome studies. Such frameworks highlight taxonomic profiling of microbial communities, microbes-host interaction, their functional annotations and disease relevance. Various established pipelines use machine learning and artificial intelligence algorithmic platforms which are discussed, putting an emphasizes on microbial profiling of samples, their comparative performance with preclinical/clinical evidences. Choice of relevant packages or collective pipelines significantly influence quantitative interpretation of microbiome datasets; the core biological inferences showed consistency yet increase in development of standard pipelines with precision is an unwaivable requirement for improving in silico dependent microbiome studies. The present study further explores applications and challenges of in silico platforms in relation to microbiome and their limited mechanistic studies. Future perspectives emphasize in development of microbial cloud-based pipelines, integrative multiomics and benchmarking in-silico platforms. Overall, this work highlights the present in silico platforms for microbiome studies of predictive modeling with mechanistic approach, shifting a focus towards an improved and better platforms from descriptive to predictive translational microbiome modeling.
Additional Links: PMID-43045922
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045922,
year = {2026},
author = {Basar, N and Nath, P and Das, M and Gunasekaran, S and Nath, D},
title = {Overview of In Silico Methods in Microbiome Studies.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {121-131},
pmid = {43045922},
issn = {0065-2598},
mesh = {*Microbiota/genetics ; Humans ; *Computer Simulation ; *Metagenomics/methods ; Software ; Multiomics ; Machine Learning ; *Computational Biology/methods ; Animals ; },
abstract = {The recent advances in in-silico platforms have paved a way in rapid evolving of bioinformatics-based microbiome platforms such as multiomics techniques like amplicon sequencing or metagenomic, metatranscriptomics datasets. Advances in silico approach in such platforms have created vast datasets which provide effective relevant biological interpretations. This chapter provides a comprehensive overview of various computational software or packages applied for microbiome studies. Such frameworks highlight taxonomic profiling of microbial communities, microbes-host interaction, their functional annotations and disease relevance. Various established pipelines use machine learning and artificial intelligence algorithmic platforms which are discussed, putting an emphasizes on microbial profiling of samples, their comparative performance with preclinical/clinical evidences. Choice of relevant packages or collective pipelines significantly influence quantitative interpretation of microbiome datasets; the core biological inferences showed consistency yet increase in development of standard pipelines with precision is an unwaivable requirement for improving in silico dependent microbiome studies. The present study further explores applications and challenges of in silico platforms in relation to microbiome and their limited mechanistic studies. Future perspectives emphasize in development of microbial cloud-based pipelines, integrative multiomics and benchmarking in-silico platforms. Overall, this work highlights the present in silico platforms for microbiome studies of predictive modeling with mechanistic approach, shifting a focus towards an improved and better platforms from descriptive to predictive translational microbiome modeling.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Microbiota/genetics
Humans
*Computer Simulation
*Metagenomics/methods
Software
Multiomics
Machine Learning
*Computational Biology/methods
Animals
RevDate: 2026-11-17
CmpDate: 2026-11-18
Technological Frontiers in Microbiome Research: From Metagenomic Profiling to Functional and Spatial Characterization.
Advances in experimental medicine and biology, 1513:133-167.
The field of microbiome research is rapidly transitioning from descriptive taxonomic inventories to mechanistic systems biology, and the state-of-the-art technologies that enable this shift are summarized in this chapter, from short-read to third-generation long-read sequencing (PacBio HiFi, Oxford Nanopore), which now routinely assemble complete, circular genomes (MAGs), resolve genomic repeats and structural variants, and allow for detailed characterization of mobile genetic elements, which changes the way we think about microbial architecture. The chapter also discusses the emergence of holo-omics, the multi-layered analytical framework that combines metagenomics with metatranscriptomics (MET), metaproteomics (MEP), and metabolomics (MEB) to bridge the gap between genetic potential and realized phenotype, which brings its own challenges, primarily statistical challenges of data compositionality and dimensionality. To address these bottlenecks, the chapter reviews the renaissance of artificial intelligence (AI) in bioinformatics, including the application of deep learning models (COMEBin) for genome recovery and large language models for functional prediction. It also discusses the spatial and cellular frontiers of the field, where single-cell genomics and spatial metabolomics are mapping the detailed biogeography of host-microbe interactions at the micron scale. Finally, the chapter highlights that resolving the reproducibility crisis in the field is key to the clinical translation of these technologies, from rational microbiome engineering to personalized live biotherapeutics.
Additional Links: PMID-43045923
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045923,
year = {2026},
author = {Roy, A and Gupta, N and Prasad, HK},
title = {Technological Frontiers in Microbiome Research: From Metagenomic Profiling to Functional and Spatial Characterization.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {133-167},
pmid = {43045923},
issn = {0065-2598},
mesh = {*Metagenomics/methods/trends ; *Microbiota/genetics ; Humans ; Metabolomics/methods ; Multiomics ; Animals ; High-Throughput Nucleotide Sequencing ; *Bacteria/genetics/classification/metabolism ; Proteomics/methods ; },
abstract = {The field of microbiome research is rapidly transitioning from descriptive taxonomic inventories to mechanistic systems biology, and the state-of-the-art technologies that enable this shift are summarized in this chapter, from short-read to third-generation long-read sequencing (PacBio HiFi, Oxford Nanopore), which now routinely assemble complete, circular genomes (MAGs), resolve genomic repeats and structural variants, and allow for detailed characterization of mobile genetic elements, which changes the way we think about microbial architecture. The chapter also discusses the emergence of holo-omics, the multi-layered analytical framework that combines metagenomics with metatranscriptomics (MET), metaproteomics (MEP), and metabolomics (MEB) to bridge the gap between genetic potential and realized phenotype, which brings its own challenges, primarily statistical challenges of data compositionality and dimensionality. To address these bottlenecks, the chapter reviews the renaissance of artificial intelligence (AI) in bioinformatics, including the application of deep learning models (COMEBin) for genome recovery and large language models for functional prediction. It also discusses the spatial and cellular frontiers of the field, where single-cell genomics and spatial metabolomics are mapping the detailed biogeography of host-microbe interactions at the micron scale. Finally, the chapter highlights that resolving the reproducibility crisis in the field is key to the clinical translation of these technologies, from rational microbiome engineering to personalized live biotherapeutics.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Metagenomics/methods/trends
*Microbiota/genetics
Humans
Metabolomics/methods
Multiomics
Animals
High-Throughput Nucleotide Sequencing
*Bacteria/genetics/classification/metabolism
Proteomics/methods
RevDate: 2026-11-17
CmpDate: 2026-11-18
Machine Learning Applications in Predicting Microbial Interactions.
Advances in experimental medicine and biology, 1513:169-212.
Health, the course of disease and treatment results are all significantly impacted by microbial interactions. However, it is challenging to examine the behaviour of microbial communities using conventional methods due to their complexity and diversity. A strong framework for identifying patterns in sizable and intricate biological datasets is provided by machine learning (ML). The use of machine learning (ML) to forecast microbial activity and comprehend how microbial populations react to drugs and other external factors is examined in this chapter. Microbiological data analysis has made extensive use of popular machine learning techniques like support vector machines, random forests and neural networks. These methods enable prediction of interspecies interactions, identification of metabolic interdependencies and classification of microbial taxa. ML models may also identify minute differences in microbial responses that affect treatment results by combining genomic, transcriptomic and metabolomic datasets. For instance, multi-omics integration can enhance predictions of microbial behaviour under stress through linking changes in gene expression with metabolite profiles. The chapter also covers how drug-induced dysbiosis, a disruption of the microbial balance brought on by medications, can be predicted using machine learning. ML techniques can identify possible changes in the composition of the microbiome and evaluate susceptibility to dysbiosis. The creation of therapeutic and preventative measures can be influenced by these forecasts. Together, these applications show how machine learning (ML) enhances drug-microbe interaction predictions, expands our knowledge of microbial dynamics and promotes precision medicine in microbiome and pharmaceutical research.
Additional Links: PMID-43045924
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045924,
year = {2026},
author = {Uddin, MJ and Sadiq, SB and Snigdha, NN and Sinthea, RS and Suchi, JY and Anamika, IJ},
title = {Machine Learning Applications in Predicting Microbial Interactions.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {169-212},
pmid = {43045924},
issn = {0065-2598},
mesh = {*Machine Learning ; Humans ; Predictive Learning Models ; *Microbial Interactions/drug effects ; Multiomics ; *Microbiota/drug effects/physiology ; Random Forest ; Prediction Algorithms ; Dysbiosis/microbiology/chemically induced ; Support Vector Machine ; Animals ; Soft Computing ; Classification Algorithms ; *Bacteria/genetics/metabolism/drug effects ; },
abstract = {Health, the course of disease and treatment results are all significantly impacted by microbial interactions. However, it is challenging to examine the behaviour of microbial communities using conventional methods due to their complexity and diversity. A strong framework for identifying patterns in sizable and intricate biological datasets is provided by machine learning (ML). The use of machine learning (ML) to forecast microbial activity and comprehend how microbial populations react to drugs and other external factors is examined in this chapter. Microbiological data analysis has made extensive use of popular machine learning techniques like support vector machines, random forests and neural networks. These methods enable prediction of interspecies interactions, identification of metabolic interdependencies and classification of microbial taxa. ML models may also identify minute differences in microbial responses that affect treatment results by combining genomic, transcriptomic and metabolomic datasets. For instance, multi-omics integration can enhance predictions of microbial behaviour under stress through linking changes in gene expression with metabolite profiles. The chapter also covers how drug-induced dysbiosis, a disruption of the microbial balance brought on by medications, can be predicted using machine learning. ML techniques can identify possible changes in the composition of the microbiome and evaluate susceptibility to dysbiosis. The creation of therapeutic and preventative measures can be influenced by these forecasts. Together, these applications show how machine learning (ML) enhances drug-microbe interaction predictions, expands our knowledge of microbial dynamics and promotes precision medicine in microbiome and pharmaceutical research.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Machine Learning
Humans
Predictive Learning Models
*Microbial Interactions/drug effects
Multiomics
*Microbiota/drug effects/physiology
Random Forest
Prediction Algorithms
Dysbiosis/microbiology/chemically induced
Support Vector Machine
Animals
Soft Computing
Classification Algorithms
*Bacteria/genetics/metabolism/drug effects
RevDate: 2026-11-17
CmpDate: 2026-11-18
Multi-omics Integration for Microbiome Analysis.
Advances in experimental medicine and biology, 1513:213-250.
Multi-omics integration combines different omics datasets to reveal the complex and dynamic relationship between the host and its microbiome. Integrating such data remains challenging, as they contain high dimensionality, data heterogeneity, limited interpretability, insufficient standardization, and the use of different analytical approaches. It requires careful data collection, advanced computational analysis, and a systemic setting to interpret the complex biological information. Advances in next-generation sequencing (NGS) and microbial community profiling have enabled multi-omic investigations that include genomics, transcriptomics, metabolomics, and proteomics, providing a holistic understanding of these systems. Integrating these diverse data layers is essential for elucidating microbial functions and their impact on hosts and environments. The emerging holo-omics framework conceptualizes the host and its microbiome as a unified holobiont, providing a powerful perspective for studying mechanisms that maintain holobiont homeostasis. As multi-omics technologies advance, sophisticated statistical and computational methods are being developed to characterize biological variation and improve integrative analyses. Nonetheless, challenges remain, including data heterogeneity, methodological biases, and risks of false positives or negatives. This study aims to highlight the importance of integrating omics technologies like genomics, transcriptomics, proteomics, and metabolomics in generating comprehensive biological data and to gain a deeper insight into microbiome-host interactions. It also presents the current analytical and computational methods used and addresses major challenges for integrating multi-omics interactions. Recent work emphasizes strategies to reduce analytical errors and refine integration frameworks. Furthermore, innovations such as large language models offer promising tools for enhancing multi-omics interpretation, enabling more robust and comprehensive insights into host-microbiome systems.
Additional Links: PMID-43045925
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045925,
year = {2026},
author = {Uddin, MJ and Dina, AA and Khandaker, S and Anamika, IJ and Siddique, SN and Anika, AJ},
title = {Multi-omics Integration for Microbiome Analysis.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {213-250},
pmid = {43045925},
issn = {0065-2598},
mesh = {*Multiomics ; *Microbiota/genetics ; Metabolomics/methods ; Humans ; Proteomics/methods ; *Genomics/methods ; Animals ; Computational Biology/methods ; High-Throughput Nucleotide Sequencing ; Host Microbial Interactions ; },
abstract = {Multi-omics integration combines different omics datasets to reveal the complex and dynamic relationship between the host and its microbiome. Integrating such data remains challenging, as they contain high dimensionality, data heterogeneity, limited interpretability, insufficient standardization, and the use of different analytical approaches. It requires careful data collection, advanced computational analysis, and a systemic setting to interpret the complex biological information. Advances in next-generation sequencing (NGS) and microbial community profiling have enabled multi-omic investigations that include genomics, transcriptomics, metabolomics, and proteomics, providing a holistic understanding of these systems. Integrating these diverse data layers is essential for elucidating microbial functions and their impact on hosts and environments. The emerging holo-omics framework conceptualizes the host and its microbiome as a unified holobiont, providing a powerful perspective for studying mechanisms that maintain holobiont homeostasis. As multi-omics technologies advance, sophisticated statistical and computational methods are being developed to characterize biological variation and improve integrative analyses. Nonetheless, challenges remain, including data heterogeneity, methodological biases, and risks of false positives or negatives. This study aims to highlight the importance of integrating omics technologies like genomics, transcriptomics, proteomics, and metabolomics in generating comprehensive biological data and to gain a deeper insight into microbiome-host interactions. It also presents the current analytical and computational methods used and addresses major challenges for integrating multi-omics interactions. Recent work emphasizes strategies to reduce analytical errors and refine integration frameworks. Furthermore, innovations such as large language models offer promising tools for enhancing multi-omics interpretation, enabling more robust and comprehensive insights into host-microbiome systems.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Multiomics
*Microbiota/genetics
Metabolomics/methods
Humans
Proteomics/methods
*Genomics/methods
Animals
Computational Biology/methods
High-Throughput Nucleotide Sequencing
Host Microbial Interactions
RevDate: 2026-11-18
CmpDate: 2026-11-18
Virtual Screening of Microbiome Modulators: Mechanisms, Computational Approaches, and Therapeutic Applications.
Advances in experimental medicine and biology, 1513:251-271.
The human gut microbiome regulates metabolism, immunity, and brain function through interactions between microbes and the host. Probiotics, prebiotics, synbiotics, and postbiotics reshape these communities to influence systemic health outcomes. These interventions address gut inflammation, obesity, infections, neurological disorders, and cancer. Virtual screening identifies compounds that target microbial or host-microbe pathways with high efficiently. This review describes modulator mechanisms with a focus on metabolic disorders, , diabetes, neurodegenerative diseases, and immune regulation. It highlights next-generation probiotics, precision probiotics, and microbiome‑derived therapeutic metabolites. This chapter presents microbiome-targeted therapies and future research directions enabled by through virtual screening.
Additional Links: PMID-43045926
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045926,
year = {2026},
author = {Nahar, L and Nath, D and Talukdar, AD and Sarker, SD},
title = {Virtual Screening of Microbiome Modulators: Mechanisms, Computational Approaches, and Therapeutic Applications.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {251-271},
pmid = {43045926},
issn = {0065-2598},
mesh = {Humans ; *Probiotics/therapeutic use ; *Gastrointestinal Microbiome/drug effects/physiology ; Animals ; Prebiotics ; },
abstract = {The human gut microbiome regulates metabolism, immunity, and brain function through interactions between microbes and the host. Probiotics, prebiotics, synbiotics, and postbiotics reshape these communities to influence systemic health outcomes. These interventions address gut inflammation, obesity, infections, neurological disorders, and cancer. Virtual screening identifies compounds that target microbial or host-microbe pathways with high efficiently. This review describes modulator mechanisms with a focus on metabolic disorders, , diabetes, neurodegenerative diseases, and immune regulation. It highlights next-generation probiotics, precision probiotics, and microbiome‑derived therapeutic metabolites. This chapter presents microbiome-targeted therapies and future research directions enabled by through virtual screening.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Probiotics/therapeutic use
*Gastrointestinal Microbiome/drug effects/physiology
Animals
Prebiotics
RevDate: 2026-11-17
CmpDate: 2026-11-18
Molecular Docking and Dynamics for Microbial Target Prediction.
Advances in experimental medicine and biology, 1513:273-279.
Predicting microbial targets is crucial for comprehending the mechanisms of various infectious diseases, which aids in the creation of novel medications by identifying biological components in microorganisms that can be targeted for intervention. To understand the mechanism, the microbial target prediction procedure mostly uses computational techniques (bioinformatics and machine learning) followed by experimental confirmation. In recent decades, the in silico approaches have attracted attention from microbial target prediction due to their potential to diminish high costs, low success rates, and extensive timelines of traditional microbial target prediction methods. This in silico process in microbial target prediction uses computational techniques to find possible targets for drug development by simulating drug-target interactions and forecasting biological behavior. These investigations use methods such as molecular docking to examine binding affinities between a drug candidate and a microbial target protein, subtractive genomics to identify critical microbial genes, and a variety of computational models to forecast a molecule's absorption, distribution, metabolism, excretion, and toxicity (ADMET). In silico approaches save money and time by reducing the number of possible targets and therapeutic candidates, however, experimental assays are still needed to validate the in silico results. Strong drug-protein binding does not, however, invariably result in the microorganism ceasing to develop or dying. These could be caused by a number of factors, including as the medicine not getting to the target inside the microbe, being digested or broken down, microbial resistance mechanisms, etc. Therefore considering the importance of in silico approaches in microbial target prediction, the usefulness of molecular docking and dynamics studies for microbial target prediction will be covered in this chapter, along with some recent developments in this area.
Additional Links: PMID-43045927
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045927,
year = {2026},
author = {Das, SK and Sahariah, B and Deka, MK},
title = {Molecular Docking and Dynamics for Microbial Target Prediction.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {273-279},
pmid = {43045927},
issn = {0065-2598},
mesh = {*Molecular Docking Simulation ; Humans ; *Bacteria/drug effects/metabolism/genetics ; *Molecular Dynamics Simulation ; Protein Binding ; *Bacterial Proteins/chemistry/metabolism ; },
abstract = {Predicting microbial targets is crucial for comprehending the mechanisms of various infectious diseases, which aids in the creation of novel medications by identifying biological components in microorganisms that can be targeted for intervention. To understand the mechanism, the microbial target prediction procedure mostly uses computational techniques (bioinformatics and machine learning) followed by experimental confirmation. In recent decades, the in silico approaches have attracted attention from microbial target prediction due to their potential to diminish high costs, low success rates, and extensive timelines of traditional microbial target prediction methods. This in silico process in microbial target prediction uses computational techniques to find possible targets for drug development by simulating drug-target interactions and forecasting biological behavior. These investigations use methods such as molecular docking to examine binding affinities between a drug candidate and a microbial target protein, subtractive genomics to identify critical microbial genes, and a variety of computational models to forecast a molecule's absorption, distribution, metabolism, excretion, and toxicity (ADMET). In silico approaches save money and time by reducing the number of possible targets and therapeutic candidates, however, experimental assays are still needed to validate the in silico results. Strong drug-protein binding does not, however, invariably result in the microorganism ceasing to develop or dying. These could be caused by a number of factors, including as the medicine not getting to the target inside the microbe, being digested or broken down, microbial resistance mechanisms, etc. Therefore considering the importance of in silico approaches in microbial target prediction, the usefulness of molecular docking and dynamics studies for microbial target prediction will be covered in this chapter, along with some recent developments in this area.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Molecular Docking Simulation
Humans
*Bacteria/drug effects/metabolism/genetics
*Molecular Dynamics Simulation
Protein Binding
*Bacterial Proteins/chemistry/metabolism
RevDate: 2026-11-18
CmpDate: 2026-11-18
Network Biology in Microbiome Modulation.
Advances in experimental medicine and biology, 1513:281-312.
Interactions between microbes and the host, together with the shared environments, form closely intertwined systems that can be studied as biological networks, which help us understand the underlying intricacies of such systems. Even still, the vast diversity and heterogeneity of these systems continue to make research involving their data a hassle. In this regard, over the past couple of decades, Network Biology has emerged as an efficient means of collection, analysis and interpretation of data obtained from such biological networks, especially microbial metabolic networks. Large databases and computational tools, along with publicly accessible online resources, have helped microbiome researchers integrate Network Biology and in silico approaches. Here, we introduce the fundamentals of a biological network, general methods of Network Biology, and means of mapping microbial networks for modulation of the microbiome. We also have explored databases for Network Biology studied such as PubMed, KEGG, MetaHIT, MiMeDB, Reactome, MGnify, BioCyc, along with open-source software tools, microbiome software, genomics software, evolutionary analysis software, sequencing methods, bioinformatics tools and online-available research tools applicable in microbiome modulation studies dependent on Network Biology principles. Lastly, we have discussed how these studies apply themselves in the health and medical sectors.
Additional Links: PMID-43045928
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045928,
year = {2026},
author = {Kc, BM and Koirala, A and Rauniyar, A and Buddhacharya, G and Shakya, G and Thapa, M and Dhungel, R and Adhikari, S and Karki, S and Gauchan, DP and Lamichhane, J and Timalsina, PM},
title = {Network Biology in Microbiome Modulation.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {281-312},
pmid = {43045928},
issn = {0065-2598},
mesh = {*Microbiota/physiology ; Humans ; Computational Biology/methods ; *Metabolic Networks and Pathways ; Software ; *Bacteria/metabolism/genetics ; Animals ; },
abstract = {Interactions between microbes and the host, together with the shared environments, form closely intertwined systems that can be studied as biological networks, which help us understand the underlying intricacies of such systems. Even still, the vast diversity and heterogeneity of these systems continue to make research involving their data a hassle. In this regard, over the past couple of decades, Network Biology has emerged as an efficient means of collection, analysis and interpretation of data obtained from such biological networks, especially microbial metabolic networks. Large databases and computational tools, along with publicly accessible online resources, have helped microbiome researchers integrate Network Biology and in silico approaches. Here, we introduce the fundamentals of a biological network, general methods of Network Biology, and means of mapping microbial networks for modulation of the microbiome. We also have explored databases for Network Biology studied such as PubMed, KEGG, MetaHIT, MiMeDB, Reactome, MGnify, BioCyc, along with open-source software tools, microbiome software, genomics software, evolutionary analysis software, sequencing methods, bioinformatics tools and online-available research tools applicable in microbiome modulation studies dependent on Network Biology principles. Lastly, we have discussed how these studies apply themselves in the health and medical sectors.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Microbiota/physiology
Humans
Computational Biology/methods
*Metabolic Networks and Pathways
Software
*Bacteria/metabolism/genetics
Animals
RevDate: 2026-11-18
CmpDate: 2026-11-18
AI-Based Tools for Predicting Gut Age Index and Health Status.
Advances in experimental medicine and biology, 1513:313-322.
The microbiota of the human gastrointestinal tract plays a vital role in overall well-being, influencing metabolic pathways, immune responses, and even brain function. Dysbiosis, disrupted microbial balance, is linked to disorders like IBD, obesity, and colorectal cancer. Conventional gut microbiome investigation approaches are limited by their restricted specificity, error, and failure to address functional diversity, as well as their reliance on gene-marker surveys, which often overlook rare microbes. Recent developments in artificial intelligence (AI) have significantly enhanced the accuracy of gut health diagnosis and prediction through the large-scale analysis of complex microbiome datasets, enabling the identification of patterns and connections that traditional statistical methods cannot. Tools including MiCoDe, GMWI2, CRCpred, DeepMicro, MicrobiomeAnalyst, GutBug, and QIIME 2 are built using AI methods, such as random forest modelling, Support Vector Machine (SVM), and network-based inference. These tools are revolutionising predictive gut microbiome analysis by allowing for early disease detection, risk evaluation, and personalised recommendations to therapies such as probiotics or dietary adjustments. Nonetheless, these developments in AI-based technologies encounter issues related to data standards, confidentiality, sample variety, and regional bias, which hinder the potential of these AI-driven tools in clinical practice. Further research on employing federated learning and the use of hybrid AI technologies can improve the transparency and reliability of these tools, since these tools can transform gut microbiome research into effective diagnostics and therapeutics for improving and optimising human gut health. This chapter explores the most recent advances in AI-powered approaches for predicting gut health, focusing on their procedures, effectiveness, and future medical implications.
Additional Links: PMID-43045929
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045929,
year = {2026},
author = {Begum, S and Mazumder, PB and Das, G and Patra, JK},
title = {AI-Based Tools for Predicting Gut Age Index and Health Status.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {313-322},
pmid = {43045929},
issn = {0065-2598},
mesh = {Humans ; *Artificial Intelligence ; *Gastrointestinal Microbiome/physiology ; *Health Status ; *Gastrointestinal Tract/microbiology ; Predictive Learning Models ; Prediction Algorithms ; },
abstract = {The microbiota of the human gastrointestinal tract plays a vital role in overall well-being, influencing metabolic pathways, immune responses, and even brain function. Dysbiosis, disrupted microbial balance, is linked to disorders like IBD, obesity, and colorectal cancer. Conventional gut microbiome investigation approaches are limited by their restricted specificity, error, and failure to address functional diversity, as well as their reliance on gene-marker surveys, which often overlook rare microbes. Recent developments in artificial intelligence (AI) have significantly enhanced the accuracy of gut health diagnosis and prediction through the large-scale analysis of complex microbiome datasets, enabling the identification of patterns and connections that traditional statistical methods cannot. Tools including MiCoDe, GMWI2, CRCpred, DeepMicro, MicrobiomeAnalyst, GutBug, and QIIME 2 are built using AI methods, such as random forest modelling, Support Vector Machine (SVM), and network-based inference. These tools are revolutionising predictive gut microbiome analysis by allowing for early disease detection, risk evaluation, and personalised recommendations to therapies such as probiotics or dietary adjustments. Nonetheless, these developments in AI-based technologies encounter issues related to data standards, confidentiality, sample variety, and regional bias, which hinder the potential of these AI-driven tools in clinical practice. Further research on employing federated learning and the use of hybrid AI technologies can improve the transparency and reliability of these tools, since these tools can transform gut microbiome research into effective diagnostics and therapeutics for improving and optimising human gut health. This chapter explores the most recent advances in AI-powered approaches for predicting gut health, focusing on their procedures, effectiveness, and future medical implications.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Artificial Intelligence
*Gastrointestinal Microbiome/physiology
*Health Status
*Gastrointestinal Tract/microbiology
Predictive Learning Models
Prediction Algorithms
RevDate: 2026-11-17
CmpDate: 2026-11-18
Systems Biology Models in Microbiome Therapeutics.
Advances in experimental medicine and biology, 1513:323-334.
Systems biology is an approach that integrates omics technologies such as genomics, transcriptomics, proteomics, metabolomics, and metagenomics with computational modelling tools for understanding complex biological systems. Systems biology approaches help to understand and capture dynamic interactions between microbial communities and the host, including metabolic cross-feeding, predicting emergent properties, and ecological relationships that influence host health and disease. This chapter reviews the use of different systems biology models used in microbiome therapeutics. The models include genome-scale metabolic models, ecological models, and multiscale simulations, which enable the prediction of microbial behaviour, their community dynamics, and host-microbe interactions. Large-scale studies such as the Human Microbiome Project, MetaHIT, and targeted dietary or probiotic interventional studies demonstrate how these integrated multi-omics and computational frameworks can facilitate the rational design of probiotics, engineered microbial consortia, and even lead to predicting personalized therapeutic strategies. Thus, the systems biology approach can be used in applications of drug discovery and precision medicine, including the prediction of drug-microbiome interactions, identification of microbial targets, and optimization of patient-specific interventions. Systems biology approaches, therefore, provide a platform for microbiome-informed therapeutics, supporting mechanistic insights, precision interventions, and accelerated translation from research to clinical application despite challenges such as individual variation and computational limitations.
Additional Links: PMID-43045930
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045930,
year = {2026},
author = {Dalukdeniya, DACK and Rathnayaka, RMUSK},
title = {Systems Biology Models in Microbiome Therapeutics.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {323-334},
pmid = {43045930},
issn = {0065-2598},
mesh = {*Systems Biology/methods ; Humans ; *Probiotics/therapeutic use ; Multiomics ; *Microbiota ; *Models, Biological ; Precision Medicine/methods ; Animals ; Host Microbial Interactions ; *Gastrointestinal Microbiome/drug effects ; },
abstract = {Systems biology is an approach that integrates omics technologies such as genomics, transcriptomics, proteomics, metabolomics, and metagenomics with computational modelling tools for understanding complex biological systems. Systems biology approaches help to understand and capture dynamic interactions between microbial communities and the host, including metabolic cross-feeding, predicting emergent properties, and ecological relationships that influence host health and disease. This chapter reviews the use of different systems biology models used in microbiome therapeutics. The models include genome-scale metabolic models, ecological models, and multiscale simulations, which enable the prediction of microbial behaviour, their community dynamics, and host-microbe interactions. Large-scale studies such as the Human Microbiome Project, MetaHIT, and targeted dietary or probiotic interventional studies demonstrate how these integrated multi-omics and computational frameworks can facilitate the rational design of probiotics, engineered microbial consortia, and even lead to predicting personalized therapeutic strategies. Thus, the systems biology approach can be used in applications of drug discovery and precision medicine, including the prediction of drug-microbiome interactions, identification of microbial targets, and optimization of patient-specific interventions. Systems biology approaches, therefore, provide a platform for microbiome-informed therapeutics, supporting mechanistic insights, precision interventions, and accelerated translation from research to clinical application despite challenges such as individual variation and computational limitations.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Systems Biology/methods
Humans
*Probiotics/therapeutic use
Multiomics
*Microbiota
*Models, Biological
Precision Medicine/methods
Animals
Host Microbial Interactions
*Gastrointestinal Microbiome/drug effects
RevDate: 2026-11-17
CmpDate: 2026-11-18
The Ethical and Regulatory Considerations in Microbiome-Based Research and Therapeutics.
Advances in experimental medicine and biology, 1513:335-349.
The human microbiome is transforming biomedical studies, clinical innovation, and the development of therapeutics. Gut microbiota is involved in vital activities of immunity, metabolism, nutrition, and homeostasis between the host and the microbe. Systems biology and sequencing technology have helped in the bench-to-bedside transformation of knowledge of microbiomes and their therapeutic applications, such as faecal microbiota transplantation (FMT), FDA-approved live biotherapeutic products (LBPs), engineered probiotics, and interventions designed by synthetic biology. Innovation also comes up with certain challenges like complicated ethical, regulatory, and governance dilemmas. Microbiome data have the potential to reveal personal information like lifestyle, health condition, and environmental exposure, which create privacy hazards. Reidentifications are also possible due to the complexity of the data. Scientific uncertainty and the long-term effects of the microbiome add to the complexity of informed consent. Donor selection, pathogen transmission, and adverse clinical events highlight why its regulation should be highly adaptive and strict. The international regulatory framework of microbiome-based treatments is not uniform. Manufacturing standards, quality-control requirements, and post-marketing surveillance systems require much attention. Global research cooperation and innovation are hampered because of these discrepancies, which also causes inequalities in patient access. Low- and middle-income countries (LMICs) such as India experience other challenges associated with capacity building of regulations and equal access to new therapies to every individual in the society. Microbiome data should be the representation of the whole population, not specific to any region; it becomes ethically challenging due to cultural diversity and data sovereignty. The application of artificial intelligence and sophisticated analytics to microbiome studies also brings some ethical issues of bias in algorithms, transparency, accountability, and fairness, especially when non-representative datasets are used to form the model. This chapter emphasizes that ethical microbiome therapeutics in clinical practice would necessitate proactive, coordinated, and global harmonized governance, but not reactive regulation. It is time to think and convert disjointed national strategies into an international harmonized regulatory frameworks that create an effective line on donor screening, manufacturing uniformity, analytical validation, safety checks, and assurance on quality. Simultaneously, the process of informed consent should be re-imagined as a dynamic and continuous involvement, openly discussing the possibility of risks over the long-term use, the use of secondary data, their biobanking, commercialization, and sharing of benefits, and capacity building in LMICs. To prevent harm to participant autonomy and trust, enhancing biobank governance is possible by enhancing clear policies regarding the ownership, access, reuse, and incidental findings. The systems of ethical oversight should also resolve the issues of conflicts of interest and commercial pressures. This chapter highlights that responsible human microbiome stewardship is the need of the hour. It is a mandatory activity to promote harmonized regulation, culturally sensitive ethical conduct, and policy creation based on equity. Such an ethically informed and globally coordinated course of action alone can see the full therapeutic potential of interventions based on microbiomes fulfilled at the same time as protecting individual rights, public trust, and common welfare.
Additional Links: PMID-43045931
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045931,
year = {2026},
author = {Giri, KR and Kothiwale, N and Palandurkar, K and Giri, RR and Trigunayat, A},
title = {The Ethical and Regulatory Considerations in Microbiome-Based Research and Therapeutics.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {335-349},
pmid = {43045931},
issn = {0065-2598},
mesh = {Humans ; *Fecal Microbiota Transplantation/ethics ; Probiotics/therapeutic use ; *Gastrointestinal Microbiome ; *Microbiota ; *Biomedical Research/ethics/legislation & jurisprudence ; },
abstract = {The human microbiome is transforming biomedical studies, clinical innovation, and the development of therapeutics. Gut microbiota is involved in vital activities of immunity, metabolism, nutrition, and homeostasis between the host and the microbe. Systems biology and sequencing technology have helped in the bench-to-bedside transformation of knowledge of microbiomes and their therapeutic applications, such as faecal microbiota transplantation (FMT), FDA-approved live biotherapeutic products (LBPs), engineered probiotics, and interventions designed by synthetic biology. Innovation also comes up with certain challenges like complicated ethical, regulatory, and governance dilemmas. Microbiome data have the potential to reveal personal information like lifestyle, health condition, and environmental exposure, which create privacy hazards. Reidentifications are also possible due to the complexity of the data. Scientific uncertainty and the long-term effects of the microbiome add to the complexity of informed consent. Donor selection, pathogen transmission, and adverse clinical events highlight why its regulation should be highly adaptive and strict. The international regulatory framework of microbiome-based treatments is not uniform. Manufacturing standards, quality-control requirements, and post-marketing surveillance systems require much attention. Global research cooperation and innovation are hampered because of these discrepancies, which also causes inequalities in patient access. Low- and middle-income countries (LMICs) such as India experience other challenges associated with capacity building of regulations and equal access to new therapies to every individual in the society. Microbiome data should be the representation of the whole population, not specific to any region; it becomes ethically challenging due to cultural diversity and data sovereignty. The application of artificial intelligence and sophisticated analytics to microbiome studies also brings some ethical issues of bias in algorithms, transparency, accountability, and fairness, especially when non-representative datasets are used to form the model. This chapter emphasizes that ethical microbiome therapeutics in clinical practice would necessitate proactive, coordinated, and global harmonized governance, but not reactive regulation. It is time to think and convert disjointed national strategies into an international harmonized regulatory frameworks that create an effective line on donor screening, manufacturing uniformity, analytical validation, safety checks, and assurance on quality. Simultaneously, the process of informed consent should be re-imagined as a dynamic and continuous involvement, openly discussing the possibility of risks over the long-term use, the use of secondary data, their biobanking, commercialization, and sharing of benefits, and capacity building in LMICs. To prevent harm to participant autonomy and trust, enhancing biobank governance is possible by enhancing clear policies regarding the ownership, access, reuse, and incidental findings. The systems of ethical oversight should also resolve the issues of conflicts of interest and commercial pressures. This chapter highlights that responsible human microbiome stewardship is the need of the hour. It is a mandatory activity to promote harmonized regulation, culturally sensitive ethical conduct, and policy creation based on equity. Such an ethically informed and globally coordinated course of action alone can see the full therapeutic potential of interventions based on microbiomes fulfilled at the same time as protecting individual rights, public trust, and common welfare.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Fecal Microbiota Transplantation/ethics
Probiotics/therapeutic use
*Gastrointestinal Microbiome
*Microbiota
*Biomedical Research/ethics/legislation & jurisprudence
RevDate: 2026-11-17
CmpDate: 2026-11-18
Translating Microbiome Research into Clinical Practice.
Advances in experimental medicine and biology, 1513:351-378.
The human microbiome can be defined as the collection of microorganisms living in and on the human body, and it plays an essential role in maintaining health and preventing disease. These microbial communities influence digestion, metabolism, immunity, and even brain function. When the balance of these microbes is disturbed, a condition called dysbiosis can occur, leading to various diseases such as inflammatory bowel disease (IBD), obesity, diabetes, allergies, and neurological disorders. Recent advances in high-throughput sequencing and bioinformatics have made it possible to study the composition and functions of the microbiome in greater detail. This knowledge has opened new opportunities for developing microbiome-based therapies, including probiotics, prebiotics, synbiotics, postbiotics, and microbiota transplantation. Among these, faecal microbiota transplantation (FMT) has shown remarkable success in treating recurrent Clostridioides difficile infections (rCDI). This chapter explores the journey of microbiome research from basic laboratory studies to clinical applications. It discusses key stages of the translational pathway, including discovery, preclinical models, clinical trials, regulatory challenges, and ethical considerations, highlighting the promise of microbiome science for future personalized and disease-preventive medicine.
Additional Links: PMID-43045932
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045932,
year = {2026},
author = {Mandal, A and Shome, S and Sen, S and Wenzel, M},
title = {Translating Microbiome Research into Clinical Practice.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {351-378},
pmid = {43045932},
issn = {0065-2598},
mesh = {Humans ; *Translational Research, Biomedical/methods ; Animals ; Fecal Microbiota Transplantation/methods ; Probiotics/therapeutic use ; *Microbiota/physiology ; Precision Medicine/methods ; Prebiotics/administration & dosage ; *Dysbiosis/microbiology/therapy ; *Gastrointestinal Microbiome ; },
abstract = {The human microbiome can be defined as the collection of microorganisms living in and on the human body, and it plays an essential role in maintaining health and preventing disease. These microbial communities influence digestion, metabolism, immunity, and even brain function. When the balance of these microbes is disturbed, a condition called dysbiosis can occur, leading to various diseases such as inflammatory bowel disease (IBD), obesity, diabetes, allergies, and neurological disorders. Recent advances in high-throughput sequencing and bioinformatics have made it possible to study the composition and functions of the microbiome in greater detail. This knowledge has opened new opportunities for developing microbiome-based therapies, including probiotics, prebiotics, synbiotics, postbiotics, and microbiota transplantation. Among these, faecal microbiota transplantation (FMT) has shown remarkable success in treating recurrent Clostridioides difficile infections (rCDI). This chapter explores the journey of microbiome research from basic laboratory studies to clinical applications. It discusses key stages of the translational pathway, including discovery, preclinical models, clinical trials, regulatory challenges, and ethical considerations, highlighting the promise of microbiome science for future personalized and disease-preventive medicine.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Translational Research, Biomedical/methods
Animals
Fecal Microbiota Transplantation/methods
Probiotics/therapeutic use
*Microbiota/physiology
Precision Medicine/methods
Prebiotics/administration & dosage
*Dysbiosis/microbiology/therapy
*Gastrointestinal Microbiome
RevDate: 2026-11-17
CmpDate: 2026-11-18
Future Direction in Gut Microbiome Modulation.
Advances in experimental medicine and biology, 1513:379-394.
The human gut microbiome has gradually moved from the margins of physiology to something much closer to the centre of the conversation. It shapes how food is broken down, helps train the immune system, nudges metabolic balance, and even appears to influence brain function, though exactly how remains open to debate. New tools, especially high-throughput sequencing, multi-omics workflows, and increasingly sophisticated computational models, have made it possible to look beyond who is there and begin asking what these microbes might be doing. Even so, working with human microbiomes is rarely straightforward. No two people carry the same microbial community, and small differences in diet, medication, or lifestyle can produce large shifts in composition and function. Add to that the lack of standardisation across studies, and it becomes difficult to draw firm causal links rather than correlations. Still, the associations keep accumulating. Altered microbial communities have been linked to conditions as varied as type 2 diabetes, colorectal cancer, neurodegenerative disorders, and chronic gut inflammation. These connections have naturally pushed interest towards ways of deliberately reshaping the gut ecosystem. Rather than treating microbiome modulation as a simple add-on, this chapter approaches it as a form of ecosystem management guided by precision data. Traditional strategies such as probiotics, prebiotics, and synbiotics are placed alongside newer ideas, including modulation driven by microbial metabolites, targeted mineral supplementation, engineered probiotic strains, synthetic microbial consortia, and even attempts to edit microbial communities in situ. The underlying argument is that these interventions make the most sense when paired with predictive metagenomic and metabolic models, which can help anticipate how a given microbiome might respond, or resist change altogether. That said, the path from concept to practice is not smooth. Long-term clinical evidence is still sparse, microbial engraftment remains unpredictable, and scaling personalised approaches beyond small cohorts poses obvious logistical challenges. Regulation is another unresolved piece of the puzzle, particularly when interventions blur the line between food, supplement, and therapy. There are also broader ecological questions. Introducing or reshaping microbial communities may have consequences that extend beyond individual patients. By keeping these constraints in view, the chapter aims to temper optimism with realism and to sketch a future in which precision microbiome interventions are developed carefully, tested rigorously, and applied where they are most likely to make a meaningful difference, especially for nutritionally vulnerable groups.
Additional Links: PMID-43045933
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43045933,
year = {2026},
author = {Das, R and Das, S and Tamang, B},
title = {Future Direction in Gut Microbiome Modulation.},
journal = {Advances in experimental medicine and biology},
volume = {1513},
number = {},
pages = {379-394},
pmid = {43045933},
issn = {0065-2598},
mesh = {Humans ; Probiotics/therapeutic use/administration & dosage ; *Gastrointestinal Microbiome/physiology/drug effects ; Prebiotics/administration & dosage ; Animals ; Synbiotics/administration & dosage ; Multiomics ; },
abstract = {The human gut microbiome has gradually moved from the margins of physiology to something much closer to the centre of the conversation. It shapes how food is broken down, helps train the immune system, nudges metabolic balance, and even appears to influence brain function, though exactly how remains open to debate. New tools, especially high-throughput sequencing, multi-omics workflows, and increasingly sophisticated computational models, have made it possible to look beyond who is there and begin asking what these microbes might be doing. Even so, working with human microbiomes is rarely straightforward. No two people carry the same microbial community, and small differences in diet, medication, or lifestyle can produce large shifts in composition and function. Add to that the lack of standardisation across studies, and it becomes difficult to draw firm causal links rather than correlations. Still, the associations keep accumulating. Altered microbial communities have been linked to conditions as varied as type 2 diabetes, colorectal cancer, neurodegenerative disorders, and chronic gut inflammation. These connections have naturally pushed interest towards ways of deliberately reshaping the gut ecosystem. Rather than treating microbiome modulation as a simple add-on, this chapter approaches it as a form of ecosystem management guided by precision data. Traditional strategies such as probiotics, prebiotics, and synbiotics are placed alongside newer ideas, including modulation driven by microbial metabolites, targeted mineral supplementation, engineered probiotic strains, synthetic microbial consortia, and even attempts to edit microbial communities in situ. The underlying argument is that these interventions make the most sense when paired with predictive metagenomic and metabolic models, which can help anticipate how a given microbiome might respond, or resist change altogether. That said, the path from concept to practice is not smooth. Long-term clinical evidence is still sparse, microbial engraftment remains unpredictable, and scaling personalised approaches beyond small cohorts poses obvious logistical challenges. Regulation is another unresolved piece of the puzzle, particularly when interventions blur the line between food, supplement, and therapy. There are also broader ecological questions. Introducing or reshaping microbial communities may have consequences that extend beyond individual patients. By keeping these constraints in view, the chapter aims to temper optimism with realism and to sketch a future in which precision microbiome interventions are developed carefully, tested rigorously, and applied where they are most likely to make a meaningful difference, especially for nutritionally vulnerable groups.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Probiotics/therapeutic use/administration & dosage
*Gastrointestinal Microbiome/physiology/drug effects
Prebiotics/administration & dosage
Animals
Synbiotics/administration & dosage
Multiomics
RevDate: 2026-11-17
Risk and Maintenance Factors for Future Onset and Persistence of Binge-Eating and Purging Symptoms: A Prospective Study of the Gut Microbiome.
The International journal of eating disorders [Epub ahead of print].
BACKGROUND: Eating disorders are severe, disabling, and costly mental disorders. Existing evidence on the gut microbiome in eating disorders is derived primarily from cross-sectional studies. This study aimed to apply a longitudinal grouping analysis to examine gut microbial factors that predict future onset and persistence of binge-eating and purging symptoms, two subtypes of eating disorder symptoms (EDSs).
METHOD: Participants from a prospective cohort (baseline N = 908; follow-up N = 407) were classified as non-afflicted controls (n = 29/26 [binge-eating/purging]; reported no EDSs at either time point), developers (n = 35/28; reported EDSs at follow-up only), maintainers (n = 20/40; reported EDSs at both time points), or remitters (n = 17/38; reported EDSs at baseline only). Using shotgun metagenomic sequencing, we examined group differences in microbial diversity (alpha and beta diversity), microbial features (at the level of phylum, genus and species), and functional pathways to identify risk factors and maintenance factors.
RESULTS: Reduced abundance of Actinobacteria, several Proteobacteria genera (e.g., Oleiphilus, Oecophyllibacter, and Novosphingopyxis), and multiple species from Actinobacteria, Proteobacteria, and Firmicutes predicted future onset of binge eating. Lower abundance of Roseburia predicted future onset of purging. Elevated abundance of specific genera or species belonging to Proteobacteria, Deferribacteres, and Cyanobacteria, as well as functional pathways enriched in terpenoid and polyketide metabolism predicted future persistence of binge eating.
CONCLUSIONS: The evidence that reduced abundance of multiple species (especially from Actinobacteria, Proteobacteria, and Firmicutes) predicted future binge-eating onset, and that reduced Roseburia abundance predicted future purging onset, extends prior findings. The evidence that elevated abundance of specific Proteobacteria, Deferribacteres, and Cyanobacteria taxa predicted future binge eating persistence is novel.
Additional Links: PMID-43046121
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046121,
year = {2026},
author = {Chen, X and Li, W and Stice, E and Qiu, J and Feng, T and He, Q and Lei, X and Chen, H},
title = {Risk and Maintenance Factors for Future Onset and Persistence of Binge-Eating and Purging Symptoms: A Prospective Study of the Gut Microbiome.},
journal = {The International journal of eating disorders},
volume = {},
number = {},
pages = {},
doi = {10.1002/eat.70273},
pmid = {43046121},
issn = {1098-108X},
support = {32271087//National Natural Science Foundation of China/ ; 32500937//National Natural Science Foundation of China/ ; SWU2509739//Fundamental Research Funds for the Central Universities/ ; },
abstract = {BACKGROUND: Eating disorders are severe, disabling, and costly mental disorders. Existing evidence on the gut microbiome in eating disorders is derived primarily from cross-sectional studies. This study aimed to apply a longitudinal grouping analysis to examine gut microbial factors that predict future onset and persistence of binge-eating and purging symptoms, two subtypes of eating disorder symptoms (EDSs).
METHOD: Participants from a prospective cohort (baseline N = 908; follow-up N = 407) were classified as non-afflicted controls (n = 29/26 [binge-eating/purging]; reported no EDSs at either time point), developers (n = 35/28; reported EDSs at follow-up only), maintainers (n = 20/40; reported EDSs at both time points), or remitters (n = 17/38; reported EDSs at baseline only). Using shotgun metagenomic sequencing, we examined group differences in microbial diversity (alpha and beta diversity), microbial features (at the level of phylum, genus and species), and functional pathways to identify risk factors and maintenance factors.
RESULTS: Reduced abundance of Actinobacteria, several Proteobacteria genera (e.g., Oleiphilus, Oecophyllibacter, and Novosphingopyxis), and multiple species from Actinobacteria, Proteobacteria, and Firmicutes predicted future onset of binge eating. Lower abundance of Roseburia predicted future onset of purging. Elevated abundance of specific genera or species belonging to Proteobacteria, Deferribacteres, and Cyanobacteria, as well as functional pathways enriched in terpenoid and polyketide metabolism predicted future persistence of binge eating.
CONCLUSIONS: The evidence that reduced abundance of multiple species (especially from Actinobacteria, Proteobacteria, and Firmicutes) predicted future binge-eating onset, and that reduced Roseburia abundance predicted future purging onset, extends prior findings. The evidence that elevated abundance of specific Proteobacteria, Deferribacteres, and Cyanobacteria taxa predicted future binge eating persistence is novel.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Large Language Model-Enhanced MFSSG Enables Effective and Accurate Integration Analysis for Microbiome-Metabolome Data.
Analytical chemistry, 98(45):32523-32533.
The massive volume of paired microbiome and metabolome measurements(?)generated through high-throughput sequencing and mass spectrometry(?)has created an urgent need for dedicated, integrative analytical pipelines. Existing tools lack the capacity to simultaneously support sample clustering, multi-omics visualization, disease risk stratification, and biological age quantification using matched dual-modal datasets. To overcome this analytical bottleneck, we introduce the matrix factorization with shared and specific graph learning (MFSSG) toolkit: an unsupervised matrix factorization framework that jointly learns both shared and modality-specific graph structures. MFSSG preserves cross-omics spatial consistency by leveraging shared nearest-neighbor graphs derived from analytical profiles and incorporates two complementary regularization terms(?)entropy regularization to enhance cluster discriminability and a pre-trained microbial graph Laplacian(?)to mitigate measurement bias inherent in microbiome sequencing versus metabolomic mass spectrometry data. Validated across three independent multi-omics cohorts derived from gastric and gut biospecimens(?)including gastric cancer, end-stage renal disease, and type 1 diabetes(?)MFSSG consistently outperforms state-of-the-art integration methods in disease classification. Furthermore, a novel pairwise learning module enables parallel and accurate quantification of the metabolic age and microbial age, facilitating refined patient risk stratification. This versatile toolkit provides a robust chemometric strategy for uncovering latent biological patterns embedded within heterogeneous multi-omics analytical data.
Additional Links: PMID-43046385
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046385,
year = {2026},
author = {Ma, Y and Liu, L and Ma, Y},
title = {Large Language Model-Enhanced MFSSG Enables Effective and Accurate Integration Analysis for Microbiome-Metabolome Data.},
journal = {Analytical chemistry},
volume = {98},
number = {45},
pages = {32523-32533},
doi = {10.1021/acs.analchem.6c04275},
pmid = {43046385},
issn = {1520-6882},
support = {2025AFD084//Natural Science Foundation of Hubei Province/ ; //Hubei Superior and Distinctive Discipline Group of New Energy Vehicle and Smart Transportation/ ; },
mesh = {*Microbiota ; *Metabolome ; Humans ; Multiomics ; Large Language Models ; *Metabolomics ; },
abstract = {The massive volume of paired microbiome and metabolome measurements(?)generated through high-throughput sequencing and mass spectrometry(?)has created an urgent need for dedicated, integrative analytical pipelines. Existing tools lack the capacity to simultaneously support sample clustering, multi-omics visualization, disease risk stratification, and biological age quantification using matched dual-modal datasets. To overcome this analytical bottleneck, we introduce the matrix factorization with shared and specific graph learning (MFSSG) toolkit: an unsupervised matrix factorization framework that jointly learns both shared and modality-specific graph structures. MFSSG preserves cross-omics spatial consistency by leveraging shared nearest-neighbor graphs derived from analytical profiles and incorporates two complementary regularization terms(?)entropy regularization to enhance cluster discriminability and a pre-trained microbial graph Laplacian(?)to mitigate measurement bias inherent in microbiome sequencing versus metabolomic mass spectrometry data. Validated across three independent multi-omics cohorts derived from gastric and gut biospecimens(?)including gastric cancer, end-stage renal disease, and type 1 diabetes(?)MFSSG consistently outperforms state-of-the-art integration methods in disease classification. Furthermore, a novel pairwise learning module enables parallel and accurate quantification of the metabolic age and microbial age, facilitating refined patient risk stratification. This versatile toolkit provides a robust chemometric strategy for uncovering latent biological patterns embedded within heterogeneous multi-omics analytical data.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Microbiota
*Metabolome
Humans
Multiomics
Large Language Models
*Metabolomics
RevDate: 2026-11-18
TM7x, an Ultrasmall Oral Episymbiont: Biology and Emerging Clinical Relevance.
Oral diseases [Epub ahead of print].
OBJECTIVE: To review the biology of Nanosynbacter lyticus strain TM7x and critically assess its proposed relevance to periodontal disease.
METHODS: This narrative review integrates foundational cultivation studies with a targeted PubMed update conducted on 29 October 2026. Human observational findings are distinguished from experimental evidence and from results concerning other Saccharibacteria.
RESULTS: TM7x is an ultrasmall, genome-reduced episymbiont whose replication requires a compatible bacterial host. Studies of its interaction with Schaalia odontolytica XH001 reveal host adaptation, specialised pili, metabolic activity during transmission and changes in host physiology. Human disease associations frequently concern broader Saccharibacteria taxa and vary with population, sampling site and analytical method. Experimental studies demonstrate reduced inflammatory responses and, for several epibiont-host pairs, reduced bone loss in mice. These effects are context-dependent and do not establish clinical protection. Detailed knowledge of the species remains concentrated on the reference strain.
CONCLUSIONS: Current evidence does not establish TM7x as a causative human periodontal pathogen. It supports a model of context-dependent microbial and immune modulation, with unresolved consequences for human disease.
Additional Links: PMID-43046504
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046504,
year = {2026},
author = {Dimitrelou, P and Alonaris, E and Sergounioti, A},
title = {TM7x, an Ultrasmall Oral Episymbiont: Biology and Emerging Clinical Relevance.},
journal = {Oral diseases},
volume = {},
number = {},
pages = {},
doi = {10.1111/odi.70584},
pmid = {43046504},
issn = {1601-0825},
abstract = {OBJECTIVE: To review the biology of Nanosynbacter lyticus strain TM7x and critically assess its proposed relevance to periodontal disease.
METHODS: This narrative review integrates foundational cultivation studies with a targeted PubMed update conducted on 29 October 2026. Human observational findings are distinguished from experimental evidence and from results concerning other Saccharibacteria.
RESULTS: TM7x is an ultrasmall, genome-reduced episymbiont whose replication requires a compatible bacterial host. Studies of its interaction with Schaalia odontolytica XH001 reveal host adaptation, specialised pili, metabolic activity during transmission and changes in host physiology. Human disease associations frequently concern broader Saccharibacteria taxa and vary with population, sampling site and analytical method. Experimental studies demonstrate reduced inflammatory responses and, for several epibiont-host pairs, reduced bone loss in mice. These effects are context-dependent and do not establish clinical protection. Detailed knowledge of the species remains concentrated on the reference strain.
CONCLUSIONS: Current evidence does not establish TM7x as a causative human periodontal pathogen. It supports a model of context-dependent microbial and immune modulation, with unresolved consequences for human disease.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
[Features of the microbiome of the nasal mucosa in chronic polypous rhinosinusitis].
Vestnik otorinolaringologii, 91(5):100-106.
UNLABELLED: The nasopharyngeal microbiome in patients with chronic rhinosinusitis with polyps is being actively studied for the development of modern antibacterial therapy strategies for this condition.
OBJECTIVE: To determine the characteristics of the nasal mucosal microbiome in male patients with chronic polypous rhinosinusitis.
MATERIAL AND METHODS: A pilot study was conducted on 10 male patients (Caucasians, aged 30-50 years, study group) with chronic polypous rhinosinusitis before surgical treatment outside of an infectious exacerbation. The control group consisted of 10 apparently healthy men (Caucasians) of the same age range (control group). DNA was isolated from nasal mucosal cells collected using a type A microbrush probe using the HostZERO Microbia DNA Kit (D4310, Zym Research, USA) in accordance with the manufacturer's instructions. The V3-V4 region of the 16S rRNA gene was amplified using primers 343F (5'-CTCCTACGGRRSGCAGCAG-3') and 806R (5'-GGACTACNVGGGTWTCTAAT-3'). Sequencing was performed in the Pharmacogenomics Laboratory (Head, Doctor of Biological Sciences M.L. Filipenko) of the D.G. Knorre Institute of Chemical Biology and Fundamental Medicine SB RAS (Novosibirsk) on a MiSeq sequencer (Illumina, USA) using the MiSeq eagent Kit v3 (2×300 bp) (Illumina, USA). The taxonomic affiliation of the operational taxonomic units sequences was determined using SINTAX and the 16S RDP training set v18 as a reference database. The taxonomic structure of the resulting 16S sequence ensemble was assessed by calculating the ratio of the number of taxon-specific sequences to the total number of sequences in the sample, expressed as a percentage.
RESULTS: A total of 339 taxonomic units were identified in the study and control groups. Non-smoking middle-aged men with chronic polypous rhinosinusitis without an atopic constitution demonstrated a significant decrease in the proportion of Proteobacteria in the Bacteria domain. Chronic polypous rhinosinusitis was associated with a significant increase in DNA markers of the genus Staphylococcus (Firmicutes/Bacilli/Bacillales/Staphylococcaceae), as well as uncultured bacteria of the genus Bacteroides (Bacteroidetes/Bacteroidia/Bacteroidales/Bacteroidaceae). Regression analysis revealed a positive association between chronic polypous rhinosinusitis and the genus Pseudomonas (Proteobacteria/Gammaproteobacteria/Pseudomonadales/Pseudomonadaceae). Conclusion. Based on the obtained results, it is possible to develop PCR test systems for identifying DNA markers of Staphylococcus, Bacteroides and Pseudomonas in male patients with chronic polypous rhinosinusitis.
Additional Links: PMID-43046749
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046749,
year = {2026},
author = {Shabaldina, EV and Abramova, NA and Bedareva, AV and Khrapov, EA and Filipenko, ML and Boyko, AO and Koryukov, MA and Davletgareeva, AA and Decheva, VK and Shabaldin, AV},
title = {[Features of the microbiome of the nasal mucosa in chronic polypous rhinosinusitis].},
journal = {Vestnik otorinolaringologii},
volume = {91},
number = {5},
pages = {100-106},
doi = {10.17116/otorino202691051100},
pmid = {43046749},
issn = {0042-4668},
mesh = {Humans ; *Rhinosinusitis/microbiology/diagnosis/physiopathology ; Male ; Adult ; *Microbiota ; *Nasal Mucosa/microbiology ; *Nasal Polyps/microbiology/diagnosis/complications ; Middle Aged ; Chronic Disease ; RNA, Ribosomal, 16S ; Pilot Projects ; *Sinusitis/microbiology/diagnosis ; },
abstract = {UNLABELLED: The nasopharyngeal microbiome in patients with chronic rhinosinusitis with polyps is being actively studied for the development of modern antibacterial therapy strategies for this condition.
OBJECTIVE: To determine the characteristics of the nasal mucosal microbiome in male patients with chronic polypous rhinosinusitis.
MATERIAL AND METHODS: A pilot study was conducted on 10 male patients (Caucasians, aged 30-50 years, study group) with chronic polypous rhinosinusitis before surgical treatment outside of an infectious exacerbation. The control group consisted of 10 apparently healthy men (Caucasians) of the same age range (control group). DNA was isolated from nasal mucosal cells collected using a type A microbrush probe using the HostZERO Microbia DNA Kit (D4310, Zym Research, USA) in accordance with the manufacturer's instructions. The V3-V4 region of the 16S rRNA gene was amplified using primers 343F (5'-CTCCTACGGRRSGCAGCAG-3') and 806R (5'-GGACTACNVGGGTWTCTAAT-3'). Sequencing was performed in the Pharmacogenomics Laboratory (Head, Doctor of Biological Sciences M.L. Filipenko) of the D.G. Knorre Institute of Chemical Biology and Fundamental Medicine SB RAS (Novosibirsk) on a MiSeq sequencer (Illumina, USA) using the MiSeq eagent Kit v3 (2×300 bp) (Illumina, USA). The taxonomic affiliation of the operational taxonomic units sequences was determined using SINTAX and the 16S RDP training set v18 as a reference database. The taxonomic structure of the resulting 16S sequence ensemble was assessed by calculating the ratio of the number of taxon-specific sequences to the total number of sequences in the sample, expressed as a percentage.
RESULTS: A total of 339 taxonomic units were identified in the study and control groups. Non-smoking middle-aged men with chronic polypous rhinosinusitis without an atopic constitution demonstrated a significant decrease in the proportion of Proteobacteria in the Bacteria domain. Chronic polypous rhinosinusitis was associated with a significant increase in DNA markers of the genus Staphylococcus (Firmicutes/Bacilli/Bacillales/Staphylococcaceae), as well as uncultured bacteria of the genus Bacteroides (Bacteroidetes/Bacteroidia/Bacteroidales/Bacteroidaceae). Regression analysis revealed a positive association between chronic polypous rhinosinusitis and the genus Pseudomonas (Proteobacteria/Gammaproteobacteria/Pseudomonadales/Pseudomonadaceae). Conclusion. Based on the obtained results, it is possible to develop PCR test systems for identifying DNA markers of Staphylococcus, Bacteroides and Pseudomonas in male patients with chronic polypous rhinosinusitis.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Rhinosinusitis/microbiology/diagnosis/physiopathology
Male
Adult
*Microbiota
*Nasal Mucosa/microbiology
*Nasal Polyps/microbiology/diagnosis/complications
Middle Aged
Chronic Disease
RNA, Ribosomal, 16S
Pilot Projects
*Sinusitis/microbiology/diagnosis
RevDate: 2026-11-18
The impact of childhood obesity on the developing skeleton.
Pediatric endocrinology, diabetes, and metabolism pii:58839 [Epub ahead of print].
Childhood obesity is an increasingly prevalent global health concern associated with significant metabolic, endocrine, and skeletal consequences. During critical periods of growth and peak bone mineralisation, excessive adiposity may impair skeletal development by disrupting bone formation and remodeling. The effects of obesity on bone metabolism are complex and multifactorial, involving altered mechanical loading, hormonal dysregulation, and chronic low-grade inflammation. Key mediators, including insulin resistance, adipose tissue dysfunction, and disturbances in calcium-phosphate-magnesium-vitamin D homeostasis, contribute to impaired osteoblastic and osteoclastic activity. Additionally, gut microbiome dysbiosis and reduced nutrient absorption may exacerbate skeletal fragility and abnormal mineralisation. This review provides an integrative overview of current evidence regarding the impact of obesity on the developing skeleton. It discusses (I) methods of bone assessment in children with excess body weight and associated diagnostic challenges, (II) biomarkers relevant to bone metabolism and obesity-related skeletal alterations, (III) the role of dietary factors, nutrient intake, and physical activity in bone development, and (IV) future research directions aimed at reducing fracture risk and improving skeletal health outcomes in paediatric populations.
Additional Links: PMID-43046770
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046770,
year = {2026},
author = {Baran, E and Wójcik, M},
title = {The impact of childhood obesity on the developing skeleton.},
journal = {Pediatric endocrinology, diabetes, and metabolism},
volume = {},
number = {},
pages = {},
doi = {10.5114/pedm.2026.166032},
pmid = {43046770},
issn = {2083-8441},
abstract = {Childhood obesity is an increasingly prevalent global health concern associated with significant metabolic, endocrine, and skeletal consequences. During critical periods of growth and peak bone mineralisation, excessive adiposity may impair skeletal development by disrupting bone formation and remodeling. The effects of obesity on bone metabolism are complex and multifactorial, involving altered mechanical loading, hormonal dysregulation, and chronic low-grade inflammation. Key mediators, including insulin resistance, adipose tissue dysfunction, and disturbances in calcium-phosphate-magnesium-vitamin D homeostasis, contribute to impaired osteoblastic and osteoclastic activity. Additionally, gut microbiome dysbiosis and reduced nutrient absorption may exacerbate skeletal fragility and abnormal mineralisation. This review provides an integrative overview of current evidence regarding the impact of obesity on the developing skeleton. It discusses (I) methods of bone assessment in children with excess body weight and associated diagnostic challenges, (II) biomarkers relevant to bone metabolism and obesity-related skeletal alterations, (III) the role of dietary factors, nutrient intake, and physical activity in bone development, and (IV) future research directions aimed at reducing fracture risk and improving skeletal health outcomes in paediatric populations.},
}
RevDate: 2026-11-18
Gut Microbiome Profiles of Pediatric HSCT Recipients and Donors in Relation to Acute Graft-versus-Host Disease: A Pilot Study.
Infection & chemotherapy pii:58.e54 [Epub ahead of print].
BACKGROUND: The changes in the gut microbiome of pediatric hematopoietic stem cell transplantation (HSCT) recipients and their association with the development of acute graft-versus-host disease (aGvHD) have not been well investigated. We conducted a prospective pilot study with a small group of pediatric HSCT recipients to evaluate this relationship and explore the association between the gut microbiome of corresponding donors and the development of aGvHD in HSCT recipients.
MATERIALS AND METHODS: We collected one fecal sample from the HSCT recipient and one from their corresponding donor before transplantation, and another from the recipient one month after HSCT. We assessed alpha diversity, beta diversity, and relative abundance in each sample and compared these measures between the aGvHD and non-aGvHD groups.
RESULTS: Among the 10 HSCT recipients, two developed skin aGvHD of grade 2 and grade 1, respectively, and one developed grade 3 gastrointestinal and skin aGvHD. The alpha diversity of the post-HSCT gut microbiome was reduced compared to that of the pre-HSCT gut microbiome and was also lower than that of the donor. The alpha diversity of the pre-HSCT and post-HSCT gut microbiome in recipients with aGvHD, as well as those of their donors, tended to be lower than in recipients without aGvHD. There were no significant differences in the beta diversity among the microbiomes of pre-HSCT and post-HSCT recipients and their donors, according to aGvHD status. At the phylum level, a marked expansion of Proteobacteria was observed post-HSCT across the entire cohort, with both the aGvHD and non-aGvHD groups demonstrating a substantial post-transplant bloom without statistical significance between the arms. In the aGvHD group, the post-HSCT gut microbiome showed a lower abundance of the Erysipelatoclostridium genus compared to the non-aGvHD group. Additionally, the pre-HSCT gut microbiome in the aGvHD group had a greater abundance of Raoultella ornithinolytica B6 species. Donors whose recipients developed aGvHD had a higher abundance of the Eubacterium eligens group and the Veillonellaceae.
CONCLUSION: After pediatric HSCT, the diversity of the gut microbiome in recipients decreases, particularly in those who develop aGvHD. Differences in the abundance of specific microorganisms are observed between recipients with and without aGvHD in both the pre-HSCT and post-HSCT gut microbiome and in the donors' gut microbiome. Evaluating the gut microbiome of recipients before and after transplantation, as well as that of their donors, may offer potential prognostic clues regarding the occurrence of aGvHD in recipients.
Additional Links: PMID-43046816
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046816,
year = {2026},
author = {Seo, E and Yoo, R and Choi, ES and Kim, JH and Kim, H and Koh, KN and Im, HJ and Lee, J},
title = {Gut Microbiome Profiles of Pediatric HSCT Recipients and Donors in Relation to Acute Graft-versus-Host Disease: A Pilot Study.},
journal = {Infection & chemotherapy},
volume = {},
number = {},
pages = {},
doi = {10.3947/ic.2026.0038},
pmid = {43046816},
issn = {2093-2340},
support = {2018IL0601//Asan Institute for Life Sciences, Asan Medical Center/Korea ; },
abstract = {BACKGROUND: The changes in the gut microbiome of pediatric hematopoietic stem cell transplantation (HSCT) recipients and their association with the development of acute graft-versus-host disease (aGvHD) have not been well investigated. We conducted a prospective pilot study with a small group of pediatric HSCT recipients to evaluate this relationship and explore the association between the gut microbiome of corresponding donors and the development of aGvHD in HSCT recipients.
MATERIALS AND METHODS: We collected one fecal sample from the HSCT recipient and one from their corresponding donor before transplantation, and another from the recipient one month after HSCT. We assessed alpha diversity, beta diversity, and relative abundance in each sample and compared these measures between the aGvHD and non-aGvHD groups.
RESULTS: Among the 10 HSCT recipients, two developed skin aGvHD of grade 2 and grade 1, respectively, and one developed grade 3 gastrointestinal and skin aGvHD. The alpha diversity of the post-HSCT gut microbiome was reduced compared to that of the pre-HSCT gut microbiome and was also lower than that of the donor. The alpha diversity of the pre-HSCT and post-HSCT gut microbiome in recipients with aGvHD, as well as those of their donors, tended to be lower than in recipients without aGvHD. There were no significant differences in the beta diversity among the microbiomes of pre-HSCT and post-HSCT recipients and their donors, according to aGvHD status. At the phylum level, a marked expansion of Proteobacteria was observed post-HSCT across the entire cohort, with both the aGvHD and non-aGvHD groups demonstrating a substantial post-transplant bloom without statistical significance between the arms. In the aGvHD group, the post-HSCT gut microbiome showed a lower abundance of the Erysipelatoclostridium genus compared to the non-aGvHD group. Additionally, the pre-HSCT gut microbiome in the aGvHD group had a greater abundance of Raoultella ornithinolytica B6 species. Donors whose recipients developed aGvHD had a higher abundance of the Eubacterium eligens group and the Veillonellaceae.
CONCLUSION: After pediatric HSCT, the diversity of the gut microbiome in recipients decreases, particularly in those who develop aGvHD. Differences in the abundance of specific microorganisms are observed between recipients with and without aGvHD in both the pre-HSCT and post-HSCT gut microbiome and in the donors' gut microbiome. Evaluating the gut microbiome of recipients before and after transplantation, as well as that of their donors, may offer potential prognostic clues regarding the occurrence of aGvHD in recipients.},
}
RevDate: 2026-11-18
RETRACTED: Kim et al. Tetragonia tetragonioides Protected Against Memory Dysfunction by Elevating Hippocampal Amyloid-β Deposition Through Potentiating Insulin Signaling and Altering Gut Microbiome Composition. Int. J. Mol. Sci. 2020, 21, 2900.
International journal of molecular sciences, 27(22):.
The Journal retracts the article "Tetragonia tetragonioides Protected against Memory Dysfunction by Elevating Hippocampal Amyloid-β Deposition through Potentiating Insulin Signaling and Altering Gut Microbiome Composition" [...].
Additional Links: PMID-43046832
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43046832,
year = {2026},
author = {Kim, DS and Ko, BS and Ryuk, JA and Park, S},
title = {RETRACTED: Kim et al. Tetragonia tetragonioides Protected Against Memory Dysfunction by Elevating Hippocampal Amyloid-β Deposition Through Potentiating Insulin Signaling and Altering Gut Microbiome Composition. Int. J. Mol. Sci. 2020, 21, 2900.},
journal = {International journal of molecular sciences},
volume = {27},
number = {22},
pages = {},
pmid = {43046832},
issn = {1422-0067},
abstract = {The Journal retracts the article "Tetragonia tetragonioides Protected against Memory Dysfunction by Elevating Hippocampal Amyloid-β Deposition through Potentiating Insulin Signaling and Altering Gut Microbiome Composition" [...].},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Efficacy and Tolerability of a Multi-Targeted Anti-Acne Regimen Incorporating Salicylic Acid, Prebiotics, and Zinc PCA: A 30-Day Clinical Trial.
Journal of cosmetic dermatology, 25(7):e71034.
INTRODUCTION AND OBJECTIVES: Acne vulgaris is a multifactorial inflammatory skin disorder that affects youths and adults, often with coincident barrier disruption and dysbiosis of the microbiome surface. The primary objective of this study was to assess the effectiveness and tolerability of a 30-day multi-targeted dermocosmetic regimen shown to improve acne-prone skin while maintaining skin barrier integrity.
MATERIALS AND METHODS: This 30-day clinical study was conducted on 20 volunteers with acne-prone skin. Participants followed an 8-product cosmetic regimen for 30 days. clinical parameters (scoring of pores visibility, seborrhoea, erythema, dryness and lesions) have been evaluated by dermatologists in conjunction with instrumental measurements of skin hydration (Corneometer CM 825) and sebum levels (Sebumeter SM 815). Subjective evaluations were collected through self-assessment questionnaires. Statistical analyses were performed using paired t-tests and Wilcoxon signed-rank tests (p < 0.05).
RESULTS: After 30 days, there were significant decreases in sebum (-9.1%), erythema, seborrhoea, pores visibility (p < 0.05), and inflammatory (23%) and non-inflammatory lesion counts (32%). Moreover, skin hydration increased (+6.2%, p < 0.01). Subjective assessments revealed high participant satisfaction regarding both product efficacy and skin feel.
CONCLUSION: The dermocosmetic regimen led to significant improvements in acne-related parameters and skin hydration; these findings support a multi-mechanical approach towards the clinical management of acne. Further studies are recommended with a larger sample size and extended study duration, incorporating more frequent or daily monitoring to better capture treatment dynamics and improve the robustness of the findings.
Additional Links: PMID-43047069
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047069,
year = {2026},
author = {Armanious, YM and Neaz, OS and Abdelghany, AH and Zaghloul, MA and Rafaat, S and Medhat, Y and Abdelrahim, NA},
title = {Efficacy and Tolerability of a Multi-Targeted Anti-Acne Regimen Incorporating Salicylic Acid, Prebiotics, and Zinc PCA: A 30-Day Clinical Trial.},
journal = {Journal of cosmetic dermatology},
volume = {25},
number = {7},
pages = {e71034},
pmid = {43047069},
issn = {1473-2165},
abstract = {INTRODUCTION AND OBJECTIVES: Acne vulgaris is a multifactorial inflammatory skin disorder that affects youths and adults, often with coincident barrier disruption and dysbiosis of the microbiome surface. The primary objective of this study was to assess the effectiveness and tolerability of a 30-day multi-targeted dermocosmetic regimen shown to improve acne-prone skin while maintaining skin barrier integrity.
MATERIALS AND METHODS: This 30-day clinical study was conducted on 20 volunteers with acne-prone skin. Participants followed an 8-product cosmetic regimen for 30 days. clinical parameters (scoring of pores visibility, seborrhoea, erythema, dryness and lesions) have been evaluated by dermatologists in conjunction with instrumental measurements of skin hydration (Corneometer CM 825) and sebum levels (Sebumeter SM 815). Subjective evaluations were collected through self-assessment questionnaires. Statistical analyses were performed using paired t-tests and Wilcoxon signed-rank tests (p < 0.05).
RESULTS: After 30 days, there were significant decreases in sebum (-9.1%), erythema, seborrhoea, pores visibility (p < 0.05), and inflammatory (23%) and non-inflammatory lesion counts (32%). Moreover, skin hydration increased (+6.2%, p < 0.01). Subjective assessments revealed high participant satisfaction regarding both product efficacy and skin feel.
CONCLUSION: The dermocosmetic regimen led to significant improvements in acne-related parameters and skin hydration; these findings support a multi-mechanical approach towards the clinical management of acne. Further studies are recommended with a larger sample size and extended study duration, incorporating more frequent or daily monitoring to better capture treatment dynamics and improve the robustness of the findings.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Predictive Biomarkers in Laser Dermatology: Toward Personalized Energy-Based Treatments.
Journal of cosmetic dermatology, 25(6):e70991.
BACKGROUND: Despite major technological advances in laser and energy-based devices, adverse events such as post-inflammatory hyperpigmentation (PIH), prolonged erythema, delayed wound healing, and dyschromia remain significant clinical challenges. Current risk assessment largely relies on Fitzpatrick Skin Type classification and clinical judgment, which inadequately capture the biological heterogeneity influencing individual treatment responses.
OBJECTIVE: To explore emerging biological biomarkers and predictive technologies that may improve individualized risk stratification, treatment planning, and complication prevention in laser dermatology, thereby supporting the transition toward precision medicine.
METHODS: This perspective article reviews current evidence regarding biological determinants of laser-induced adverse events, including skin barrier integrity, inflammatory activity, pigmentary response pathways, oxidative stress, microbiome composition, and biological aging. Potential applications of minimally invasive biomarker assessment and artificial intelligence (AI)-driven predictive modeling are discussed within the context of personalized energy-based treatments.
RESULTS: Emerging biomarkers such as transepidermal water loss (TEWL), epidermal cytokine profiles obtained through tape stripping, melanogenic gene expression signatures, oxidative stress markers, microbiome-associated parameters, and indicators of biological age may provide clinically meaningful information beyond conventional phototype assessment. These markers have the potential to identify patients at increased risk of adverse outcomes, enabling tailored treatment parameters, optimized preconditioning strategies, and enhanced posttreatment monitoring. Furthermore, AI-based platforms may integrate multimodal biological, imaging, and clinical data to generate individualized safety predictions and support real-time treatment optimization.
CONCLUSIONS: A biology-centric approach to laser dermatology may complement existing safety frameworks by incorporating objective molecular and biophysical markers into clinical decision-making. Although many proposed biomarkers remain investigational, their future integration, particularly when combined with AI-driven analytics, may improve treatment predictability, reduce complications, and advance equitable, personalized care across diverse patient populations. Further validation studies are needed to establish clinical feasibility, reproducibility, and cost-effectiveness before routine implementation.
Additional Links: PMID-43047074
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047074,
year = {2026},
author = {Haykal, D and Filippo, AA and Filippo, GR and Rocha, M and Badawi, A},
title = {Predictive Biomarkers in Laser Dermatology: Toward Personalized Energy-Based Treatments.},
journal = {Journal of cosmetic dermatology},
volume = {25},
number = {6},
pages = {e70991},
pmid = {43047074},
issn = {1473-2165},
abstract = {BACKGROUND: Despite major technological advances in laser and energy-based devices, adverse events such as post-inflammatory hyperpigmentation (PIH), prolonged erythema, delayed wound healing, and dyschromia remain significant clinical challenges. Current risk assessment largely relies on Fitzpatrick Skin Type classification and clinical judgment, which inadequately capture the biological heterogeneity influencing individual treatment responses.
OBJECTIVE: To explore emerging biological biomarkers and predictive technologies that may improve individualized risk stratification, treatment planning, and complication prevention in laser dermatology, thereby supporting the transition toward precision medicine.
METHODS: This perspective article reviews current evidence regarding biological determinants of laser-induced adverse events, including skin barrier integrity, inflammatory activity, pigmentary response pathways, oxidative stress, microbiome composition, and biological aging. Potential applications of minimally invasive biomarker assessment and artificial intelligence (AI)-driven predictive modeling are discussed within the context of personalized energy-based treatments.
RESULTS: Emerging biomarkers such as transepidermal water loss (TEWL), epidermal cytokine profiles obtained through tape stripping, melanogenic gene expression signatures, oxidative stress markers, microbiome-associated parameters, and indicators of biological age may provide clinically meaningful information beyond conventional phototype assessment. These markers have the potential to identify patients at increased risk of adverse outcomes, enabling tailored treatment parameters, optimized preconditioning strategies, and enhanced posttreatment monitoring. Furthermore, AI-based platforms may integrate multimodal biological, imaging, and clinical data to generate individualized safety predictions and support real-time treatment optimization.
CONCLUSIONS: A biology-centric approach to laser dermatology may complement existing safety frameworks by incorporating objective molecular and biophysical markers into clinical decision-making. Although many proposed biomarkers remain investigational, their future integration, particularly when combined with AI-driven analytics, may improve treatment predictability, reduce complications, and advance equitable, personalized care across diverse patient populations. Further validation studies are needed to establish clinical feasibility, reproducibility, and cost-effectiveness before routine implementation.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Impact of Oral Herbal Supplementation on Human Skin Aging: A Systematic Review of Clinical Trials.
Journal of cosmetic dermatology, 25(8):e71094.
BACKGROUND: Skin aging, characterized by wrinkles, decreased elasticity, and dryness, is both a public health and esthetic issue, affecting most adults and leading to lowered quality of life and higher healthcare costs. While topical treatments are common, systemic approaches are gaining interest for their potential to enhance skin hydration, elasticity, and barrier function. Nonetheless, the effects of oral herbal supplements remain less examined.
AIM: This systematic review evaluated the effectiveness of oral herbal supplements in reducing skin aging in humans, focusing on elasticity, hydration, wrinkle depth, and antioxidant activity.
METHODS: Randomized controlled trials (RCTs) were identified through structured database searches (March-August 2025). Twelve RCTs published between 2020 and 2025 met the inclusion criteria, involving adults who received oral herbal supplements versus placebo or standard care. Outcomes measured included skin elasticity, hydration, wrinkle depth, smoothness, antioxidant capacity, and inflammatory markers. Quality assessment using the Cochrane RoB 2 tool indicated that all 12 RCTs were judged as having some concerns of bias.
RESULTS: Interventions included Glycine max, bilberry, cranberry, Hydrangea serrata, Pycnogenol, and others. Most studies reported significant improvements in dermatological outcomes. Proposed mechanisms involve antioxidant activity, anti-inflammatory effects, collagen synthesis, barrier restoration, photoprotection, DNA repair, and microbiome modulation.
CONCLUSION: In conclusion, oral herbal supplements show promising potential in improving skin aging outcomes by targeting multiple biological pathways. Further research with larger populations, longer durations, and biomarker-based endpoints is needed to confirm efficacy and support standardized use in dermatology and esthetic medicine.
Additional Links: PMID-43047158
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047158,
year = {2026},
author = {Sanjaya, GM and Putri, BVK and Anneke, H and Alfarafisa, NM and Khairani, AF and Atik, N},
title = {Impact of Oral Herbal Supplementation on Human Skin Aging: A Systematic Review of Clinical Trials.},
journal = {Journal of cosmetic dermatology},
volume = {25},
number = {8},
pages = {e71094},
pmid = {43047158},
issn = {1473-2165},
abstract = {BACKGROUND: Skin aging, characterized by wrinkles, decreased elasticity, and dryness, is both a public health and esthetic issue, affecting most adults and leading to lowered quality of life and higher healthcare costs. While topical treatments are common, systemic approaches are gaining interest for their potential to enhance skin hydration, elasticity, and barrier function. Nonetheless, the effects of oral herbal supplements remain less examined.
AIM: This systematic review evaluated the effectiveness of oral herbal supplements in reducing skin aging in humans, focusing on elasticity, hydration, wrinkle depth, and antioxidant activity.
METHODS: Randomized controlled trials (RCTs) were identified through structured database searches (March-August 2025). Twelve RCTs published between 2020 and 2025 met the inclusion criteria, involving adults who received oral herbal supplements versus placebo or standard care. Outcomes measured included skin elasticity, hydration, wrinkle depth, smoothness, antioxidant capacity, and inflammatory markers. Quality assessment using the Cochrane RoB 2 tool indicated that all 12 RCTs were judged as having some concerns of bias.
RESULTS: Interventions included Glycine max, bilberry, cranberry, Hydrangea serrata, Pycnogenol, and others. Most studies reported significant improvements in dermatological outcomes. Proposed mechanisms involve antioxidant activity, anti-inflammatory effects, collagen synthesis, barrier restoration, photoprotection, DNA repair, and microbiome modulation.
CONCLUSION: In conclusion, oral herbal supplements show promising potential in improving skin aging outcomes by targeting multiple biological pathways. Further research with larger populations, longer durations, and biomarker-based endpoints is needed to confirm efficacy and support standardized use in dermatology and esthetic medicine.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Human Skin Odor Throughout Life: A Literature Review.
Journal of cosmetic dermatology, 25(9):e71194.
BACKGROUND: Human skin continuously releases volatile organic compounds (VOCs) that constitute the skin volatilome, a dynamic chemical signature reflecting genetic, hormonal, microbial, and environmental influences.
OBJECTIVE: To provide a comprehensive, critically appraised synthesis of current knowledge on the human skin volatilome across the lifespan, emphasizing age-related dynamics, sex-specific profiles, microbiome contributions, analytical methodologies, and translational applications, while systematically evaluating evidence quality and identifying knowledge gaps.
METHODS: We conducted a narrative review with systematic search methodology. A systematic search of PubMed/MEDLINE, Scopus, and Web of Science was performed from database inception to May 2026, following a pre-defined protocol. Of 487 initially identified records, 55 studies met the inclusion criteria following systematic screening, full-text assessment, and reference list review. Quality appraisal was performed using five predefined criteria (sample size adequacy, analytical validation, control for confounding, study design appropriateness, and reporting completeness), with studies graded as High (≥ 4 criteria met), Moderate (3 criteria met), or Low (≤ 2 criteria met). Data were synthesized thematically across six domains: chemical composition, lifespan dynamics, sex differences, microbiome determinants, analytical methodologies, and translational applications.
RESULTS: Age-dependent transformations are well-documented: infant odor is dominated by acidic VOCs; puberty introduces qualitative changes via apocrine gland activation; reproductive-age profiles exhibit consistent sex-specific patterns; geriatric odor is characterized by 2-nonenal emergence. Quality appraisal revealed that 22 studies (38%) were rated high quality, 24 (41%) moderate, and 12 (21%) low, with small sample sizes (median n = 35) and lack of analytical validation being the primary limitations. The skin microbiome, particularly Corynebacterium, Cutibacterium, and Staphylococcus, significantly modulates odor profiles.
CONCLUSIONS: The skin volatilome reflects age, sex, microbiome, and health status. While VOC analysis offers promise as a noninvasive biosensing approach, methodological heterogeneity, limited longitudinal data, and incomplete mechanistic understanding constrain translation.
Additional Links: PMID-43047215
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047215,
year = {2026},
author = {Mohammed, GF and Alantary, AK and Al-Dhubaibi, MS and Bahaj, SS and Aziz, NS and Al-Dhubaibi, AM},
title = {Human Skin Odor Throughout Life: A Literature Review.},
journal = {Journal of cosmetic dermatology},
volume = {25},
number = {9},
pages = {e71194},
pmid = {43047215},
issn = {1473-2165},
abstract = {BACKGROUND: Human skin continuously releases volatile organic compounds (VOCs) that constitute the skin volatilome, a dynamic chemical signature reflecting genetic, hormonal, microbial, and environmental influences.
OBJECTIVE: To provide a comprehensive, critically appraised synthesis of current knowledge on the human skin volatilome across the lifespan, emphasizing age-related dynamics, sex-specific profiles, microbiome contributions, analytical methodologies, and translational applications, while systematically evaluating evidence quality and identifying knowledge gaps.
METHODS: We conducted a narrative review with systematic search methodology. A systematic search of PubMed/MEDLINE, Scopus, and Web of Science was performed from database inception to May 2026, following a pre-defined protocol. Of 487 initially identified records, 55 studies met the inclusion criteria following systematic screening, full-text assessment, and reference list review. Quality appraisal was performed using five predefined criteria (sample size adequacy, analytical validation, control for confounding, study design appropriateness, and reporting completeness), with studies graded as High (≥ 4 criteria met), Moderate (3 criteria met), or Low (≤ 2 criteria met). Data were synthesized thematically across six domains: chemical composition, lifespan dynamics, sex differences, microbiome determinants, analytical methodologies, and translational applications.
RESULTS: Age-dependent transformations are well-documented: infant odor is dominated by acidic VOCs; puberty introduces qualitative changes via apocrine gland activation; reproductive-age profiles exhibit consistent sex-specific patterns; geriatric odor is characterized by 2-nonenal emergence. Quality appraisal revealed that 22 studies (38%) were rated high quality, 24 (41%) moderate, and 12 (21%) low, with small sample sizes (median n = 35) and lack of analytical validation being the primary limitations. The skin microbiome, particularly Corynebacterium, Cutibacterium, and Staphylococcus, significantly modulates odor profiles.
CONCLUSIONS: The skin volatilome reflects age, sex, microbiome, and health status. While VOC analysis offers promise as a noninvasive biosensing approach, methodological heterogeneity, limited longitudinal data, and incomplete mechanistic understanding constrain translation.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
A Multimodal Multi-task Model Integrating Scalp Imaging, Lipidomics, and Microbiome Data for Scalp Condition and Social Stigma: An Algorithm Development and Validation Study Across Multi-ethnic Cohorts.
Journal of cosmetic dermatology, 25(10):e71217.
Additional Links: PMID-43047276
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047276,
year = {2026},
author = {Oh, J and Kim, S and Choi, T and Son, SM and Lim, K and Shin, KO and Kang, SM and Lee, KE and Park, K and Jeon, D and Ahn, HJ and Jin, SB and Jung, DR and Kim, HB and Kyung, S and Lee, DG and Shin, JH and Kang, S and Park, C and Woo, S and Jo, H and Yon, DK},
title = {A Multimodal Multi-task Model Integrating Scalp Imaging, Lipidomics, and Microbiome Data for Scalp Condition and Social Stigma: An Algorithm Development and Validation Study Across Multi-ethnic Cohorts.},
journal = {Journal of cosmetic dermatology},
volume = {25},
number = {10},
pages = {e71217},
pmid = {43047276},
issn = {1473-2165},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Beyond class assumptions: a clinical decision framework for navigating drug-supplement interactions in oncology.
Frontiers in pharmacology, 17:1877127.
BACKGROUND: Dietary supplement use is common among patients with cancer, with nearly half reporting concurrent use alongside conventional therapy. Despite widespread use, drug-supplement interactions in oncology are often difficult to interpret due to heterogeneous evidence, outdated case reports, reliance on in vitro and animal data, and a traditional focus on drug class effects rather than drug-specific vulnerability. Translation of preclinical findings is further complicated by host factors such as inflammation, pharmacogenomic variability, and the gut microbiome. The purpose of this review is to provide a mechanistic overview of drug-supplement interactions in oncology and characterize the existing literature to support clinical decision-making.
METHODS: This narrative review synthesizes current literature on pharmacokinetic and pharmacodynamic interactions between dietary supplements and anticancer therapies, focusing on key mechanistic domains, including drug metabolism (CYP450 and UDP-glucuronosyltransferase enzymes), transporter systems, and immune modulation, and clinically relevant uncertainty. Interaction risk was evaluated across major anticancer drug classes, including tyrosine kinase inhibitors, hormonal therapies, oral chemotherapies, and immune checkpoint inhibitors.
RESULTS: Interaction vulnerability varies substantially by drug class but is not uniform across individual agents. Tyrosine kinase inhibitors have substantial interaction potential due to CYP3A4 dependence, exposure-response relationships, and, for some agents, narrow therapeutic margins, with vulnerability varying by agent. Hormonal therapies present mechanism-specific risks, particularly CYP2D6-mediated activation of tamoxifen. Oral chemotherapies demonstrate variable interaction potential, with capecitabine associated with increased bleeding risk and cyclophosphamide dependent on CYP-mediated activation. Immune checkpoint inhibitors are less susceptible to metabolic interactions but present interpretation challenges related to immune modulation and emerging microbiome-related evidence, where theoretical risks often exceed clinical evidence. Across drug classes, many reported interactions remain theoretical, are derived from non-clinical data, or lack standardized product verification, limiting clinical interpretation.
CONCLUSION: Drug-supplement interaction risk in oncology is best understood through a mechanism-based, drug-specific framework rather than isolated supplement-based or class-level approaches. A structured assessment incorporating drug metabolism, supplement activity, host factors, and clinical context may improve risk stratification and patient counseling, although management remains challenging in the absence of robust clinical data. Routine medication reconciliation and increased patient disclosure remain essential to minimizing avoidable harm and supporting safe, individualized cancer care.
Additional Links: PMID-43047311
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047311,
year = {2026},
author = {Tsourounis, C},
title = {Beyond class assumptions: a clinical decision framework for navigating drug-supplement interactions in oncology.},
journal = {Frontiers in pharmacology},
volume = {17},
number = {},
pages = {1877127},
pmid = {43047311},
issn = {1663-9812},
abstract = {BACKGROUND: Dietary supplement use is common among patients with cancer, with nearly half reporting concurrent use alongside conventional therapy. Despite widespread use, drug-supplement interactions in oncology are often difficult to interpret due to heterogeneous evidence, outdated case reports, reliance on in vitro and animal data, and a traditional focus on drug class effects rather than drug-specific vulnerability. Translation of preclinical findings is further complicated by host factors such as inflammation, pharmacogenomic variability, and the gut microbiome. The purpose of this review is to provide a mechanistic overview of drug-supplement interactions in oncology and characterize the existing literature to support clinical decision-making.
METHODS: This narrative review synthesizes current literature on pharmacokinetic and pharmacodynamic interactions between dietary supplements and anticancer therapies, focusing on key mechanistic domains, including drug metabolism (CYP450 and UDP-glucuronosyltransferase enzymes), transporter systems, and immune modulation, and clinically relevant uncertainty. Interaction risk was evaluated across major anticancer drug classes, including tyrosine kinase inhibitors, hormonal therapies, oral chemotherapies, and immune checkpoint inhibitors.
RESULTS: Interaction vulnerability varies substantially by drug class but is not uniform across individual agents. Tyrosine kinase inhibitors have substantial interaction potential due to CYP3A4 dependence, exposure-response relationships, and, for some agents, narrow therapeutic margins, with vulnerability varying by agent. Hormonal therapies present mechanism-specific risks, particularly CYP2D6-mediated activation of tamoxifen. Oral chemotherapies demonstrate variable interaction potential, with capecitabine associated with increased bleeding risk and cyclophosphamide dependent on CYP-mediated activation. Immune checkpoint inhibitors are less susceptible to metabolic interactions but present interpretation challenges related to immune modulation and emerging microbiome-related evidence, where theoretical risks often exceed clinical evidence. Across drug classes, many reported interactions remain theoretical, are derived from non-clinical data, or lack standardized product verification, limiting clinical interpretation.
CONCLUSION: Drug-supplement interaction risk in oncology is best understood through a mechanism-based, drug-specific framework rather than isolated supplement-based or class-level approaches. A structured assessment incorporating drug metabolism, supplement activity, host factors, and clinical context may improve risk stratification and patient counseling, although management remains challenging in the absence of robust clinical data. Routine medication reconciliation and increased patient disclosure remain essential to minimizing avoidable harm and supporting safe, individualized cancer care.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Microbiome-Based Assessment of Topical Scalp Product-Associated Microbiome Modulation.
Journal of cosmetic dermatology, 25(11):e71238.
BACKGROUND: The scalp microbiome plays a crucial role in maintaining scalp health, yet few studies have examined how topical scalp cosmeceuticals affect bacterial and fungal communities. In this study we aim to investigate the impact of a scalp serum on the scalp microbiome and physiology.
METHODS: In this 12-week IRB-approved study, changes in the scalp microbiome before, during, and after the use of a scalp serum were measured in 56 participants. The bacterial and fungal microbiomes were assessed using 16S rRNA and ITS2 amplicon sequencing and analyzed key scalp parameters such as scalp thickness, intensity, moisture and pH.
RESULTS: We identified a significant increase in the bacteria-to-fungi load ratio after 4 and 12 weeks of product use relative to baseline, driven primarily by increased bacterial load. Fungal Shannon diversity also increased after 4 and 12 weeks of product use relative to baseline, while beta-diversity analysis showed a significant shift in bacterial composition. Pairwise comparisons of the dominant taxa identified significant increases in Cutibacterium namnetense and Cladosporium sp. abundances, along with a significant increases in other low-abundance species after 12 weeks of product use. Spearman's correlation testing identified a significant negative correlation between Malassezia sympodialis and scalp thickness, with additional nonsignificant trends linking microbial composition to hydration and pH.
CONCLUSION: In conclusion, this study suggests that topical treatments may support scalp health by respecting the balance of the scalp microbiome.
Additional Links: PMID-43047317
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047317,
year = {2026},
author = {Nguyen, UT and Skarlupka, J and Iglesia, S and Kononov, T and Zahr, A and Jungman, E and Park, HG},
title = {Microbiome-Based Assessment of Topical Scalp Product-Associated Microbiome Modulation.},
journal = {Journal of cosmetic dermatology},
volume = {25},
number = {11},
pages = {e71238},
pmid = {43047317},
issn = {1473-2165},
abstract = {BACKGROUND: The scalp microbiome plays a crucial role in maintaining scalp health, yet few studies have examined how topical scalp cosmeceuticals affect bacterial and fungal communities. In this study we aim to investigate the impact of a scalp serum on the scalp microbiome and physiology.
METHODS: In this 12-week IRB-approved study, changes in the scalp microbiome before, during, and after the use of a scalp serum were measured in 56 participants. The bacterial and fungal microbiomes were assessed using 16S rRNA and ITS2 amplicon sequencing and analyzed key scalp parameters such as scalp thickness, intensity, moisture and pH.
RESULTS: We identified a significant increase in the bacteria-to-fungi load ratio after 4 and 12 weeks of product use relative to baseline, driven primarily by increased bacterial load. Fungal Shannon diversity also increased after 4 and 12 weeks of product use relative to baseline, while beta-diversity analysis showed a significant shift in bacterial composition. Pairwise comparisons of the dominant taxa identified significant increases in Cutibacterium namnetense and Cladosporium sp. abundances, along with a significant increases in other low-abundance species after 12 weeks of product use. Spearman's correlation testing identified a significant negative correlation between Malassezia sympodialis and scalp thickness, with additional nonsignificant trends linking microbial composition to hydration and pH.
CONCLUSION: In conclusion, this study suggests that topical treatments may support scalp health by respecting the balance of the scalp microbiome.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Host-associated microbiomes act as reservoirs of antimicrobial resistance in Mediterranean coastal waters.
Frontiers in microbiomes, 5:1974573.
INTRODUCTION: Understanding how host-associated microbiomes contribute to the environmental ecology of antimicrobial resistance (AMR) remains a major challenge for coastal One Health surveillance. We compared seawater, commercially farmed Mediterranean mussels (Mytilus galloprovincialis), and the invasive ascidian Styela plicata to assess differences in microbiome composition, resistomes, mobilomes, and putative pathobiomes across interconnected coastal compartments.
METHODS: Samples collected from Mediterranean coastal environments were analysed using 16S rRNA gene sequencing and high-throughput quantitative PCR targeting 71 AMR determinants, including antimicrobial resistance genes (ARGs) and mobile genetic elements (MGEs).
RESULTS: Host-associated microbiomes were consistently distinct from surrounding seawater and remained comparatively stable across sampling periods. Seawater exhibited greater richness of AMR determinants, whereas mussels and ascidians harboured higher relative abundances of ARGs, MGEs, and several clinically relevant resistance determinants. AMR profile composition differed significantly among biotypes but only partially mirrored microbiome structure, indicating that bacterial community composition alone does not explain resistance gene organization. Putative pathogenic bacterial communities also differed among biotypes, with mussels enriched in several human-associated genera whose abundances positively correlated with ARGs.
DISCUSSION: Although these associations do not demonstrate genetic linkage or pathogenicity, they identify host-associated microbiomes as ecologically relevant compartments where clinically relevant resistance determinants, mobile genetic elements, and bacterial genera containing recognized human-associated or opportunistic pathogens coexist. Our findings demonstrate that marine invertebrates complement seawater for environmental AMR surveillance and support their inclusion in integrated coastal One Health monitoring strategies.
Additional Links: PMID-43047336
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047336,
year = {2026},
author = {Gionchetta, G and Alacid, E and Zarcero, J and Fernandez-Tejedor, M and Subirats, J and Turon, M},
title = {Host-associated microbiomes act as reservoirs of antimicrobial resistance in Mediterranean coastal waters.},
journal = {Frontiers in microbiomes},
volume = {5},
number = {},
pages = {1974573},
pmid = {43047336},
issn = {2813-4338},
abstract = {INTRODUCTION: Understanding how host-associated microbiomes contribute to the environmental ecology of antimicrobial resistance (AMR) remains a major challenge for coastal One Health surveillance. We compared seawater, commercially farmed Mediterranean mussels (Mytilus galloprovincialis), and the invasive ascidian Styela plicata to assess differences in microbiome composition, resistomes, mobilomes, and putative pathobiomes across interconnected coastal compartments.
METHODS: Samples collected from Mediterranean coastal environments were analysed using 16S rRNA gene sequencing and high-throughput quantitative PCR targeting 71 AMR determinants, including antimicrobial resistance genes (ARGs) and mobile genetic elements (MGEs).
RESULTS: Host-associated microbiomes were consistently distinct from surrounding seawater and remained comparatively stable across sampling periods. Seawater exhibited greater richness of AMR determinants, whereas mussels and ascidians harboured higher relative abundances of ARGs, MGEs, and several clinically relevant resistance determinants. AMR profile composition differed significantly among biotypes but only partially mirrored microbiome structure, indicating that bacterial community composition alone does not explain resistance gene organization. Putative pathogenic bacterial communities also differed among biotypes, with mussels enriched in several human-associated genera whose abundances positively correlated with ARGs.
DISCUSSION: Although these associations do not demonstrate genetic linkage or pathogenicity, they identify host-associated microbiomes as ecologically relevant compartments where clinically relevant resistance determinants, mobile genetic elements, and bacterial genera containing recognized human-associated or opportunistic pathogens coexist. Our findings demonstrate that marine invertebrates complement seawater for environmental AMR surveillance and support their inclusion in integrated coastal One Health monitoring strategies.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Data-Driven Precision Nutrition Improves Clinical Outcomes and Risk Scores for IBS, Depression, Anxiety, and T2D.
American journal of lifestyle medicine, 20(8):1150-1162.
Many studies have shown that foods and nutritional ingredients play an important role in healthy human homeostasis, either directly or via the microbiome. We have developed an objective, integrated, and automated approach to personalized food and supplement recommendations that is powered by artificial intelligence and individualized molecular data from the gut microbiome, the human host, and their interactions. The process starts with a clinically validated transcriptomic analysis of a person's stool (and some cases also blood) sample. These molecular data are converted into personalized nutritional recommendations (foods and supplements) using algorithms derived from clinical research studies and domain knowledge. We describe an application of our precision nutrition technology platform to human populations with irritable bowel syndrome (IBS), depression, anxiety, and type 2 diabetes (T2D). In these pilot interventional studies, our precision nutrition program achieved significant improvements in clinical outcomes of IBS (39% for severe IBS), depression (31% for severe depression), anxiety (31% for severe anxiety), and the risk score for T2D (>30% reduction relative to the control arm). These data support the integration of data-driven precision nutrition into the standard of care.
Additional Links: PMID-43047493
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047493,
year = {2026},
author = {Connell, J and Toma, R and Ho, CH and Shen, N and Moura, P and Le, T and Patridge, E and Antoine, G and Keiser, H and Julian, C and Naidoo, U and Tanton, D and Banavar, G and Vuyisich, M},
title = {Data-Driven Precision Nutrition Improves Clinical Outcomes and Risk Scores for IBS, Depression, Anxiety, and T2D.},
journal = {American journal of lifestyle medicine},
volume = {20},
number = {8},
pages = {1150-1162},
pmid = {43047493},
issn = {1559-8284},
abstract = {Many studies have shown that foods and nutritional ingredients play an important role in healthy human homeostasis, either directly or via the microbiome. We have developed an objective, integrated, and automated approach to personalized food and supplement recommendations that is powered by artificial intelligence and individualized molecular data from the gut microbiome, the human host, and their interactions. The process starts with a clinically validated transcriptomic analysis of a person's stool (and some cases also blood) sample. These molecular data are converted into personalized nutritional recommendations (foods and supplements) using algorithms derived from clinical research studies and domain knowledge. We describe an application of our precision nutrition technology platform to human populations with irritable bowel syndrome (IBS), depression, anxiety, and type 2 diabetes (T2D). In these pilot interventional studies, our precision nutrition program achieved significant improvements in clinical outcomes of IBS (39% for severe IBS), depression (31% for severe depression), anxiety (31% for severe anxiety), and the risk score for T2D (>30% reduction relative to the control arm). These data support the integration of data-driven precision nutrition into the standard of care.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
From conventional monitoring to agentic AI: integration of data streams and computational tools for real-time microalgal surveillance.
Frontiers in systems biology, 6:1931534.
Microalgal cultivation generates continuous and diverse data streams, including physicochemical sensor measurements, optical and spectroscopic signals, and episodic molecular tests. Together, these data characterize cultivation conditions at different biological scales. Existing AI/ML frameworks can interpret these streams independently; however, human intervention is required to translate predictions into cultivation decisions, adding delays and limiting adaptability across strains, reactors, and environmental conditions. This mini-review describes the transition from conventional monitoring to agentic AI as the progressive integration of sensing, interpretation, and action. The real-time sensing modalities that constitute an agent's perceptual field include AI/ML models and genome-scale metabolic models, which serve as callable tools in the proposed agentic architecture for coordinated data-model integration in algal systems biology. Emerging evidence from agentic systems in microbiome research and precision oncology supports the conceptual and technical plausibility of a multi-agent, tool-enabled framework for autonomous microalgal cultivation and management. However, the proposed integrated architecture holds significant potential for microalgal cultivation systems, it has not yet been implemented and requires experimental validation.
Additional Links: PMID-43047535
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047535,
year = {2026},
author = {Lekhana, HL and Mukunthan, KS and Balaji, S},
title = {From conventional monitoring to agentic AI: integration of data streams and computational tools for real-time microalgal surveillance.},
journal = {Frontiers in systems biology},
volume = {6},
number = {},
pages = {1931534},
pmid = {43047535},
issn = {2674-0702},
abstract = {Microalgal cultivation generates continuous and diverse data streams, including physicochemical sensor measurements, optical and spectroscopic signals, and episodic molecular tests. Together, these data characterize cultivation conditions at different biological scales. Existing AI/ML frameworks can interpret these streams independently; however, human intervention is required to translate predictions into cultivation decisions, adding delays and limiting adaptability across strains, reactors, and environmental conditions. This mini-review describes the transition from conventional monitoring to agentic AI as the progressive integration of sensing, interpretation, and action. The real-time sensing modalities that constitute an agent's perceptual field include AI/ML models and genome-scale metabolic models, which serve as callable tools in the proposed agentic architecture for coordinated data-model integration in algal systems biology. Emerging evidence from agentic systems in microbiome research and precision oncology supports the conceptual and technical plausibility of a multi-agent, tool-enabled framework for autonomous microalgal cultivation and management. However, the proposed integrated architecture holds significant potential for microalgal cultivation systems, it has not yet been implemented and requires experimental validation.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Bone metastases at the nutrition-bone-immune interface: implications for immune checkpoint blockade.
Frontiers in immunology, 17:1982392.
Bone metastases develop within a mineralized and hematopoietic environment shaped by continuous skeletal remodeling, immune-cell trafficking, and systemic host physiology. This specialized niche can restrict immune checkpoint blockade, but the factors governing its responsiveness remain incompletely defined. Evidence linking nutritional status and related endocrine or metabolic factors to bone-specific immunity is fragmented across osteoimmunology, tumor immunology, nutrition, endocrinology, and translational oncology. We distinguish direct nutritional exposures from host-state indices, mineral endocrine regulators, and microbiome-derived metabolites. Mechanistic studies identify osteoclast-associated pathways, including RANK-RANKL signaling and osteopontin, as direct links between skeletal remodeling, impaired T-cell recruitment, and experimental resistance to checkpoint blockade. By contrast, albumin-based indices, cachexia, anemia-related measures, glucocorticoid exposure, thyroid dysfunction, and microbiome features generally provide prognostic, treatment-related, or associative evidence across heterogeneous cancer cohorts. They do not establish ICI-specific prediction, causal reversibility, or therapeutic benefit. Clinical evidence for combining checkpoint inhibitors with antiresorptive, nutritional, endocrine, or microbiome interventions remains inconsistent or preliminary. We therefore use the nutrition-bone-immune axis as a conceptual, evidence-organizing framework, not as a clinically validated unified causal pathway. Clinical translation will require prospective bone-specific cohorts, paired systemic and lesion-level profiling, rigorous temporal definitions, treatment-interaction analyses, and randomized trials integrating skeletal, immune, and oncological endpoints.
Additional Links: PMID-43047537
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047537,
year = {2026},
author = {Liu, W and Shui, T and Zhao, J and Li, L},
title = {Bone metastases at the nutrition-bone-immune interface: implications for immune checkpoint blockade.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1982392},
pmid = {43047537},
issn = {1664-3224},
mesh = {Humans ; *Immune Checkpoint Inhibitors/therapeutic use ; *Bone Neoplasms/secondary/immunology/metabolism/drug therapy ; Animals ; *Nutritional Status ; *Bone and Bones/immunology/metabolism/pathology ; Tumor Microenvironment/immunology ; Bone Remodeling/immunology ; },
abstract = {Bone metastases develop within a mineralized and hematopoietic environment shaped by continuous skeletal remodeling, immune-cell trafficking, and systemic host physiology. This specialized niche can restrict immune checkpoint blockade, but the factors governing its responsiveness remain incompletely defined. Evidence linking nutritional status and related endocrine or metabolic factors to bone-specific immunity is fragmented across osteoimmunology, tumor immunology, nutrition, endocrinology, and translational oncology. We distinguish direct nutritional exposures from host-state indices, mineral endocrine regulators, and microbiome-derived metabolites. Mechanistic studies identify osteoclast-associated pathways, including RANK-RANKL signaling and osteopontin, as direct links between skeletal remodeling, impaired T-cell recruitment, and experimental resistance to checkpoint blockade. By contrast, albumin-based indices, cachexia, anemia-related measures, glucocorticoid exposure, thyroid dysfunction, and microbiome features generally provide prognostic, treatment-related, or associative evidence across heterogeneous cancer cohorts. They do not establish ICI-specific prediction, causal reversibility, or therapeutic benefit. Clinical evidence for combining checkpoint inhibitors with antiresorptive, nutritional, endocrine, or microbiome interventions remains inconsistent or preliminary. We therefore use the nutrition-bone-immune axis as a conceptual, evidence-organizing framework, not as a clinically validated unified causal pathway. Clinical translation will require prospective bone-specific cohorts, paired systemic and lesion-level profiling, rigorous temporal definitions, treatment-interaction analyses, and randomized trials integrating skeletal, immune, and oncological endpoints.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Immune Checkpoint Inhibitors/therapeutic use
*Bone Neoplasms/secondary/immunology/metabolism/drug therapy
Animals
*Nutritional Status
*Bone and Bones/immunology/metabolism/pathology
Tumor Microenvironment/immunology
Bone Remodeling/immunology
RevDate: 2026-11-18
CmpDate: 2026-11-18
Transient ecological states shape interpatient heterogeneity in the periodontal immune-microbial ecosystem.
ISME communications, 6(1):ycag287.
The oral cavity hosts a dynamic immune-microbial ecosystem in which interactions between host responses and microbial communities contribute to periodontal disease. However, how this biological mechanism is organized across patients, sites, and time remains poorly understood. Here, we asked whether longitudinal periodontal samples from the same patient maintain patient-associated immune-microbial similarity over time or undergo temporal and site-specific diversification. We addressed this question using distance-based sample trees to represent similarity among longitudinal cell, cytokine, and microbiome profiles from patients with comparable disease status followed for 1 year. We found that some patients exhibited patient-specific clustering, but these clusters did not consistently contain all longitudinal samples, implying patient-associated temporal and site-specific organization. Characterization of patient-specific clusters suggested candidate microbial and host-associated signatures, including patterns related to immune activity and tissue remodeling for some patients. Overall, the sample-tree framework provides a representation of longitudinal heterogeneity and a means of generating hypotheses about ecological states.
Additional Links: PMID-43047561
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047561,
year = {2026},
author = {Dawadi, P and Tobin, RM and Benmansour, Y and Frias-Lopez, J and Kantarci, A and Miura, S and Teles, F},
title = {Transient ecological states shape interpatient heterogeneity in the periodontal immune-microbial ecosystem.},
journal = {ISME communications},
volume = {6},
number = {1},
pages = {ycag287},
pmid = {43047561},
issn = {2730-6151},
abstract = {The oral cavity hosts a dynamic immune-microbial ecosystem in which interactions between host responses and microbial communities contribute to periodontal disease. However, how this biological mechanism is organized across patients, sites, and time remains poorly understood. Here, we asked whether longitudinal periodontal samples from the same patient maintain patient-associated immune-microbial similarity over time or undergo temporal and site-specific diversification. We addressed this question using distance-based sample trees to represent similarity among longitudinal cell, cytokine, and microbiome profiles from patients with comparable disease status followed for 1 year. We found that some patients exhibited patient-specific clustering, but these clusters did not consistently contain all longitudinal samples, implying patient-associated temporal and site-specific organization. Characterization of patient-specific clusters suggested candidate microbial and host-associated signatures, including patterns related to immune activity and tissue remodeling for some patients. Overall, the sample-tree framework provides a representation of longitudinal heterogeneity and a means of generating hypotheses about ecological states.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Microbiota-derived deoxycholic and lithocholic acids attenuate diabetic kidney disease through suppression of podocyte ferroptosis via TGR5-SLC7A11 interaction.
Frontiers in microbiology, 17:1983926.
OBJECTIVES: Diabetic kidney disease (DKD) is related to gut dysbiosis, yet the specific causative microbes remain unclear. This study integrated multi-omics, including 16S rRNA sequencing, metagenomics, and bile acid metabolomics on fecal samples from DKD patients and mice.
METHODS: Parabacteroides goldsteinii (P. goldsteinii) was orally administered to DKD mice, with assessment of podocyte injury, glomerular function, renal inflammation, and gut barrier integrity.
RESULTS: In this study, we found a significant depletion of the gut commensal P. goldsteinii in both murine models and patients with DKD. Oral administration of P. goldsteinii ameliorated podocyte injury, glomerular dysfunction, renal inflammation, and gut barrier disruption in diabetic mice. The protective effects were mediated by microbially derived bile acids, deoxycholic acid (DCA) and lithocholic acid (LCA), which activate Takeda G protein-coupled receptor 5 (TGR5), with the combined treatment producing greater protective effects than either bile acid alone. Furthermore, inhibition of bile acid hydrolysis (BSH) activity blocked the production of DCA/LCA and eliminated the renal benefits of P. goldsteinii. Mechanistically, DCA and LCA inhibited ferroptosis by promoting the interaction between TGR5 and SLC7A11 in podocytes. This interaction may contribute to the preservation of SLC7A11 function and enhancement of cellular antioxidant capacity, thereby attenuating iron-dependent lipid peroxidation. Podocyte-specific knockdown of TGR5 abolished the renoprotection conferred by P. goldsteinii and DCA/LCA.
CONCLUSION: Collectively, our work identified a gut-kidney axis in which P. goldsteinii-derived bile acids regulated the TGR5-SLC7A11 macromolecular interaction to suppress podocyte ferroptosis, thereby attenuating DKD progression. These findings revealed a functional interaction between TGR5 and SLC7A11 and highlighted its regulation by microbial metabolites as a potential therapeutic mechanism for DKD.
Additional Links: PMID-43047582
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047582,
year = {2026},
author = {Zheng, GL and Yin, AL and Lu, XX and Liu, HT and Yang, MT and Zhu, XX and Lin, SB and Sun, HJ and Lu, QB},
title = {Microbiota-derived deoxycholic and lithocholic acids attenuate diabetic kidney disease through suppression of podocyte ferroptosis via TGR5-SLC7A11 interaction.},
journal = {Frontiers in microbiology},
volume = {17},
number = {},
pages = {1983926},
pmid = {43047582},
issn = {1664-302X},
abstract = {OBJECTIVES: Diabetic kidney disease (DKD) is related to gut dysbiosis, yet the specific causative microbes remain unclear. This study integrated multi-omics, including 16S rRNA sequencing, metagenomics, and bile acid metabolomics on fecal samples from DKD patients and mice.
METHODS: Parabacteroides goldsteinii (P. goldsteinii) was orally administered to DKD mice, with assessment of podocyte injury, glomerular function, renal inflammation, and gut barrier integrity.
RESULTS: In this study, we found a significant depletion of the gut commensal P. goldsteinii in both murine models and patients with DKD. Oral administration of P. goldsteinii ameliorated podocyte injury, glomerular dysfunction, renal inflammation, and gut barrier disruption in diabetic mice. The protective effects were mediated by microbially derived bile acids, deoxycholic acid (DCA) and lithocholic acid (LCA), which activate Takeda G protein-coupled receptor 5 (TGR5), with the combined treatment producing greater protective effects than either bile acid alone. Furthermore, inhibition of bile acid hydrolysis (BSH) activity blocked the production of DCA/LCA and eliminated the renal benefits of P. goldsteinii. Mechanistically, DCA and LCA inhibited ferroptosis by promoting the interaction between TGR5 and SLC7A11 in podocytes. This interaction may contribute to the preservation of SLC7A11 function and enhancement of cellular antioxidant capacity, thereby attenuating iron-dependent lipid peroxidation. Podocyte-specific knockdown of TGR5 abolished the renoprotection conferred by P. goldsteinii and DCA/LCA.
CONCLUSION: Collectively, our work identified a gut-kidney axis in which P. goldsteinii-derived bile acids regulated the TGR5-SLC7A11 macromolecular interaction to suppress podocyte ferroptosis, thereby attenuating DKD progression. These findings revealed a functional interaction between TGR5 and SLC7A11 and highlighted its regulation by microbial metabolites as a potential therapeutic mechanism for DKD.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
The rising burden of chronic gastrointestinal diseases: the role of Mediterranean diet.
Frontiers in pediatrics, 14:1928678.
Chronic gastrointestinal (GI) and metabolic diseases represent a growing global healthcare burden, heavily influenced by environmental factors and the exposome. This comprehensive review evaluates the therapeutic and preventative role of the Mediterranean diet (MD) as a potent non-pharmacological intervention in modulating gut health. A literature analysis was conducted focusing on the mechanisms of the MD-rich in polyphenols, monounsaturated fatty acids, and dietary fiber-and its clinical impact on pediatric Inflammatory Bowel Disease (IBD), gluten-related disorders, functional GI disorders, and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The MD acts as a critical modulator of the gut microbiome, effectively reversing dysbiosis and promoting microbial diversity. Nutraceutical components of the diet significantly reduce systemic and localized inflammation by downregulating pro-inflammatory cytokines. Furthermore, the MD reinforces the gut epithelial barrier and enhances mucosal immunity. Clinical data demonstrate that high MD adherence correlates with reduced disease activity in pediatric IBD, improved symptom management in functional GI disorders, and attenuated hepatic steatosis and metabolic syndrome markers in MASLD patients. The Mediterranean diet serves as a powerful, evidence-based strategy for mitigating chronic gastrointestinal and metabolic disorders. By directly targeting dysbiosis and inflammation, it offers an effective lifestyle-based modulation tool to alleviate the rising clinical burden of modern digestive pathologies.
Additional Links: PMID-43047629
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047629,
year = {2026},
author = {Argyri, I and Matara, DI and Bachou, T and Mentesidou, L and Zellos, A},
title = {The rising burden of chronic gastrointestinal diseases: the role of Mediterranean diet.},
journal = {Frontiers in pediatrics},
volume = {14},
number = {},
pages = {1928678},
pmid = {43047629},
issn = {2296-2360},
abstract = {Chronic gastrointestinal (GI) and metabolic diseases represent a growing global healthcare burden, heavily influenced by environmental factors and the exposome. This comprehensive review evaluates the therapeutic and preventative role of the Mediterranean diet (MD) as a potent non-pharmacological intervention in modulating gut health. A literature analysis was conducted focusing on the mechanisms of the MD-rich in polyphenols, monounsaturated fatty acids, and dietary fiber-and its clinical impact on pediatric Inflammatory Bowel Disease (IBD), gluten-related disorders, functional GI disorders, and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The MD acts as a critical modulator of the gut microbiome, effectively reversing dysbiosis and promoting microbial diversity. Nutraceutical components of the diet significantly reduce systemic and localized inflammation by downregulating pro-inflammatory cytokines. Furthermore, the MD reinforces the gut epithelial barrier and enhances mucosal immunity. Clinical data demonstrate that high MD adherence correlates with reduced disease activity in pediatric IBD, improved symptom management in functional GI disorders, and attenuated hepatic steatosis and metabolic syndrome markers in MASLD patients. The Mediterranean diet serves as a powerful, evidence-based strategy for mitigating chronic gastrointestinal and metabolic disorders. By directly targeting dysbiosis and inflammation, it offers an effective lifestyle-based modulation tool to alleviate the rising clinical burden of modern digestive pathologies.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
6-pentyl-2H-pyran-2-one: from a fungal volatile metabolite to an ecological signaling hub for sustainable crop protection.
Frontiers in microbiology, 17:1989293.
6-Pentyl-2H-pyran-2-one (6-PP) is a characteristic volatile secondary metabolite produced by Trichoderma species and was initially studied for its coconut-like odor and antifungal activity. Recent studies have revealed that 6-PP has broader roles in fungal ecology, influencing pathogen interactions, plant responses, and associated microbial communities. Here, we summarize recent advances in 6-PP biology, focusing on four aspects: the evolution of its biosynthetic model, the regulation of its production, its ecological functions, and its potential applications in crop protection. The discovery of the Pks1-mediated pathway has revised previous views based mainly on fatty acid metabolism and provided genetic evidence for 6-PP biosynthesis. We further discuss how environmental signals, intracellular signaling pathways, transcriptional regulators, chromatin modification, and metabolic states collectively influence 6-PP production. At the ecological level, 6-PP acts as a signaling molecule that affects pathogen fitness, plant growth and defense responses, and plant-associated microbiome assembly. Finally, we highlight strategies for translating 6-PP biology into agricultural applications through strain engineering, controlled-release formulations, and microbial consortium-based biocontrol. Key challenges include elucidating downstream biosynthetic steps, identifying plant perception mechanisms, clarifying the ecological effects of 6-PP on microbial communities, and validating its efficacy under field conditions. Addressing these knowledge gaps will advance our understanding of 6-PP as a potential ecological signaling molecule and support the development of sustainable crop protection strategies.
Additional Links: PMID-43047648
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047648,
year = {2026},
author = {Wang, S and Liu, H and Zhang, C and Zhang, X and Wang, X and Zhou, Y and Chen, J and Li, Y},
title = {6-pentyl-2H-pyran-2-one: from a fungal volatile metabolite to an ecological signaling hub for sustainable crop protection.},
journal = {Frontiers in microbiology},
volume = {17},
number = {},
pages = {1989293},
pmid = {43047648},
issn = {1664-302X},
abstract = {6-Pentyl-2H-pyran-2-one (6-PP) is a characteristic volatile secondary metabolite produced by Trichoderma species and was initially studied for its coconut-like odor and antifungal activity. Recent studies have revealed that 6-PP has broader roles in fungal ecology, influencing pathogen interactions, plant responses, and associated microbial communities. Here, we summarize recent advances in 6-PP biology, focusing on four aspects: the evolution of its biosynthetic model, the regulation of its production, its ecological functions, and its potential applications in crop protection. The discovery of the Pks1-mediated pathway has revised previous views based mainly on fatty acid metabolism and provided genetic evidence for 6-PP biosynthesis. We further discuss how environmental signals, intracellular signaling pathways, transcriptional regulators, chromatin modification, and metabolic states collectively influence 6-PP production. At the ecological level, 6-PP acts as a signaling molecule that affects pathogen fitness, plant growth and defense responses, and plant-associated microbiome assembly. Finally, we highlight strategies for translating 6-PP biology into agricultural applications through strain engineering, controlled-release formulations, and microbial consortium-based biocontrol. Key challenges include elucidating downstream biosynthetic steps, identifying plant perception mechanisms, clarifying the ecological effects of 6-PP on microbial communities, and validating its efficacy under field conditions. Addressing these knowledge gaps will advance our understanding of 6-PP as a potential ecological signaling molecule and support the development of sustainable crop protection strategies.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Context matters: fermented foods and the gut microbiota.
Frontiers in nutrition, 13:1953038.
Additional Links: PMID-43047702
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047702,
year = {2026},
author = {Piccardi, P and Abraham, A and Mamtani, R and Cheema, S},
title = {Context matters: fermented foods and the gut microbiota.},
journal = {Frontiers in nutrition},
volume = {13},
number = {},
pages = {1953038},
pmid = {43047702},
issn = {2296-861X},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Ultra-processed food ingredients as environmental contributors to chronic diseases and cancer: emerging evidence linking gut dysbiosis, inflammation, oxidative stress, and metabolic dysfunction.
Frontiers in oncology, 16:1978662.
Ultra-processed foods (UPFs) are industrially manufactured formulations composed primarily of refined ingredients, modified fats, added sugars, salt, and numerous cosmetic additives designed to enhance palatability, appearance, texture, and shelf life. As UPFs constitute an increasingly large proportion of diets worldwide, growing epidemiological and experimental evidence links their consumption to a broad spectrum of chronic diseases, including obesity, metabolic syndrome, type 2 diabetes, cardiovascular disease, renal disorders, neurodegenerative conditions, and several forms of cancer. Common UPF constituents include refined flour, high levels of added sugars and artificial sweeteners, processed fats, sodium chloride, flavor enhancers, emulsifiers, thickeners, artificial colorants, preservatives, and processing-derived contaminants that may adversely affect human health. Emerging evidence suggests that the cumulative and interactive effects of these ingredients create a tumor-promoting biological milieu, herein referred to as onkoperigenesis (Greek: tumor-inducing environment). Multiple mechanisms appear to contribute to this process, including chronic low-grade inflammation, oxidative stress, genomic instability, epigenetic dysregulation, mitochondrial dysfunction, metabolic disturbances, and alterations in host immune responses. Many UPF additives and processing-related compounds increase the generation of reactive oxygen species, promote lipid peroxidation, induce DNA damage, and interfere with cellular repair mechanisms, thereby increasing susceptibility to malignant transformation and disease progression. A central pathway linking UPFs to chronic disease and cancer involves disruption of the gut microbiome. Emulsifiers, artificial sweeteners, preservatives, and other food additives have been shown to alter microbial diversity, reduce beneficial bacterial populations, impair gut barrier integrity, and promote intestinal permeability. These changes facilitate the systemic translocation of microbial products and inflammatory mediators, resulting in persistent immune activation. Diet-induced dysbiosis may further reduce the production of protective short-chain fatty acids, alter bile acid metabolism, and enhance signaling pathways associated with cellular proliferation, inflammation, and carcinogenesis. UPFs also contribute to metabolic dysfunction through effects on glucose regulation, insulin signaling, adiposity, and pancreatic β-cell function. These alterations promote insulin resistance, hyperinsulinemia, and chronic systemic inflammation, all of which are recognized contributors to both chronic disease development and tumor growth. In parallel, several food additives and processing-generated compounds have been associated with epigenetic modifications, endocrine disruption, apoptosis dysregulation, and mitochondrial impairment, creating conditions favorable for disease initiation and progression. This review examines the mechanistic pathways through which UPFs contribute to chronic diseases and cancer, emphasizing the interconnected roles of oxidative stress, inflammation, metabolic abnormalities, immune dysregulation, and microbiome disruption. Chronic conditions such as obesity, cardiovascular disease, renal dysfunction, neurological disorders, and skeletal abnormalities are discussed primarily as manifestations of these shared pathogenic mechanisms and as intermediary states that may further increase cancer risk. Collectively, current evidence indicates that UPFs promote a biological environment conducive to both chronic disease development and carcinogenesis. A deeper understanding of the individual and synergistic effects of UPF ingredients is essential for improving dietary risk assessment, informing regulatory policies, and developing effective public health strategies aimed at reducing the global burden of chronic diseases and cancer.
Additional Links: PMID-43047723
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047723,
year = {2026},
author = {Thomas, S and Lutz, O and Albert, N},
title = {Ultra-processed food ingredients as environmental contributors to chronic diseases and cancer: emerging evidence linking gut dysbiosis, inflammation, oxidative stress, and metabolic dysfunction.},
journal = {Frontiers in oncology},
volume = {16},
number = {},
pages = {1978662},
pmid = {43047723},
issn = {2234-943X},
abstract = {Ultra-processed foods (UPFs) are industrially manufactured formulations composed primarily of refined ingredients, modified fats, added sugars, salt, and numerous cosmetic additives designed to enhance palatability, appearance, texture, and shelf life. As UPFs constitute an increasingly large proportion of diets worldwide, growing epidemiological and experimental evidence links their consumption to a broad spectrum of chronic diseases, including obesity, metabolic syndrome, type 2 diabetes, cardiovascular disease, renal disorders, neurodegenerative conditions, and several forms of cancer. Common UPF constituents include refined flour, high levels of added sugars and artificial sweeteners, processed fats, sodium chloride, flavor enhancers, emulsifiers, thickeners, artificial colorants, preservatives, and processing-derived contaminants that may adversely affect human health. Emerging evidence suggests that the cumulative and interactive effects of these ingredients create a tumor-promoting biological milieu, herein referred to as onkoperigenesis (Greek: tumor-inducing environment). Multiple mechanisms appear to contribute to this process, including chronic low-grade inflammation, oxidative stress, genomic instability, epigenetic dysregulation, mitochondrial dysfunction, metabolic disturbances, and alterations in host immune responses. Many UPF additives and processing-related compounds increase the generation of reactive oxygen species, promote lipid peroxidation, induce DNA damage, and interfere with cellular repair mechanisms, thereby increasing susceptibility to malignant transformation and disease progression. A central pathway linking UPFs to chronic disease and cancer involves disruption of the gut microbiome. Emulsifiers, artificial sweeteners, preservatives, and other food additives have been shown to alter microbial diversity, reduce beneficial bacterial populations, impair gut barrier integrity, and promote intestinal permeability. These changes facilitate the systemic translocation of microbial products and inflammatory mediators, resulting in persistent immune activation. Diet-induced dysbiosis may further reduce the production of protective short-chain fatty acids, alter bile acid metabolism, and enhance signaling pathways associated with cellular proliferation, inflammation, and carcinogenesis. UPFs also contribute to metabolic dysfunction through effects on glucose regulation, insulin signaling, adiposity, and pancreatic β-cell function. These alterations promote insulin resistance, hyperinsulinemia, and chronic systemic inflammation, all of which are recognized contributors to both chronic disease development and tumor growth. In parallel, several food additives and processing-generated compounds have been associated with epigenetic modifications, endocrine disruption, apoptosis dysregulation, and mitochondrial impairment, creating conditions favorable for disease initiation and progression. This review examines the mechanistic pathways through which UPFs contribute to chronic diseases and cancer, emphasizing the interconnected roles of oxidative stress, inflammation, metabolic abnormalities, immune dysregulation, and microbiome disruption. Chronic conditions such as obesity, cardiovascular disease, renal dysfunction, neurological disorders, and skeletal abnormalities are discussed primarily as manifestations of these shared pathogenic mechanisms and as intermediary states that may further increase cancer risk. Collectively, current evidence indicates that UPFs promote a biological environment conducive to both chronic disease development and carcinogenesis. A deeper understanding of the individual and synergistic effects of UPF ingredients is essential for improving dietary risk assessment, informing regulatory policies, and developing effective public health strategies aimed at reducing the global burden of chronic diseases and cancer.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Detection and identification of Neisseria subflava in saliva stains using recombinant polymerase amplification combined with lateral flow dipstick.
Frontiers in microbiology, 17:1961596.
In forensic practice, the unequivocal identification of questioned biological stains is indispensable for evidence triage, investigative guidance, and the attribution of criminal responsibility. Among these traces, saliva is one of the most prevalent yet challenging biological matrices to detect. Classical analytical strategies-chemical colorimetry, enzymatic assays, immunochromatography, vibrational spectroscopy, and microscopical techniques-frequently suffer from elevated false-positive and false-negative rates, insufficient analytical sensitivity, and stringent demands regarding sample integrity and environmental background. These limitations are further exacerbated by the intrinsic scarcity and unpredictable degradation of forensic specimens, which often preclude acquisition of material in requisite quantity and quality. To overcome these constraints, we have developed an integrated assay that couples recombinase polymerase amplification with lateral-flow dipstick technology, selectively targeting Neisseria subflava-a microorganism highly enriched in human saliva-for definitive identification of saliva stains. The optimised system exhibits exceptional analytical parameters: 100% specificity, an overall accuracy of 87.1%, and a limit of detection at 0.625 copies/μL, while retaining functionality on samples aged under ambient conditions for extended periods. Importantly, the isothermal reaction proceeds efficiently at human body temperature, enabling on-scene deployment. This capability allows immediate probative determination at the crime scene and provides critical guidance for subsequent targeted DNA extraction and individual identification workflows.
Additional Links: PMID-43047772
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047772,
year = {2026},
author = {Li, X and Wang, C and Liu, S and Wang, X and Chen, S and Wen, D and Zha, L},
title = {Detection and identification of Neisseria subflava in saliva stains using recombinant polymerase amplification combined with lateral flow dipstick.},
journal = {Frontiers in microbiology},
volume = {17},
number = {},
pages = {1961596},
pmid = {43047772},
issn = {1664-302X},
abstract = {In forensic practice, the unequivocal identification of questioned biological stains is indispensable for evidence triage, investigative guidance, and the attribution of criminal responsibility. Among these traces, saliva is one of the most prevalent yet challenging biological matrices to detect. Classical analytical strategies-chemical colorimetry, enzymatic assays, immunochromatography, vibrational spectroscopy, and microscopical techniques-frequently suffer from elevated false-positive and false-negative rates, insufficient analytical sensitivity, and stringent demands regarding sample integrity and environmental background. These limitations are further exacerbated by the intrinsic scarcity and unpredictable degradation of forensic specimens, which often preclude acquisition of material in requisite quantity and quality. To overcome these constraints, we have developed an integrated assay that couples recombinase polymerase amplification with lateral-flow dipstick technology, selectively targeting Neisseria subflava-a microorganism highly enriched in human saliva-for definitive identification of saliva stains. The optimised system exhibits exceptional analytical parameters: 100% specificity, an overall accuracy of 87.1%, and a limit of detection at 0.625 copies/μL, while retaining functionality on samples aged under ambient conditions for extended periods. Importantly, the isothermal reaction proceeds efficiently at human body temperature, enabling on-scene deployment. This capability allows immediate probative determination at the crime scene and provides critical guidance for subsequent targeted DNA extraction and individual identification workflows.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
The potential role of infections in melanoma.
Frontiers in public health, 14:1950224.
INTRODUCTION: Several infectious agents have been implicated in the development of human cancers; however, whether infections contribute to the etiology of melanoma remains unclear. This review evaluated the available evidence regarding potential infectious causes of melanoma. The objective is to determine the evidence available regarding the associations of infectious agents with the development of melanoma.
METHODS: A scoping review of the literature was conducted to identify studies investigating the links between infectious agents and melanoma. Four databases were searched using a combination of keywords and controlled vocabulary for published academic articles. Based on the inclusion criteria, 791 titles and abstracts were screened, and 22 articles were obtained. Inclusion criteria were for studies examining associations between viral infectious agents and melanoma; no language restrictions; and no date range restrictions. The review was broadly inclusive of study types including epidemiologic studies such as meta-analyses, systematic and narrative reviews and observational studies; laboratory and mechanistic studies; and case reports. Studies were grouped into three categories: epidemiologic studies evaluating direct associations between infections and melanoma; laboratory and mechanistic studies investigating potential infection-related carcinogenic pathways for melanoma; and studies examining infections that may predispose to cancers overall, including melanoma. Appropriate-for-study-design criteria were applied to each group of studies to assess and summarize their quality.
RESULTS: Twenty-two studies met inclusion criteria and were determined to be of moderate to high quality. Infectious agents investigated included human papillomavirus (HPV), Human Herpesvirus 8 (HHV-8), herpes simplex virus type 2 (HSV-2), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and the cutaneous microbiome. Three epidemiologic studies directly examined the relationship between infections and melanoma; however, complete study data were available for only one study. These studies had inconsistent results. Seven laboratory and experimental studies demonstrated biologically plausible pathways through which infectious agents, particularly human papillomavirus (HPV) and herpes simplex virus (HSV), may contribute to carcinogenesis. However, the most evidence for biological plausibility was from studies of general cancer biology or non-melanoma skin cancers. Studies examining infections as potential cancer-predisposing conditions generally were the most abundant (12 of 22 studies) and consistently identified HIV-associated immunosuppression as a risk factor for cancers, including increased melanoma incidence and poorer outcomes.
CONCLUSION: The available evidence is currently insufficient to determine whether infectious agents are direct causes of melanoma. There are very few epidemiologic studies assessing the associations of infections and melanoma specifically, and these studies demonstrate inconsistent results. Available laboratory and mechanistic studies show biological plausibility for infectious contributions to melanoma-related carcinogenesis; however, direct evidence supporting specific roles in melanoma development remains limited. The largest numbers of studies available have identified that infections such as HIV and their associated immunosuppression that influence cancer risk overall, also influence melanoma risk, indirectly through immune dysfunction. Some available descriptive surveillance databases have shown increased melanoma rates among occupational groups at increased risk of person-to-person infection transmission exposure. Thus, more epidemiologic and laboratory studies are needed to investigate the potential role of infections in melanomas specifically.
Additional Links: PMID-43047802
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047802,
year = {2026},
author = {Olaoye, F and Urrutia-Bastardo, R and Kung, JY and Doroshenko, A and Rahman, S and Shah, I and Xiong, Y and Lee, KK},
title = {The potential role of infections in melanoma.},
journal = {Frontiers in public health},
volume = {14},
number = {},
pages = {1950224},
pmid = {43047802},
issn = {2296-2565},
mesh = {Humans ; *Melanoma/etiology/virology/epidemiology ; *Skin Neoplasms/virology ; Papillomavirus Infections/complications ; },
abstract = {INTRODUCTION: Several infectious agents have been implicated in the development of human cancers; however, whether infections contribute to the etiology of melanoma remains unclear. This review evaluated the available evidence regarding potential infectious causes of melanoma. The objective is to determine the evidence available regarding the associations of infectious agents with the development of melanoma.
METHODS: A scoping review of the literature was conducted to identify studies investigating the links between infectious agents and melanoma. Four databases were searched using a combination of keywords and controlled vocabulary for published academic articles. Based on the inclusion criteria, 791 titles and abstracts were screened, and 22 articles were obtained. Inclusion criteria were for studies examining associations between viral infectious agents and melanoma; no language restrictions; and no date range restrictions. The review was broadly inclusive of study types including epidemiologic studies such as meta-analyses, systematic and narrative reviews and observational studies; laboratory and mechanistic studies; and case reports. Studies were grouped into three categories: epidemiologic studies evaluating direct associations between infections and melanoma; laboratory and mechanistic studies investigating potential infection-related carcinogenic pathways for melanoma; and studies examining infections that may predispose to cancers overall, including melanoma. Appropriate-for-study-design criteria were applied to each group of studies to assess and summarize their quality.
RESULTS: Twenty-two studies met inclusion criteria and were determined to be of moderate to high quality. Infectious agents investigated included human papillomavirus (HPV), Human Herpesvirus 8 (HHV-8), herpes simplex virus type 2 (HSV-2), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and the cutaneous microbiome. Three epidemiologic studies directly examined the relationship between infections and melanoma; however, complete study data were available for only one study. These studies had inconsistent results. Seven laboratory and experimental studies demonstrated biologically plausible pathways through which infectious agents, particularly human papillomavirus (HPV) and herpes simplex virus (HSV), may contribute to carcinogenesis. However, the most evidence for biological plausibility was from studies of general cancer biology or non-melanoma skin cancers. Studies examining infections as potential cancer-predisposing conditions generally were the most abundant (12 of 22 studies) and consistently identified HIV-associated immunosuppression as a risk factor for cancers, including increased melanoma incidence and poorer outcomes.
CONCLUSION: The available evidence is currently insufficient to determine whether infectious agents are direct causes of melanoma. There are very few epidemiologic studies assessing the associations of infections and melanoma specifically, and these studies demonstrate inconsistent results. Available laboratory and mechanistic studies show biological plausibility for infectious contributions to melanoma-related carcinogenesis; however, direct evidence supporting specific roles in melanoma development remains limited. The largest numbers of studies available have identified that infections such as HIV and their associated immunosuppression that influence cancer risk overall, also influence melanoma risk, indirectly through immune dysfunction. Some available descriptive surveillance databases have shown increased melanoma rates among occupational groups at increased risk of person-to-person infection transmission exposure. Thus, more epidemiologic and laboratory studies are needed to investigate the potential role of infections in melanomas specifically.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Melanoma/etiology/virology/epidemiology
*Skin Neoplasms/virology
Papillomavirus Infections/complications
RevDate: 2026-11-18
CmpDate: 2026-11-18
Gastric microbiome dysbiosis in chronic atrophic gastritis and gastric cancer: evidence beyond Helicobacter pylori.
American journal of cancer research, 16(10):4529-4555.
Chronic atrophic gastritis (CAG) is a key precancerous condition in the multistep development of gastric cancer (GC), but the risk of malignant progression varies markedly among patients. Although Helicobacter pylori is the best-established trigger of chronic gastritis, glandular atrophy, and intestinal metaplasia, progressive hypochlorhydria, mucosal barrier impairment, and altered local immunity may also reshape the broader gastric microbiota. Apparent H. pylori-negative status should therefore be interpreted cautiously, as it may reflect previous infection, eradication, false-negative testing, low bacterial burden in advanced lesions, true never-infected status, or autoimmune AG. Enrichment of non-H. pylori taxa alone does not prove microbial replacement or H. pylori-independent causation. This review evaluates links between gastric microbiome remodeling and GC risk in CAG, focusing on microbial composition, functional pathways, mucosal immunity, oxidative stress, and epigenetic alterations. Evidence is interpreted according to disease stage, sample source, study design, and causal strength. Cross-sectional studies show stage-associated microbial differences across non-atrophic gastritis (NAG), CAG, intestinal metaplasia, dysplasia, and GC, but cannot establish temporal direction. Mechanistic data from animal, organoid, and cell models remain model-specific, whereas findings from established GC, intratumoral or fecal microbiota, metastasis, prognosis, and immunotherapy mainly reflect tumor-stage biology. Current evidence supports gastric dysbiosis as a plausible marker or context-dependent modifier, rather than an established independent driver. Prospective CAG-stage cohorts, standardized protocols, rigorous H. pylori classification, and direct functional validation are needed for clinical translation.
Additional Links: PMID-43047981
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047981,
year = {2026},
author = {Qin, X and Wang, K and Wu, Y and Wang, X and Sun, K and Ma, L and Hu, Z and Wei, H and Lu, J and He, Z and Wang, H and Chen, H and Li, Z and Zhang, H},
title = {Gastric microbiome dysbiosis in chronic atrophic gastritis and gastric cancer: evidence beyond Helicobacter pylori.},
journal = {American journal of cancer research},
volume = {16},
number = {10},
pages = {4529-4555},
pmid = {43047981},
issn = {2156-6976},
abstract = {Chronic atrophic gastritis (CAG) is a key precancerous condition in the multistep development of gastric cancer (GC), but the risk of malignant progression varies markedly among patients. Although Helicobacter pylori is the best-established trigger of chronic gastritis, glandular atrophy, and intestinal metaplasia, progressive hypochlorhydria, mucosal barrier impairment, and altered local immunity may also reshape the broader gastric microbiota. Apparent H. pylori-negative status should therefore be interpreted cautiously, as it may reflect previous infection, eradication, false-negative testing, low bacterial burden in advanced lesions, true never-infected status, or autoimmune AG. Enrichment of non-H. pylori taxa alone does not prove microbial replacement or H. pylori-independent causation. This review evaluates links between gastric microbiome remodeling and GC risk in CAG, focusing on microbial composition, functional pathways, mucosal immunity, oxidative stress, and epigenetic alterations. Evidence is interpreted according to disease stage, sample source, study design, and causal strength. Cross-sectional studies show stage-associated microbial differences across non-atrophic gastritis (NAG), CAG, intestinal metaplasia, dysplasia, and GC, but cannot establish temporal direction. Mechanistic data from animal, organoid, and cell models remain model-specific, whereas findings from established GC, intratumoral or fecal microbiota, metastasis, prognosis, and immunotherapy mainly reflect tumor-stage biology. Current evidence supports gastric dysbiosis as a plausible marker or context-dependent modifier, rather than an established independent driver. Prospective CAG-stage cohorts, standardized protocols, rigorous H. pylori classification, and direct functional validation are needed for clinical translation.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Microbiome variation across the intestinal dysbiosis landscape is linked to inflammation and transit time.
eGastroenterology, 4(4):e100362.
BACKGROUND: Intestinal dysbiosis, an imbalance in gut microbial composition and host-microbiome interaction, has been linked to various conditions and disorders. Although characterised by multiple features, such as reduced microbial diversity and bacterial load, as well as an underrepresentation of beneficial microorganisms and an overrepresentation of pathobionts, an exact definition remains elusive. Whether all dysbiotic individuals share similar microbial composition and host properties is currently unclear.
METHODS: Here, we analysed 4500 faecal microbiomes from five cohorts, spanning various pathologies and degrees of health, collected and processed using identical laboratory and bioinformatics protocols. Focusing on Bacteroides 2 (Bact2) microbiome profiles (n=754) as representatives of dysbiosis, we studied the dysbiotic landscape of microbiota composition and associated host variables.
RESULTS: Two of the three identified Bact2 areas were clearly biologically defined, showing distinct host properties in transit time and inflammatory tone. The inflammatory area exhibits established dysbiosis properties, such as strongly decreased microbial load and richness and increased pathobiont prevalence, and is found in patients with active inflammatory bowel disease and increased faecal calprotectin values. In addition, a second, novel dysbiotic profile was identified, characterised by slower intestinal transit and an increase in slow-growing bacteria, while still exhibiting dysbiotic features compared with eubiotic enterotypes. Both areas are associated with recent antibiotic use yet they manifest in different compositions due to other drivers.
CONCLUSION: Together, these results show significant variation in composition and host factors within the dysbiosis landscape, with potential implications for the interpretation of microbiome-based diagnostics and future microbiome-modulation studies.
Additional Links: PMID-43047989
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43047989,
year = {2026},
author = {Daryoush, T and Proost, S and Vieira-Silva, S and Vázquez Castellanos, JF and Falony, G and Devolder, L and Tito, R and Vermeire, S and Caenepeel, C and Sabino, J and Tack, J and Carbone, F and Van den Houte, K and D'Hooghe, M and Pauwels, A and Verbandt, S and Aguirre-Vazquez, M and Tejpar, S and Raes, J},
title = {Microbiome variation across the intestinal dysbiosis landscape is linked to inflammation and transit time.},
journal = {eGastroenterology},
volume = {4},
number = {4},
pages = {e100362},
pmid = {43047989},
issn = {2976-7296},
abstract = {BACKGROUND: Intestinal dysbiosis, an imbalance in gut microbial composition and host-microbiome interaction, has been linked to various conditions and disorders. Although characterised by multiple features, such as reduced microbial diversity and bacterial load, as well as an underrepresentation of beneficial microorganisms and an overrepresentation of pathobionts, an exact definition remains elusive. Whether all dysbiotic individuals share similar microbial composition and host properties is currently unclear.
METHODS: Here, we analysed 4500 faecal microbiomes from five cohorts, spanning various pathologies and degrees of health, collected and processed using identical laboratory and bioinformatics protocols. Focusing on Bacteroides 2 (Bact2) microbiome profiles (n=754) as representatives of dysbiosis, we studied the dysbiotic landscape of microbiota composition and associated host variables.
RESULTS: Two of the three identified Bact2 areas were clearly biologically defined, showing distinct host properties in transit time and inflammatory tone. The inflammatory area exhibits established dysbiosis properties, such as strongly decreased microbial load and richness and increased pathobiont prevalence, and is found in patients with active inflammatory bowel disease and increased faecal calprotectin values. In addition, a second, novel dysbiotic profile was identified, characterised by slower intestinal transit and an increase in slow-growing bacteria, while still exhibiting dysbiotic features compared with eubiotic enterotypes. Both areas are associated with recent antibiotic use yet they manifest in different compositions due to other drivers.
CONCLUSION: Together, these results show significant variation in composition and host factors within the dysbiosis landscape, with potential implications for the interpretation of microbiome-based diagnostics and future microbiome-modulation studies.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
The Microbiome in Cancer: Composition, Mechanisms, and Therapeutic Implications.
MedComm, 7(12):e71133.
Cancer complexity arises not only from host genetics but also from interactions between the host and microbial communities. However, the field remains fragmented, and a systems-level framework is needed to guide precision diagnostics and therapy. We develop the "oncobiome" as an integrative framework linking commensal, pathobiont, and tumor-associated microbial activities to cancer development, progression, and treatment response. We describe how diet, antibiotics, therapy, and environmental factors may shape the shift from microbiome homeostasis to a malignancy-associated oncobiome. An organ-specific overview of the oncobiome illustrates how microbial communities interact with systemic microbial, immune, and metabolic networks. Mechanistically, we examine how microbial signals may influence the hallmarks of cancer, including genomic instability, altered tumor metabolism, and immune evasion, as well as epithelial barrier disruption, metastatic progression, and therapeutic resistance. Finally, we assess candidate microbial biomarkers for cancer detection, prognosis, and treatment-response monitoring, alongside fecal microbiota transplantation, rationally designed microbial consortia, and selected probiotics. We distinguish preliminary anticancer findings from microbiota-restoration and supportive-care applications and highlight the need for prospective validation and contamination control. By integrating temporal microbial variation, anatomical niches, and cancer-relevant functions, this review identifies priorities for development and clinical evaluation of microbiome-based diagnostics and interventions.
Additional Links: PMID-43048000
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048000,
year = {2026},
author = {Zhang, X and Lou, N and Dong, J and Li, H and Wang, N and Li, Y and Han, X},
title = {The Microbiome in Cancer: Composition, Mechanisms, and Therapeutic Implications.},
journal = {MedComm},
volume = {7},
number = {12},
pages = {e71133},
pmid = {43048000},
issn = {2688-2663},
abstract = {Cancer complexity arises not only from host genetics but also from interactions between the host and microbial communities. However, the field remains fragmented, and a systems-level framework is needed to guide precision diagnostics and therapy. We develop the "oncobiome" as an integrative framework linking commensal, pathobiont, and tumor-associated microbial activities to cancer development, progression, and treatment response. We describe how diet, antibiotics, therapy, and environmental factors may shape the shift from microbiome homeostasis to a malignancy-associated oncobiome. An organ-specific overview of the oncobiome illustrates how microbial communities interact with systemic microbial, immune, and metabolic networks. Mechanistically, we examine how microbial signals may influence the hallmarks of cancer, including genomic instability, altered tumor metabolism, and immune evasion, as well as epithelial barrier disruption, metastatic progression, and therapeutic resistance. Finally, we assess candidate microbial biomarkers for cancer detection, prognosis, and treatment-response monitoring, alongside fecal microbiota transplantation, rationally designed microbial consortia, and selected probiotics. We distinguish preliminary anticancer findings from microbiota-restoration and supportive-care applications and highlight the need for prospective validation and contamination control. By integrating temporal microbial variation, anatomical niches, and cancer-relevant functions, this review identifies priorities for development and clinical evaluation of microbiome-based diagnostics and interventions.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Shifting climates, shifting microbes: environmental determinants of the Anopheles microbiome and impact on malaria transmission.
Frontiers in cellular and infection microbiology, 16:2010190.
Malaria transmission dynamics are governed by complex tripartite interactions between the Anopheles mosquito, the Plasmodium parasite, and the vector's gut microbiota, all mediated by the mosquito's innate immune system. Although global malaria control is increasingly hindered by drug and insecticide resistance, significant knowledge gaps persist regarding how climate shifts and environmental variations impact vector competence. While most experimental research relies on static laboratory conditions (typically fixed at 27 °C and 75-80% relative humidity), mosquitoes in nature experience continuous diurnal and seasonal environmental fluctuations that alter their physiology, immune responses, and microbiome. Here, we focus on how these environmental shifts likely influence the efficacy and translational success of innovative, microbial-based control strategies, including paratransgenesis, Wolbachia-based interventions, and microbial larvicides. By examining how climate-driven variations impact both the mosquito-microbiota-parasite system and the performance of biocontrol tools, we bridge ecological and molecular perspectives to identify the current understanding of how shifting environments influence the mosquito microbiome and microbial-based tools. We highlight the critical need to integrate dynamic climatic regimes into upstream laboratory evaluations to ensure future malaria control tools remain resilient in a global changing climate.
Additional Links: PMID-43048157
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048157,
year = {2026},
author = {Archaga, O and Simões, ML},
title = {Shifting climates, shifting microbes: environmental determinants of the Anopheles microbiome and impact on malaria transmission.},
journal = {Frontiers in cellular and infection microbiology},
volume = {16},
number = {},
pages = {2010190},
pmid = {43048157},
issn = {2235-2988},
mesh = {Animals ; *Anopheles/microbiology/parasitology/immunology ; *Malaria/transmission/prevention & control ; *Microbiota ; *Mosquito Vectors/microbiology/parasitology ; Plasmodium ; Humans ; *Climate Change ; Mosquito Control/methods ; Climate ; },
abstract = {Malaria transmission dynamics are governed by complex tripartite interactions between the Anopheles mosquito, the Plasmodium parasite, and the vector's gut microbiota, all mediated by the mosquito's innate immune system. Although global malaria control is increasingly hindered by drug and insecticide resistance, significant knowledge gaps persist regarding how climate shifts and environmental variations impact vector competence. While most experimental research relies on static laboratory conditions (typically fixed at 27 °C and 75-80% relative humidity), mosquitoes in nature experience continuous diurnal and seasonal environmental fluctuations that alter their physiology, immune responses, and microbiome. Here, we focus on how these environmental shifts likely influence the efficacy and translational success of innovative, microbial-based control strategies, including paratransgenesis, Wolbachia-based interventions, and microbial larvicides. By examining how climate-driven variations impact both the mosquito-microbiota-parasite system and the performance of biocontrol tools, we bridge ecological and molecular perspectives to identify the current understanding of how shifting environments influence the mosquito microbiome and microbial-based tools. We highlight the critical need to integrate dynamic climatic regimes into upstream laboratory evaluations to ensure future malaria control tools remain resilient in a global changing climate.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Anopheles/microbiology/parasitology/immunology
*Malaria/transmission/prevention & control
*Microbiota
*Mosquito Vectors/microbiology/parasitology
Plasmodium
Humans
*Climate Change
Mosquito Control/methods
Climate
RevDate: 2026-11-18
CmpDate: 2026-11-18
A multi-omics study links human disturbance to antibiotic resistance gene changes in food-plant phyllosphere and wildlife gut microbiomes.
ISME communications, 6(1):ycag310.
Human disturbance can alter antibiotic resistance gene (ARG) profiles in environmental and host-associated microbiomes, but the role of food-plant phyllosphere communities in linking these changes remains unclear. We integrated phyllosphere metagenomes from 18 food-plant samples with previously generated gut metagenomes and fecal metabolomes from 30 fecal samples collected from two wild Sichuan snub-nosed monkey (Rhinopithecus roxellana) populations inhabiting contrasting human-disturbance contexts. The human-disturbed phyllosphere contained more ARG-carrying contigs, including 24 582 habitat-specific contigs compared with 9308 in the control habitat, and five Rank I ARG subtypes detected only in the disturbed habitat, whereas the abundance of shared Rank I ARGs did not differ significantly. An abundance-weighted genomic compatibility index integrating sequence homology and local collinearity was higher between phyllosphere ARG-associated regions and gut metagenome-assembled genomes in the human-disturbance group, particularly for Acidobacteria, Actinobacteria, and Firmicutes. Functional annotation of genomic regions flanking collinear ARGs showed differences in replication and repair, translation, signal transduction, membrane transport, and cofactor and vitamin metabolism. Fecal metabolomics showed lower 2-oxoglutarate, isocitrate, and D-sedoheptulose 7-phosphate and higher 6-phosphogluconic acid and reduced nicotinamide adenine dinucleotide (NADH) in the human-disturbance group, consistent with variation in the gut luminal carbon metabolic environment. These coordinated patterns may partly reflect disturbance-associated microbial community restructuring and species sorting. Collectively, our findings suggest that the food-plant phyllosphere may represent an ecological interface linking environmental ARG variation with wildlife gut microbiomes and provide a basis for ARG monitoring and microbial risk assessment under the One Health framework.
Additional Links: PMID-43048198
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048198,
year = {2026},
author = {Zhang, H and Ma, J and Liang, S and Xia, Z and Feng, X and Li, D and Zou, S},
title = {A multi-omics study links human disturbance to antibiotic resistance gene changes in food-plant phyllosphere and wildlife gut microbiomes.},
journal = {ISME communications},
volume = {6},
number = {1},
pages = {ycag310},
pmid = {43048198},
issn = {2730-6151},
abstract = {Human disturbance can alter antibiotic resistance gene (ARG) profiles in environmental and host-associated microbiomes, but the role of food-plant phyllosphere communities in linking these changes remains unclear. We integrated phyllosphere metagenomes from 18 food-plant samples with previously generated gut metagenomes and fecal metabolomes from 30 fecal samples collected from two wild Sichuan snub-nosed monkey (Rhinopithecus roxellana) populations inhabiting contrasting human-disturbance contexts. The human-disturbed phyllosphere contained more ARG-carrying contigs, including 24 582 habitat-specific contigs compared with 9308 in the control habitat, and five Rank I ARG subtypes detected only in the disturbed habitat, whereas the abundance of shared Rank I ARGs did not differ significantly. An abundance-weighted genomic compatibility index integrating sequence homology and local collinearity was higher between phyllosphere ARG-associated regions and gut metagenome-assembled genomes in the human-disturbance group, particularly for Acidobacteria, Actinobacteria, and Firmicutes. Functional annotation of genomic regions flanking collinear ARGs showed differences in replication and repair, translation, signal transduction, membrane transport, and cofactor and vitamin metabolism. Fecal metabolomics showed lower 2-oxoglutarate, isocitrate, and D-sedoheptulose 7-phosphate and higher 6-phosphogluconic acid and reduced nicotinamide adenine dinucleotide (NADH) in the human-disturbance group, consistent with variation in the gut luminal carbon metabolic environment. These coordinated patterns may partly reflect disturbance-associated microbial community restructuring and species sorting. Collectively, our findings suggest that the food-plant phyllosphere may represent an ecological interface linking environmental ARG variation with wildlife gut microbiomes and provide a basis for ARG monitoring and microbial risk assessment under the One Health framework.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Late-life depletion of the gut microbiome attenuates aging-induced frailty in male mice.
Gut microbes reports, 3(1):2763224.
Frailty summarizes aging-related decline independently of chronological age. Although the gut microbiome covaries with frailty in older populations, its causal contribution to frailty remains unclear. We profiled middle-aged (72-week-old) and young (10-week-old) male mice across six data layers including physio-behavioral phenotypes, fecal metagenomic taxa and pathways, serum lipidome, and liver and hippocampal transcriptomes. Aged mice exhibited elevated frailty, reduced motor coordination, and microbiome alterations, with members of Lactobacillus and Bacteroidia correlating with frailty. To assess microbiome dependence, we depleted the microbiome by late-life treatment with antibiotics or germ-free rearing from birth. With both, frailty in aged male mice shifted toward young-mouse values, but motor coordination and recognition memory did not, indicating selective microbiome regulation of aging phenotypes. Reduced frailty coincided with attenuated hepatic inflammatory signatures, including decreased expression of acute-phase reactants and altered fatty acid and bile acid metabolism. Microbiome depletion attenuated aging-associated lipidomic patterns, including reduced polyunsaturated-to-monounsaturated fatty acid ratio associated with diminished metabolic health. Multi-omics integration implicated lipoteichoic acid, microbial phytoestrogen metabolites, and reductions in immunomodulatory microbes in hepatic senescence, impaired bioenergetics, and inflammation. These findings suggest that the microbiome contributes to aging-induced frailty and provides new hypotheses for future mechanistic studies, including gut-liver regulation of immunometabolic function.
Additional Links: PMID-43048242
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048242,
year = {2026},
author = {Chandra, F and Olson, CA and Lum, GR and Ha, SM and Liberty, N and Paramo, J and Yang, X and Hsiao, EY},
title = {Late-life depletion of the gut microbiome attenuates aging-induced frailty in male mice.},
journal = {Gut microbes reports},
volume = {3},
number = {1},
pages = {2763224},
pmid = {43048242},
issn = {2993-3935},
abstract = {Frailty summarizes aging-related decline independently of chronological age. Although the gut microbiome covaries with frailty in older populations, its causal contribution to frailty remains unclear. We profiled middle-aged (72-week-old) and young (10-week-old) male mice across six data layers including physio-behavioral phenotypes, fecal metagenomic taxa and pathways, serum lipidome, and liver and hippocampal transcriptomes. Aged mice exhibited elevated frailty, reduced motor coordination, and microbiome alterations, with members of Lactobacillus and Bacteroidia correlating with frailty. To assess microbiome dependence, we depleted the microbiome by late-life treatment with antibiotics or germ-free rearing from birth. With both, frailty in aged male mice shifted toward young-mouse values, but motor coordination and recognition memory did not, indicating selective microbiome regulation of aging phenotypes. Reduced frailty coincided with attenuated hepatic inflammatory signatures, including decreased expression of acute-phase reactants and altered fatty acid and bile acid metabolism. Microbiome depletion attenuated aging-associated lipidomic patterns, including reduced polyunsaturated-to-monounsaturated fatty acid ratio associated with diminished metabolic health. Multi-omics integration implicated lipoteichoic acid, microbial phytoestrogen metabolites, and reductions in immunomodulatory microbes in hepatic senescence, impaired bioenergetics, and inflammation. These findings suggest that the microbiome contributes to aging-induced frailty and provides new hypotheses for future mechanistic studies, including gut-liver regulation of immunometabolic function.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Vonoprazan in school-aged children and adolescents: A narrative review of emerging evidence for gastroesophageal reflux disease and Helicobacter pylori infection.
Therapeutic advances in gastroenterology, 19:17562848261496058.
This narrative review synthesizes available evidence on vonoprazan (VPZ), a potassium-competitive acid blocker (P-CAB) that achieves rapid, potent gastric acid suppression with minimal CYP2C19 dependence, in pediatric patients with gastroesophageal reflux disease (GERD) or Helicobacter pylori (H. pylori) infection. VPZ has been approved for adult indications in Japan (2014) and the United States (2022-2023) but has not received pediatric approval in any country or region as of mid-2026. Current clinical data derive almost exclusively from adolescents (12-17 years) and children aged ≥6 years weighing ≥30 kg; evidence in younger children (<6 years or <30 kg) is essentially absent, and this gap is highlighted throughout. Following the SANRA guidance for narrative reviews, PubMed/MEDLINE and ClinicalTrials.gov were searched through July 2026, supplemented by conference abstracts, reference lists, and regulatory documents, with adult data included where required for pharmacological or bridging rationale. For GERD, clinical evidence remains limited to Phase 1 pharmacokinetic/safety studies in adolescents (VPED-102) and children ≥6 years/≥30 kg (VPED-103), now reported in a peer-reviewed pooled analysis and integrated into a population pharmacokinetic (popPK) model; these confirm adult-concordant VPZ exposures at 10 and 20 mg with acceptable short-term tolerability and no age- or weight-related differences in clearance across 6-54 years, and model-based simulations support the same fixed doses in children as young as approximately 1 year, though no efficacy randomized controlled trial has been completed. For H. pylori eradication, prospective data from Japanese adolescents (n = 645) report a first-line VPZ triple-therapy intention-to-treat eradication rate of 73.6%, below the ≥90% guideline threshold, with clarithromycin resistance identified as a key contributor, while VPZ-based rescue therapy achieved 100% eradication in a small retrospective Western series (n = 11). Pediatric safety data are limited to short-term exposure; long-term effects on growth, bone metabolism, and the gut microbiome remain unstudied. Overall, VPZ is a pharmacologically promising alternative to proton pump inhibitors in pediatric acid-related disease, but current evidence is insufficient to support routine use outside clinical trials, and completion of ongoing randomized controlled trials, pediatric dose optimization, age-appropriate formulations, and long-term safety studies are prerequisites for guideline-level recommendations.
Additional Links: PMID-43048297
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048297,
year = {2026},
author = {Jing, Y and Yu, Y},
title = {Vonoprazan in school-aged children and adolescents: A narrative review of emerging evidence for gastroesophageal reflux disease and Helicobacter pylori infection.},
journal = {Therapeutic advances in gastroenterology},
volume = {19},
number = {},
pages = {17562848261496058},
pmid = {43048297},
issn = {1756-283X},
abstract = {This narrative review synthesizes available evidence on vonoprazan (VPZ), a potassium-competitive acid blocker (P-CAB) that achieves rapid, potent gastric acid suppression with minimal CYP2C19 dependence, in pediatric patients with gastroesophageal reflux disease (GERD) or Helicobacter pylori (H. pylori) infection. VPZ has been approved for adult indications in Japan (2014) and the United States (2022-2023) but has not received pediatric approval in any country or region as of mid-2026. Current clinical data derive almost exclusively from adolescents (12-17 years) and children aged ≥6 years weighing ≥30 kg; evidence in younger children (<6 years or <30 kg) is essentially absent, and this gap is highlighted throughout. Following the SANRA guidance for narrative reviews, PubMed/MEDLINE and ClinicalTrials.gov were searched through July 2026, supplemented by conference abstracts, reference lists, and regulatory documents, with adult data included where required for pharmacological or bridging rationale. For GERD, clinical evidence remains limited to Phase 1 pharmacokinetic/safety studies in adolescents (VPED-102) and children ≥6 years/≥30 kg (VPED-103), now reported in a peer-reviewed pooled analysis and integrated into a population pharmacokinetic (popPK) model; these confirm adult-concordant VPZ exposures at 10 and 20 mg with acceptable short-term tolerability and no age- or weight-related differences in clearance across 6-54 years, and model-based simulations support the same fixed doses in children as young as approximately 1 year, though no efficacy randomized controlled trial has been completed. For H. pylori eradication, prospective data from Japanese adolescents (n = 645) report a first-line VPZ triple-therapy intention-to-treat eradication rate of 73.6%, below the ≥90% guideline threshold, with clarithromycin resistance identified as a key contributor, while VPZ-based rescue therapy achieved 100% eradication in a small retrospective Western series (n = 11). Pediatric safety data are limited to short-term exposure; long-term effects on growth, bone metabolism, and the gut microbiome remain unstudied. Overall, VPZ is a pharmacologically promising alternative to proton pump inhibitors in pediatric acid-related disease, but current evidence is insufficient to support routine use outside clinical trials, and completion of ongoing randomized controlled trials, pediatric dose optimization, age-appropriate formulations, and long-term safety studies are prerequisites for guideline-level recommendations.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Machine Learning Approaches to Biologic Therapy Response in Inflammatory Bowel Disease: A Review Article.
Sage open pathology, 19:30502098261502319.
Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, remains a complex and heterogeneous condition with variable response to biologic therapies. Despite significant advances with anti-TNF agents, integrin inhibitors, and interleukin-12/23 blockers, treatment outcomes are limited by primary nonresponse, secondary loss of efficacy, immunogenicity, and substantial healthcare costs. The advent of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL) algorithms, offers new opportunities to address these challenges by integrating diverse clinical, laboratory, imaging, histologic, genetic, and microbiome data. Recent studies demonstrate that AI-based models achieve high accuracy in predicting biologic response, remission, and adverse outcomes, outperforming conventional statistical approaches. AI has also shown promise in real-time endoscopic assessment, histologic grading, and forecasting disease progression, enabling earlier intervention and personalized therapy. However, current models are constrained by limited datasets, heterogeneity, lack of large-scale prospective validation, and concerns regarding interpretability, transparency, and patient privacy. Future efforts should prioritize multicenter trials, external validation, and ethical integration into clinical workflows. Collectively, AI-driven prediction of biologic therapy response represents a pivotal step toward precision medicine in IBD, with the potential to optimize therapeutic strategies, reduce ineffective treatment exposure, and improve patient outcomes.
Additional Links: PMID-43048562
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43048562,
year = {2026},
author = {Chamchoum, E and Chamchoum, N and Khouzami, K and Ghaleb, J and Ghaleb, N and Kfoury, K and Tayoun, N and Bou Rizk, R and Karam, K and Hallak, M and Fiani, E},
title = {Machine Learning Approaches to Biologic Therapy Response in Inflammatory Bowel Disease: A Review Article.},
journal = {Sage open pathology},
volume = {19},
number = {},
pages = {30502098261502319},
pmid = {43048562},
issn = {3050-2098},
abstract = {Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, remains a complex and heterogeneous condition with variable response to biologic therapies. Despite significant advances with anti-TNF agents, integrin inhibitors, and interleukin-12/23 blockers, treatment outcomes are limited by primary nonresponse, secondary loss of efficacy, immunogenicity, and substantial healthcare costs. The advent of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL) algorithms, offers new opportunities to address these challenges by integrating diverse clinical, laboratory, imaging, histologic, genetic, and microbiome data. Recent studies demonstrate that AI-based models achieve high accuracy in predicting biologic response, remission, and adverse outcomes, outperforming conventional statistical approaches. AI has also shown promise in real-time endoscopic assessment, histologic grading, and forecasting disease progression, enabling earlier intervention and personalized therapy. However, current models are constrained by limited datasets, heterogeneity, lack of large-scale prospective validation, and concerns regarding interpretability, transparency, and patient privacy. Future efforts should prioritize multicenter trials, external validation, and ethical integration into clinical workflows. Collectively, AI-driven prediction of biologic therapy response represents a pivotal step toward precision medicine in IBD, with the potential to optimize therapeutic strategies, reduce ineffective treatment exposure, and improve patient outcomes.},
}
RevDate: 2026-11-18
Full-length 16S rRNA gene sequences of lettuce-associated bacterial communities across soil-root compartments under antibiotic exposure.
Microbiology resource announcements [Epub ahead of print].
Antibiotic contamination in agricultural soils poses increasing threats to plant-associated microbiome structure and function. Here, we present a full-length 16S rRNA gene amplicon data set generated from lettuce soil-root compartments under sulfamethoxazole and trimethoprim exposure. The data set provides a resource for investigating compartment-specific microbiome responses to pharmaceutical contamination in agricultural systems.
Additional Links: PMID-43049120
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049120,
year = {2026},
author = {Lenonyane, CK and Molale-Tom, LG and Tsholo, K and Bezuidenhout, CC and Olanrewaju, OS},
title = {Full-length 16S rRNA gene sequences of lettuce-associated bacterial communities across soil-root compartments under antibiotic exposure.},
journal = {Microbiology resource announcements},
volume = {},
number = {},
pages = {e0114926},
doi = {10.1128/mra.01149-26},
pmid = {43049120},
issn = {2576-098X},
abstract = {Antibiotic contamination in agricultural soils poses increasing threats to plant-associated microbiome structure and function. Here, we present a full-length 16S rRNA gene amplicon data set generated from lettuce soil-root compartments under sulfamethoxazole and trimethoprim exposure. The data set provides a resource for investigating compartment-specific microbiome responses to pharmaceutical contamination in agricultural systems.},
}
RevDate: 2026-11-18
Genome-resolved multi-omics characterizes bacterial, viral, and metabolic components associated with Parkinson's disease gut ecosystem variation.
Microbiology spectrum [Epub ahead of print].
Parkinson's disease (PD) is increasingly recognized as a disorder involving the gut-brain axis, yet genome-resolved characterization of bacterial and viral communities with metabolic context remains limited. Here, we performed deep shotgun metagenomic sequencing and fecal metabolomic profiling in a high-altitude cohort comprising patients with PD and environmentally matched spouse controls (living at approximately 1,900 m altitude). We reconstructed 455 species-level genome bins (SGBs) and 2,957 non-redundant viral operational taxonomic units (vOTUs), enabling high-resolution profiling of bacterial and viral community composition. Rather than a uniform shift of the entire microbial community, PD-associated variation involved specific bacterial, viral, and metabolic components. Indicator analysis identified 23 bacterial and 86 viral candidate indicators associated with PD or control status, with predicted temperate phages representing the predominant lifestyle category among indicator vOTUs. Several PD-associated bacterial indicators included taxa previously linked to anaerobic fermentation and short-chain fatty acid (SCFA)-associated metabolism, accompanied by increased fecal valerate. Abundance correlation analysis identified covariation patterns between bacterial and viral indicators, including associations between controls (CK)-associated Agathobacter faecis and Lachnospiraceae-linked vOTUs. Integrating microbial abundance profiles and metabolomic measurements revealed exploratory associations among microbial indicators and metabolic alterations associated with PD. Cross-layer analyses further showed reduced dispersion of microbial-metabolomic alignment patterns in PD samples, suggesting a more constrained ecological state. Together, these findings provide a genome-resolved view of bacterial, viral, and metabolic variation in the PD gut ecosystem, extending characterization of PD-associated dysbiosis beyond bacterial taxonomy and identifying candidate microbial indicators and metabolic alterations for further investigation.IMPORTANCEParkinson's disease (PD) is a complex neurological disorder in which interactions between the host and the gut ecosystem are increasingly recognized as relevant to disease-associated biological processes. Previous microbiome studies of Parkinson's disease have largely focused on bacterial taxonomic changes, while gut viral communities and their relationships with microbial metabolism remain less characterized. In this study, we used genome-resolved metagenomics and metabolomics to characterize bacterial, viral, and metabolic components associated with PD in individuals with Parkinson's disease and environmentally matched controls. Our findings provide a broader view of Parkinson's disease-associated gut ecosystem alterations beyond bacterial composition alone, highlighting bacteriophages as an underexplored ecological component and identifying microbial indicators and metabolic alterations for future investigation.
Additional Links: PMID-43049130
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049130,
year = {2026},
author = {Shi, G and Liu, W and Zhuang, D and Wang, Y and Wu, T and Huang, M and Shi, G and Zhao, D and Li, W and Fu, Y and Li, Y and Zhang, Z and Yan, J and Zhao, N},
title = {Genome-resolved multi-omics characterizes bacterial, viral, and metabolic components associated with Parkinson's disease gut ecosystem variation.},
journal = {Microbiology spectrum},
volume = {},
number = {},
pages = {e0233726},
doi = {10.1128/spectrum.02337-26},
pmid = {43049130},
issn = {2165-0497},
abstract = {Parkinson's disease (PD) is increasingly recognized as a disorder involving the gut-brain axis, yet genome-resolved characterization of bacterial and viral communities with metabolic context remains limited. Here, we performed deep shotgun metagenomic sequencing and fecal metabolomic profiling in a high-altitude cohort comprising patients with PD and environmentally matched spouse controls (living at approximately 1,900 m altitude). We reconstructed 455 species-level genome bins (SGBs) and 2,957 non-redundant viral operational taxonomic units (vOTUs), enabling high-resolution profiling of bacterial and viral community composition. Rather than a uniform shift of the entire microbial community, PD-associated variation involved specific bacterial, viral, and metabolic components. Indicator analysis identified 23 bacterial and 86 viral candidate indicators associated with PD or control status, with predicted temperate phages representing the predominant lifestyle category among indicator vOTUs. Several PD-associated bacterial indicators included taxa previously linked to anaerobic fermentation and short-chain fatty acid (SCFA)-associated metabolism, accompanied by increased fecal valerate. Abundance correlation analysis identified covariation patterns between bacterial and viral indicators, including associations between controls (CK)-associated Agathobacter faecis and Lachnospiraceae-linked vOTUs. Integrating microbial abundance profiles and metabolomic measurements revealed exploratory associations among microbial indicators and metabolic alterations associated with PD. Cross-layer analyses further showed reduced dispersion of microbial-metabolomic alignment patterns in PD samples, suggesting a more constrained ecological state. Together, these findings provide a genome-resolved view of bacterial, viral, and metabolic variation in the PD gut ecosystem, extending characterization of PD-associated dysbiosis beyond bacterial taxonomy and identifying candidate microbial indicators and metabolic alterations for further investigation.IMPORTANCEParkinson's disease (PD) is a complex neurological disorder in which interactions between the host and the gut ecosystem are increasingly recognized as relevant to disease-associated biological processes. Previous microbiome studies of Parkinson's disease have largely focused on bacterial taxonomic changes, while gut viral communities and their relationships with microbial metabolism remain less characterized. In this study, we used genome-resolved metagenomics and metabolomics to characterize bacterial, viral, and metabolic components associated with PD in individuals with Parkinson's disease and environmentally matched controls. Our findings provide a broader view of Parkinson's disease-associated gut ecosystem alterations beyond bacterial composition alone, highlighting bacteriophages as an underexplored ecological component and identifying microbial indicators and metabolic alterations for future investigation.},
}
RevDate: 2026-11-18
CmpDate: 2026-11-18
Sexual, Pharmaceutical, and Lifestyle Variables in a Cohort of Pregnant Western Australian Women, and Their Association With Detection of Vaginal Microorganisms and Preterm Birth.
The Australian & New Zealand journal of obstetrics & gynaecology, 66(6):.
BACKGROUND: The vaginal microbiome is shaped by factors such as sexual behaviour, smoking, and feminine hygiene practices. Although these associations are well documented in non-pregnant women, less is known in pregnancy, particularly in Australia, despite links between the vaginal microbiome and complications like preterm birth (PTB).
AIM: To document sexual, pharmaceutical, and lifestyle variables in pregnant Australian women and examine their associations with vaginal microorganisms and, secondarily, PTB risk.
MATERIAL AND METHODS: Mid-pregnancy (12-23 weeks' gestation) vaginal swabs from 936 women in the Predict1000 study were analysed for key microorganisms using qPCR. Participants completed a recruitment survey on medication use, urinary/vaginal infections, smoking, alcohol use, sexual practices, and vaginal douching. Associations between these factors, PTB (spontaneous and indicated), and specific microorganisms were assessed using Chi-square, Fisher's exact, and Mann-Whitney tests.
RESULTS: Thirteen percent of women reported smoking during pregnancy. Over half reported vaginal intercourse 1-2 times per week, although one quarter reported none. Thirty-two percent engaged in other sexual activities, most commonly oral sex (25%), followed by use of sex toys (11%). Vaginal douching was uncommon (3%). Sexual behaviour and douching were not associated with PTB risk. Smoking was associated with increased rates of non-optimal microbes, an association that persisted after correction for multiple comparisons. Associations between reduced frequency of vaginal intercourse (< 2 times/week) and lower prevalence of non-optimal vaginal microbes, and between douching and higher detection of Gardnerella vaginalis and Ureaplasma parvum, were also observed but did not remain significant after correction.
CONCLUSION: Sexual, pharmaceutical, and lifestyle factors influenced the vaginal microbiota in pregnancy, but none were associated with PTB risk.
Additional Links: PMID-43049184
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049184,
year = {2026},
author = {Payne, MS and Doherty, DA and Furfaro, LL and Pendal, NL and Loh, DE and Keelan, JA and Newnham, JP},
title = {Sexual, Pharmaceutical, and Lifestyle Variables in a Cohort of Pregnant Western Australian Women, and Their Association With Detection of Vaginal Microorganisms and Preterm Birth.},
journal = {The Australian & New Zealand journal of obstetrics & gynaecology},
volume = {66},
number = {6},
pages = {},
pmid = {43049184},
issn = {1479-828X},
support = {1077931//National Health and Medical Research Council/ ; //Channel 7 Telethon Trust/ ; //Women and Infants Research Foundation/ ; },
mesh = {Humans ; Female ; Pregnancy ; *Vagina/microbiology ; Adult ; *Premature Birth/epidemiology/microbiology ; *Sexual Behavior/statistics & numerical data ; *Life Style ; Smoking/epidemiology ; Western Australia/epidemiology ; Young Adult ; Alcohol Drinking/epidemiology ; *Microbiota ; Gardnerella vaginalis/isolation & purification ; Vaginal Douching/statistics & numerical data ; Ureaplasma/isolation & purification ; Lactobacillus/isolation & purification ; Risk Factors ; Cohort Studies ; Adolescent ; Lactobacillus crispatus/isolation & purification ; },
abstract = {BACKGROUND: The vaginal microbiome is shaped by factors such as sexual behaviour, smoking, and feminine hygiene practices. Although these associations are well documented in non-pregnant women, less is known in pregnancy, particularly in Australia, despite links between the vaginal microbiome and complications like preterm birth (PTB).
AIM: To document sexual, pharmaceutical, and lifestyle variables in pregnant Australian women and examine their associations with vaginal microorganisms and, secondarily, PTB risk.
MATERIAL AND METHODS: Mid-pregnancy (12-23 weeks' gestation) vaginal swabs from 936 women in the Predict1000 study were analysed for key microorganisms using qPCR. Participants completed a recruitment survey on medication use, urinary/vaginal infections, smoking, alcohol use, sexual practices, and vaginal douching. Associations between these factors, PTB (spontaneous and indicated), and specific microorganisms were assessed using Chi-square, Fisher's exact, and Mann-Whitney tests.
RESULTS: Thirteen percent of women reported smoking during pregnancy. Over half reported vaginal intercourse 1-2 times per week, although one quarter reported none. Thirty-two percent engaged in other sexual activities, most commonly oral sex (25%), followed by use of sex toys (11%). Vaginal douching was uncommon (3%). Sexual behaviour and douching were not associated with PTB risk. Smoking was associated with increased rates of non-optimal microbes, an association that persisted after correction for multiple comparisons. Associations between reduced frequency of vaginal intercourse (< 2 times/week) and lower prevalence of non-optimal vaginal microbes, and between douching and higher detection of Gardnerella vaginalis and Ureaplasma parvum, were also observed but did not remain significant after correction.
CONCLUSION: Sexual, pharmaceutical, and lifestyle factors influenced the vaginal microbiota in pregnancy, but none were associated with PTB risk.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
Pregnancy
*Vagina/microbiology
Adult
*Premature Birth/epidemiology/microbiology
*Sexual Behavior/statistics & numerical data
*Life Style
Smoking/epidemiology
Western Australia/epidemiology
Young Adult
Alcohol Drinking/epidemiology
*Microbiota
Gardnerella vaginalis/isolation & purification
Vaginal Douching/statistics & numerical data
Ureaplasma/isolation & purification
Lactobacillus/isolation & purification
Risk Factors
Cohort Studies
Adolescent
Lactobacillus crispatus/isolation & purification
RevDate: 2026-11-18
CmpDate: 2026-11-18
Keystone Microbial Taxa Regulate Nitrification and Denitrification Processes in Riverine Wetlands Across Eastern and Central China.
Environmental microbiology, 28(11):.
Excess nitrogen (N) inputs threaten riverine wetlands worldwide, where microbially mediated nitrification and denitrification are key pathways for N transformation and removal. Although microbial communities are known to regulate riverine N cycling, the contribution of keystone microbial species remains unclear. Here, we combined high-throughput sequencing of archaeal and bacterial amoA, nirK, and nirS genes with measurements of potential nitrification and denitrification rates in channel sediments, riparian rhizosphere soils, and riparian bulk soils across 30 riverine wetlands in eastern and central China. Habitat type and latitudinal zone significantly shaped nitrification and denitrification rates, with rhizosphere soils serving as hotspots of N removal. Local environmental factors, particularly total N and iron availability, strongly influenced these processes. Keystone species composition explained spatial variation in nitrification and denitrification more effectively than keystone species richness or whole-community attributes. Moreover, keystone species regulated N removal through both direct functional effects and indirect, network-mediated pathways. These findings highlight the critical role of keystone microbial species in sustaining N removal functions across riverine wetlands and provide new insights into microbiome-informed management of nutrient-enriched river ecosystems.
Additional Links: PMID-43049224
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43049224,
year = {2026},
author = {Xiong, X and Zhang, W and Jiang, X and Liu, H and Li, L and Shi, D and Liu, W},
title = {Keystone Microbial Taxa Regulate Nitrification and Denitrification Processes in Riverine Wetlands Across Eastern and Central China.},
journal = {Environmental microbiology},
volume = {28},
number = {11},
pages = {},
doi = {10.1111/1462-2920.70502},
pmid = {43049224},
issn = {1462-2920},
support = {U24A20641//National Natural Science Foundation of China/ ; 32401363//National Natural Science Foundation of China/ ; 2025AFB983//Natural Science Foundation of Hubei Province/ ; },
mesh = {*Wetlands ; China ; *Denitrification ; *Nitrification ; *Bacteria/metabolism/genetics/classification/isolation & purification ; *Archaea/metabolism/genetics/classification ; Nitrogen/metabolism ; *Microbiota ; *Rivers/microbiology ; Soil Microbiology ; Rhizosphere ; },
abstract = {Excess nitrogen (N) inputs threaten riverine wetlands worldwide, where microbially mediated nitrification and denitrification are key pathways for N transformation and removal. Although microbial communities are known to regulate riverine N cycling, the contribution of keystone microbial species remains unclear. Here, we combined high-throughput sequencing of archaeal and bacterial amoA, nirK, and nirS genes with measurements of potential nitrification and denitrification rates in channel sediments, riparian rhizosphere soils, and riparian bulk soils across 30 riverine wetlands in eastern and central China. Habitat type and latitudinal zone significantly shaped nitrification and denitrification rates, with rhizosphere soils serving as hotspots of N removal. Local environmental factors, particularly total N and iron availability, strongly influenced these processes. Keystone species composition explained spatial variation in nitrification and denitrification more effectively than keystone species richness or whole-community attributes. Moreover, keystone species regulated N removal through both direct functional effects and indirect, network-mediated pathways. These findings highlight the critical role of keystone microbial species in sustaining N removal functions across riverine wetlands and provide new insights into microbiome-informed management of nutrient-enriched river ecosystems.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Wetlands
China
*Denitrification
*Nitrification
*Bacteria/metabolism/genetics/classification/isolation & purification
*Archaea/metabolism/genetics/classification
Nitrogen/metabolism
*Microbiota
*Rivers/microbiology
Soil Microbiology
Rhizosphere
RevDate: 2026-11-16
CmpDate: 2026-11-16
Prevalence of Vaginitis in Different Age Groups Among Females in Nanping Area of Fujian Province in China: A Retrospective Observational Study.
International journal of women's health, 18:619685.
BACKGROUND: The composition of the vaginal microbiome varies across different age groups and geographic regions.
PURPOSE: This study aimed to characterize pathogenic infections in the vaginal secretions of women from the Nanping area of Fujian Province, China.
METHODS: From January 2020 to December 2022, a total of 22,580 vaginal swab specimens were collected from patients across multiple hospitals in Nanping, prepared via slide, and analyzed using a combination of morphological and enzymatic assays.
RESULTS: Findings indicated that a majority of patients exhibited imbalanced vaginal flora, with 59.11%classified as grade III and 32.00% as grade II. Bacterial vaginosis (BV) was the most commonly detected infection, followed by vulvovaginal candidiasis (VVC). The distribution of vaginitis types varied across age groups, with the largest number of detected infection cases observed among women aged 31-40 years. Women aged 18-30 and 31-40 showed significantly higher rates of VVC, whereas BV was most prominent in those over 50. Mixed vaginal infections (MVI) were most frequent in the 18-30 group, typically involving co-infections of BV and VVC, while women over 50 more commonly presented with combinations of aerobic vaginitis and BV.
CONCLUSION: The high incidence of BV highlights the importance of enhancing monitoring and promoting proper vaginal hygiene practices in this population.
Additional Links: PMID-43036687
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43036687,
year = {2026},
author = {Ge, S and Luo, Y and Wen, Y and Yuan, W and Lin, Y and Ye, Q and Wang, Y and Lu, J and Hu, F and Luo, J},
title = {Prevalence of Vaginitis in Different Age Groups Among Females in Nanping Area of Fujian Province in China: A Retrospective Observational Study.},
journal = {International journal of women's health},
volume = {18},
number = {},
pages = {619685},
pmid = {43036687},
issn = {1179-1411},
abstract = {BACKGROUND: The composition of the vaginal microbiome varies across different age groups and geographic regions.
PURPOSE: This study aimed to characterize pathogenic infections in the vaginal secretions of women from the Nanping area of Fujian Province, China.
METHODS: From January 2020 to December 2022, a total of 22,580 vaginal swab specimens were collected from patients across multiple hospitals in Nanping, prepared via slide, and analyzed using a combination of morphological and enzymatic assays.
RESULTS: Findings indicated that a majority of patients exhibited imbalanced vaginal flora, with 59.11%classified as grade III and 32.00% as grade II. Bacterial vaginosis (BV) was the most commonly detected infection, followed by vulvovaginal candidiasis (VVC). The distribution of vaginitis types varied across age groups, with the largest number of detected infection cases observed among women aged 31-40 years. Women aged 18-30 and 31-40 showed significantly higher rates of VVC, whereas BV was most prominent in those over 50. Mixed vaginal infections (MVI) were most frequent in the 18-30 group, typically involving co-infections of BV and VVC, while women over 50 more commonly presented with combinations of aerobic vaginitis and BV.
CONCLUSION: The high incidence of BV highlights the importance of enhancing monitoring and promoting proper vaginal hygiene practices in this population.},
}
RevDate: 2026-11-16
CmpDate: 2026-11-16
Bac2Feature: an easy-to-use interface to predict prokaryotic traits from 16S rRNA gene sequences.
Bioinformatics advances, 6(1):vbaf136.
MOTIVATION: Annotating physiological, morphological, or genomic features to diverse bacterial and archaeal species is essential for the trait-based interpretations of complex microbiomes in community ecology. One promising way for high-throughput trait annotation is taxonomic marker gene-based trait prediction, where traits are predicted from 16S rRNA gene sequences based on their homology, taxonomy, or phylogeny. Many tools have been developed using different prediction methods and trait datasets; however, this situation lacks a unified framework of different prediction methods and their systematic evaluation, resulting in low accessibility to preferred methods.
RESULTS: Here, we proposed Bac2Feature, an easy-to-use web tool that integrates different prediction methods in standardized trait dataset and systematically evaluated the prediction performance. We found that the prediction method based on 16S rRNA gene phylogenetic tree displayed superior prediction accuracy than that of other methods. The prediction accuracy of each trait was strongly associated with its phylogenetic signal. Furthermore, we set prediction thresholds for phylogenetic distance to avoid spurious trait prediction. Applied to the infant gut microbiome, Bac2Feature could reproduce trait-based shifts during primary succession. Our unified framework widens access to the trait-based approach and its applications to other fields, such as medical research.
Bac2Feature is available at https://github.com/fuyo780/Bac2Feature (command line interface) and https://www.genome.jp/bac2feature/ (web interface).
Additional Links: PMID-43036763
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43036763,
year = {2026},
author = {Fujiyoshi, M and Suzuki, TK and Furusawa, C and Matsui, M},
title = {Bac2Feature: an easy-to-use interface to predict prokaryotic traits from 16S rRNA gene sequences.},
journal = {Bioinformatics advances},
volume = {6},
number = {1},
pages = {vbaf136},
pmid = {43036763},
issn = {2635-0041},
abstract = {MOTIVATION: Annotating physiological, morphological, or genomic features to diverse bacterial and archaeal species is essential for the trait-based interpretations of complex microbiomes in community ecology. One promising way for high-throughput trait annotation is taxonomic marker gene-based trait prediction, where traits are predicted from 16S rRNA gene sequences based on their homology, taxonomy, or phylogeny. Many tools have been developed using different prediction methods and trait datasets; however, this situation lacks a unified framework of different prediction methods and their systematic evaluation, resulting in low accessibility to preferred methods.
RESULTS: Here, we proposed Bac2Feature, an easy-to-use web tool that integrates different prediction methods in standardized trait dataset and systematically evaluated the prediction performance. We found that the prediction method based on 16S rRNA gene phylogenetic tree displayed superior prediction accuracy than that of other methods. The prediction accuracy of each trait was strongly associated with its phylogenetic signal. Furthermore, we set prediction thresholds for phylogenetic distance to avoid spurious trait prediction. Applied to the infant gut microbiome, Bac2Feature could reproduce trait-based shifts during primary succession. Our unified framework widens access to the trait-based approach and its applications to other fields, such as medical research.
Bac2Feature is available at https://github.com/fuyo780/Bac2Feature (command line interface) and https://www.genome.jp/bac2feature/ (web interface).},
}
RevDate: 2026-11-16
CmpDate: 2026-11-16
Fecal microbiota transplantation for pediatric Clostridioides difficile infection: efficacy, challenges, and the path to next-generation microbiome therapies.
Gut microbes, 18(1):2761763.
Clostridioides difficile infection (CDI) is an increasing cause of morbidity in children, with recurrent disease posing substantial therapeutic challenges. Antibiotic therapy remains the cornerstone of initial management; however, up to 30% of children experience recurrence, and those with underlying comorbidities face recurrence rates as high as 65%. Fecal microbiota transplantation (FMT) has demonstrated superior efficacy over antibiotics for recurrent CDI (rCDI) in adults and has emerged as the most effective available intervention for pediatric rCDI. In this review, we synthesize current evidence on FMT efficacy, microbiome changes, and safety in children with CDI. Data from large multicenter cohort studies demonstrate cure rates exceeding 80%, with comparable efficacy observed in high-risk subpopulations, including those with inflammatory bowel disease and immunocompromising conditions. Critical research gaps remain, including the absence of randomized controlled trials and limited long-term safety data in children. Despite demonstrated effectiveness, significant barriers limit FMT accessibility for children. The COVID-19 pandemic has substantially impacted availability, and current regulatory changes have further restricted access. The lack of FDA-approved live biotherapeutic products approved for CDI in children creates additional challenges. We critically examine the emerging pipeline of next-generation microbiome-based therapies and identify the steps required to ensure children with recurrent CDI have access to safe, effective, and approved treatments.
Additional Links: PMID-43037257
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037257,
year = {2026},
author = {Nicholson, MR and Conrad, MA and Diaz De Leon, S and Strength, R and Kelsen, JR and Kahn, SA and Hourigan, SK},
title = {Fecal microbiota transplantation for pediatric Clostridioides difficile infection: efficacy, challenges, and the path to next-generation microbiome therapies.},
journal = {Gut microbes},
volume = {18},
number = {1},
pages = {2761763},
doi = {10.1080/19490976.2026.2761763},
pmid = {43037257},
issn = {1949-0984},
mesh = {Humans ; *Fecal Microbiota Transplantation/methods/adverse effects ; *Clostridium Infections/therapy/microbiology ; Child ; Clostridioides difficile/physiology ; Treatment Outcome ; *Gastrointestinal Microbiome ; Recurrence ; Anti-Bacterial Agents/therapeutic use ; },
abstract = {Clostridioides difficile infection (CDI) is an increasing cause of morbidity in children, with recurrent disease posing substantial therapeutic challenges. Antibiotic therapy remains the cornerstone of initial management; however, up to 30% of children experience recurrence, and those with underlying comorbidities face recurrence rates as high as 65%. Fecal microbiota transplantation (FMT) has demonstrated superior efficacy over antibiotics for recurrent CDI (rCDI) in adults and has emerged as the most effective available intervention for pediatric rCDI. In this review, we synthesize current evidence on FMT efficacy, microbiome changes, and safety in children with CDI. Data from large multicenter cohort studies demonstrate cure rates exceeding 80%, with comparable efficacy observed in high-risk subpopulations, including those with inflammatory bowel disease and immunocompromising conditions. Critical research gaps remain, including the absence of randomized controlled trials and limited long-term safety data in children. Despite demonstrated effectiveness, significant barriers limit FMT accessibility for children. The COVID-19 pandemic has substantially impacted availability, and current regulatory changes have further restricted access. The lack of FDA-approved live biotherapeutic products approved for CDI in children creates additional challenges. We critically examine the emerging pipeline of next-generation microbiome-based therapies and identify the steps required to ensure children with recurrent CDI have access to safe, effective, and approved treatments.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Fecal Microbiota Transplantation/methods/adverse effects
*Clostridium Infections/therapy/microbiology
Child
Clostridioides difficile/physiology
Treatment Outcome
*Gastrointestinal Microbiome
Recurrence
Anti-Bacterial Agents/therapeutic use
RevDate: 2026-11-16
Host Genetic Variants and Human Gut Microbiota: A Systematic Review of Associations, Mechanisms, and Gaps.
Medical principles and practice : international journal of the Kuwait University, Health Science Centre pii:9065344 [Epub ahead of print].
BACKGROUND: Gut microbiome composition reflects environmental and host factors, including genetic variation, but the consistency of reported gene-microbiome associations remains uncertain.
METHODS: Following PRISMA 2020, we searched PubMed, Scopus, and Google Scholar for peer-reviewed English-language human studies published from January 2010 to October 2026 that linked host genetic variants to gut microbiome composition or diversity. Two reviewers independently extracted genetic markers, microbial taxa, microbiome characteristics, and associations. Study quality was assessed using the Newcastle-Ottawa Scale (NOS).
RESULTS: A total of 15 studies were included in the review, identifying potential relationships between host genetic factors, including ABO, IL23R, FUT2, LCT, and MCM6, and gut bacterial genera such as Roseburia, Bifidobacterium, and Ruminococcus. Among the reported findings, the association between LCT and Bifidobacterium demonstrated the greatest consistency across studies, whereas other gene-microbiome relationships were less consistently replicated. Variations in study populations, microbial profiling techniques, statistical approaches, and effect-size reporting limited comparability across studies and precluded quantitative synthesis.
CONCLUSIONS: Host genetics may shape gut microbiome composition, but effects vary across genetic loci and populations. Limited replication and methodological differences weaken current evidence. Larger, longitudinal, harmonized studies combining genetic, dietary, environmental, and microbiome data are needed to assess genetics' contribution and the functional significance of these associations.
Additional Links: PMID-43037293
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037293,
year = {2026},
author = {Karimi, MA and Amirfakhrian, R and Paryan, M and Marouzi, P and Hosseini Bafghi, M},
title = {Host Genetic Variants and Human Gut Microbiota: A Systematic Review of Associations, Mechanisms, and Gaps.},
journal = {Medical principles and practice : international journal of the Kuwait University, Health Science Centre},
volume = {},
number = {},
pages = {},
doi = {10.1159/mpp/adpag046},
pmid = {43037293},
issn = {1423-0151},
abstract = {BACKGROUND: Gut microbiome composition reflects environmental and host factors, including genetic variation, but the consistency of reported gene-microbiome associations remains uncertain.
METHODS: Following PRISMA 2020, we searched PubMed, Scopus, and Google Scholar for peer-reviewed English-language human studies published from January 2010 to October 2026 that linked host genetic variants to gut microbiome composition or diversity. Two reviewers independently extracted genetic markers, microbial taxa, microbiome characteristics, and associations. Study quality was assessed using the Newcastle-Ottawa Scale (NOS).
RESULTS: A total of 15 studies were included in the review, identifying potential relationships between host genetic factors, including ABO, IL23R, FUT2, LCT, and MCM6, and gut bacterial genera such as Roseburia, Bifidobacterium, and Ruminococcus. Among the reported findings, the association between LCT and Bifidobacterium demonstrated the greatest consistency across studies, whereas other gene-microbiome relationships were less consistently replicated. Variations in study populations, microbial profiling techniques, statistical approaches, and effect-size reporting limited comparability across studies and precluded quantitative synthesis.
CONCLUSIONS: Host genetics may shape gut microbiome composition, but effects vary across genetic loci and populations. Limited replication and methodological differences weaken current evidence. Larger, longitudinal, harmonized studies combining genetic, dietary, environmental, and microbiome data are needed to assess genetics' contribution and the functional significance of these associations.},
}
RevDate: 2026-11-16
Japanese encephalitis virus infection reshapes the gut microbiome and induces colonic inflammation in neonatal mice.
mBio [Epub ahead of print].
Japanese encephalitis virus (JEV), a neurotropic flavivirus, predominantly causes severe infection in children, leading to neuropsychiatric complications. Given that the juvenile period is a transitional window for the gut microbiota to develop into a stable community profile, any alterations to the microbiota during infections can result in chronic inflammation. Therefore, we investigated changes in the gut microbiota of neonatal mice during the early and late stages of JEV infection. Postnatal day 10, BALB/c mice challenged with JEV succumbed to acute infection at 6 to 7 days post-infection. This severity was marked by a surge in systemic pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, and MCP-1) and reduced food intake. Fecal 16S rRNA V3-V4 sequencing revealed distinct β-diversity between mock and JEV-infected groups, with the dominant phyla being Firmicutes, Bacteroidota, and Proteobacteria. The relative abundance of these phyla shifted, with Firmicutes decreasing from ~63.7% (control) to ~39% (JEV), whereas Proteobacteria remained unchanged in JEV. The Firmicutes/Bacteroidota ratio decreased in JEV, along with a reduction in Lactobacillus. Simultaneously, altered mucosal secretion, reduced tight-junction protein ZO-1, increased pNF-κB, and cleaved caspase-3 together indicated colonic inflammation. Prediction of microbial pathways using PICRUSt2 suggested a reduction in specific pathways associated with beneficial secondary metabolites and short-chain fatty acids (SCFAs) in JEV. Intragastric administration of the SCFA cocktail prolonged survival and delayed the onset of clinical signs and the inflammatory response. Our findings suggest that systemic inflammation and reduced feeding during an acute infection could result in colonic dysbiosis, reduced beneficial bacteria, and trigger inflammation. SCFAs displayed a transient therapeutic effect in JEV infection, highlighting the potential of gut microbiota modulation to manage acute viral infection.IMPORTANCEJapanese encephalitis remains a leading cause of viral encephalitis in children across the Asia-Pacific region, with new outbreaks driven by evolving demographic factors. The need for targeted therapies beyond existing supportive care underscores the need for new host-directed interventions. Our findings suggest that gut-brain axis interactions may play a role in acute viral infections, potentially amplifying disease severity through infection-driven reduction in feeding, increased cytokine production, and shifts in the gut microbiome. We propose that SCFA supplementation can serve as a microbiota-modulating strategy that offers a safe, translatable approach to managing inflammation and JEV outcomes in pediatric viral encephalitis. This could be utilized as a supplement along with supportive care in other flavivirus infections.
Additional Links: PMID-43037395
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037395,
year = {2026},
author = {Satheesan, A and Priyadarsani, A and Basu, A},
title = {Japanese encephalitis virus infection reshapes the gut microbiome and induces colonic inflammation in neonatal mice.},
journal = {mBio},
volume = {},
number = {},
pages = {e0243726},
doi = {10.1128/mbio.02437-26},
pmid = {43037395},
issn = {2150-7511},
abstract = {Japanese encephalitis virus (JEV), a neurotropic flavivirus, predominantly causes severe infection in children, leading to neuropsychiatric complications. Given that the juvenile period is a transitional window for the gut microbiota to develop into a stable community profile, any alterations to the microbiota during infections can result in chronic inflammation. Therefore, we investigated changes in the gut microbiota of neonatal mice during the early and late stages of JEV infection. Postnatal day 10, BALB/c mice challenged with JEV succumbed to acute infection at 6 to 7 days post-infection. This severity was marked by a surge in systemic pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, and MCP-1) and reduced food intake. Fecal 16S rRNA V3-V4 sequencing revealed distinct β-diversity between mock and JEV-infected groups, with the dominant phyla being Firmicutes, Bacteroidota, and Proteobacteria. The relative abundance of these phyla shifted, with Firmicutes decreasing from ~63.7% (control) to ~39% (JEV), whereas Proteobacteria remained unchanged in JEV. The Firmicutes/Bacteroidota ratio decreased in JEV, along with a reduction in Lactobacillus. Simultaneously, altered mucosal secretion, reduced tight-junction protein ZO-1, increased pNF-κB, and cleaved caspase-3 together indicated colonic inflammation. Prediction of microbial pathways using PICRUSt2 suggested a reduction in specific pathways associated with beneficial secondary metabolites and short-chain fatty acids (SCFAs) in JEV. Intragastric administration of the SCFA cocktail prolonged survival and delayed the onset of clinical signs and the inflammatory response. Our findings suggest that systemic inflammation and reduced feeding during an acute infection could result in colonic dysbiosis, reduced beneficial bacteria, and trigger inflammation. SCFAs displayed a transient therapeutic effect in JEV infection, highlighting the potential of gut microbiota modulation to manage acute viral infection.IMPORTANCEJapanese encephalitis remains a leading cause of viral encephalitis in children across the Asia-Pacific region, with new outbreaks driven by evolving demographic factors. The need for targeted therapies beyond existing supportive care underscores the need for new host-directed interventions. Our findings suggest that gut-brain axis interactions may play a role in acute viral infections, potentially amplifying disease severity through infection-driven reduction in feeding, increased cytokine production, and shifts in the gut microbiome. We propose that SCFA supplementation can serve as a microbiota-modulating strategy that offers a safe, translatable approach to managing inflammation and JEV outcomes in pediatric viral encephalitis. This could be utilized as a supplement along with supportive care in other flavivirus infections.},
}
RevDate: 2026-11-16
Novel wounded porcine skin ex vivo methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa infection models.
Infection and immunity [Epub ahead of print].
Chronic wounds are a growing challenge in clinical practice and can be associated with infection by antimicrobial-resistant bacteria. With increasing demand for pathophysiology research and therapeutic technology development, biologically relevant platforms like infected swine skin explants are used; however, explants are not typically studied in conjunction with normal microbiota, which recapitulates the clinical scenario. The current study generated 1- and 8-cm diameter wounded swine skin explants from shaved, sanitized swine skin harvested immediately after euthanasia. Tissue morphology was evaluated over 9 days using a custom histological grading scale and growth dynamics of skin microbiota monitored. Explant viability decreased after 3 days in association with a peak in normal microbiota of varying diversity. Stable co-colonization of wound beds with clinical Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus isolates alongside microbiota over 3 days was demonstrated. In summary, the presented 1- and 8-cm explant models maintain normal microbiota and are suitable for microbiome and/or wound infection treatment or prevention studies.
Additional Links: PMID-43037414
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037414,
year = {2026},
author = {Kies, PJ and Gades, NM and Tian, A and Soto, ML and Mandrekar, JN and Garcia, EJ and Patel, R},
title = {Novel wounded porcine skin ex vivo methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa infection models.},
journal = {Infection and immunity},
volume = {},
number = {},
pages = {e0048926},
doi = {10.1128/iai.00489-26},
pmid = {43037414},
issn = {1098-5522},
abstract = {Chronic wounds are a growing challenge in clinical practice and can be associated with infection by antimicrobial-resistant bacteria. With increasing demand for pathophysiology research and therapeutic technology development, biologically relevant platforms like infected swine skin explants are used; however, explants are not typically studied in conjunction with normal microbiota, which recapitulates the clinical scenario. The current study generated 1- and 8-cm diameter wounded swine skin explants from shaved, sanitized swine skin harvested immediately after euthanasia. Tissue morphology was evaluated over 9 days using a custom histological grading scale and growth dynamics of skin microbiota monitored. Explant viability decreased after 3 days in association with a peak in normal microbiota of varying diversity. Stable co-colonization of wound beds with clinical Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus isolates alongside microbiota over 3 days was demonstrated. In summary, the presented 1- and 8-cm explant models maintain normal microbiota and are suitable for microbiome and/or wound infection treatment or prevention studies.},
}
RevDate: 2026-11-16
CmpDate: 2026-11-16
Chlorination-driven enrichment of Firmicutes in a full-scale drinking water treatment system revealed by 16 S rRNA gene sequencing.
Environmental monitoring and assessment, 198(12):.
Drinking water treatment systems (DWTS) strongly shape microbial communities by imposing physicochemical and disinfectant-driven selective pressures. However, the ecological mechanisms underlying microbial persistence and enrichment during drinking water treatment remain poorly understood, particularly in tropical regions. In this study, we investigated bacterial community dynamics across a full-scale drinking water treatment system (DWTS) in southeastern Brazil, evaluating raw water (RW), post-treatment water (PTW), and tap water (TW) during rainy and dry seasons using 16 S rRNA gene sequencing and quantitative PCR. Marked differences in bacterial community composition were observed between raw and treated water samples. RW was dominated by Proteobacteria, particularly Betaproteobacteria, whereas Firmicutes, mainly members of the class Bacilli, became dominant in PTW and TW, reaching relative abundances above 90% in the dry season. Genera affiliated with Geobacillus, Bacillus, Paenibacillus, and Enterococcus persisted throughout the system and increased proportionally after chlorination. Alpha diversity and total bacterial 16 S rRNA gene copy numbers decreased markedly following treatment, confirming effective biomass reduction but indicating strong ecological selection. Several genera that include opportunistic pathogens (e.g., Acinetobacter, Pseudomonas, Mycobacterium, Enterococcus) were detected at low relative abundance in treated water; however, species-level identification and viability cannot be inferred from amplicon sequencing alone. Our findings suggest that drinking water treatment exerts selective pressure favoring resistant Gram-positive taxa, particularly spore-forming Firmicutes. These results contribute to understanding microbial ecology in chlorinated drinking water systems in tropical regions.
Additional Links: PMID-43037735
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037735,
year = {2026},
author = {Oliveira, AGG and Dias, MF and Ferreira, JFG and Silva, CP and Moreira, M and da Silva Lanna, MC and Dos Santos Rodrigues, L and de Macêdo Farias, L and Magalhães, PP},
title = {Chlorination-driven enrichment of Firmicutes in a full-scale drinking water treatment system revealed by 16 S rRNA gene sequencing.},
journal = {Environmental monitoring and assessment},
volume = {198},
number = {12},
pages = {},
pmid = {43037735},
issn = {1573-2959},
mesh = {*Drinking Water/microbiology/chemistry ; RNA, Ribosomal, 16S/genetics ; Brazil ; *Water Microbiology ; *Water Purification/methods ; Halogenation ; *Bacillota/genetics/growth & development/classification ; Environmental Monitoring ; },
abstract = {Drinking water treatment systems (DWTS) strongly shape microbial communities by imposing physicochemical and disinfectant-driven selective pressures. However, the ecological mechanisms underlying microbial persistence and enrichment during drinking water treatment remain poorly understood, particularly in tropical regions. In this study, we investigated bacterial community dynamics across a full-scale drinking water treatment system (DWTS) in southeastern Brazil, evaluating raw water (RW), post-treatment water (PTW), and tap water (TW) during rainy and dry seasons using 16 S rRNA gene sequencing and quantitative PCR. Marked differences in bacterial community composition were observed between raw and treated water samples. RW was dominated by Proteobacteria, particularly Betaproteobacteria, whereas Firmicutes, mainly members of the class Bacilli, became dominant in PTW and TW, reaching relative abundances above 90% in the dry season. Genera affiliated with Geobacillus, Bacillus, Paenibacillus, and Enterococcus persisted throughout the system and increased proportionally after chlorination. Alpha diversity and total bacterial 16 S rRNA gene copy numbers decreased markedly following treatment, confirming effective biomass reduction but indicating strong ecological selection. Several genera that include opportunistic pathogens (e.g., Acinetobacter, Pseudomonas, Mycobacterium, Enterococcus) were detected at low relative abundance in treated water; however, species-level identification and viability cannot be inferred from amplicon sequencing alone. Our findings suggest that drinking water treatment exerts selective pressure favoring resistant Gram-positive taxa, particularly spore-forming Firmicutes. These results contribute to understanding microbial ecology in chlorinated drinking water systems in tropical regions.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Drinking Water/microbiology/chemistry
RNA, Ribosomal, 16S/genetics
Brazil
*Water Microbiology
*Water Purification/methods
Halogenation
*Bacillota/genetics/growth & development/classification
Environmental Monitoring
RevDate: 2026-11-16
CmpDate: 2026-11-16
Effects of feeding antibiotic-containing waste milk or commercial milk replacer on preweaning growth performance of Holstein dairy calves.
Tropical animal health and production, 58(9):.
The preweaning period is a critical stage in dairy calf development, and liquid-feeding strategies may influence early growth performance. Feeding nonsalable waste milk from antimicrobial-treated cows is a common practice on commercial dairy farms; however, its association with calf growth outcomes remains uncertain. This retrospective observational study aimed to compare preweaning growth performance of Holstein dairy calves fed antibiotic-containing waste milk or commercial milk replacer under commercial farm conditions. A total of 283 calf records were evaluated, including 140 calves fed antibiotic-containing waste milk and 143 calves fed commercial milk replacer. Growth outcomes included birth weight, weaning age, weaning weight, total weight gain, and average daily gain (ADG). Data were analyzed using the GLM procedure of SAS, with feeding program as the main fixed effect and calf sex and dam type included as adjustment factors. Calves fed milk replacer had greater birth weight (36.64 ± 2.90 vs. 35.73 ± 4.70 kg; P = 0.0508) and tended to have a longer weaning age (73.71 ± 7.52 vs. 72.07 ± 7.51 d; P = 0.0685) compared with calves fed antibiotic-containing waste milk. Weaning weight did not differ between groups (95.15 ± 3.21 vs. 95.34 ± 3.35 kg; P = 0.6280). Calves receiving antibiotic-containing waste milk had greater total weight gain (59.61 ± 2.73 vs. 58.51 ± 1.78 kg; P < 0.001) and ADG (0.836 ± 0.093 vs. 0.802 ± 0.086 kg/d; P = 0.0017). Under the conditions of this commercial dairy herd, feeding antibiotic-containing waste milk was associated with greater preweaning growth rate than commercial milk replacer. Further prospective studies evaluating health outcomes, antimicrobial residues, nutrient composition, microbiome changes, and economic aspects are needed to better characterize this feeding strategy.
Additional Links: PMID-43037751
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037751,
year = {2026},
author = {Avarseji, A and Nazari, A and Kashi, S},
title = {Effects of feeding antibiotic-containing waste milk or commercial milk replacer on preweaning growth performance of Holstein dairy calves.},
journal = {Tropical animal health and production},
volume = {58},
number = {9},
pages = {},
pmid = {43037751},
issn = {1573-7438},
mesh = {Animals ; Cattle/growth & development ; *Anti-Bacterial Agents/administration & dosage/analysis ; *Milk/chemistry ; *Animal Feed/analysis ; Female ; Retrospective Studies ; Weaning ; Dairying ; Weight Gain/drug effects ; *Milk Substitutes ; Diet/veterinary ; Male ; Animal Nutritional Physiological Phenomena ; },
abstract = {The preweaning period is a critical stage in dairy calf development, and liquid-feeding strategies may influence early growth performance. Feeding nonsalable waste milk from antimicrobial-treated cows is a common practice on commercial dairy farms; however, its association with calf growth outcomes remains uncertain. This retrospective observational study aimed to compare preweaning growth performance of Holstein dairy calves fed antibiotic-containing waste milk or commercial milk replacer under commercial farm conditions. A total of 283 calf records were evaluated, including 140 calves fed antibiotic-containing waste milk and 143 calves fed commercial milk replacer. Growth outcomes included birth weight, weaning age, weaning weight, total weight gain, and average daily gain (ADG). Data were analyzed using the GLM procedure of SAS, with feeding program as the main fixed effect and calf sex and dam type included as adjustment factors. Calves fed milk replacer had greater birth weight (36.64 ± 2.90 vs. 35.73 ± 4.70 kg; P = 0.0508) and tended to have a longer weaning age (73.71 ± 7.52 vs. 72.07 ± 7.51 d; P = 0.0685) compared with calves fed antibiotic-containing waste milk. Weaning weight did not differ between groups (95.15 ± 3.21 vs. 95.34 ± 3.35 kg; P = 0.6280). Calves receiving antibiotic-containing waste milk had greater total weight gain (59.61 ± 2.73 vs. 58.51 ± 1.78 kg; P < 0.001) and ADG (0.836 ± 0.093 vs. 0.802 ± 0.086 kg/d; P = 0.0017). Under the conditions of this commercial dairy herd, feeding antibiotic-containing waste milk was associated with greater preweaning growth rate than commercial milk replacer. Further prospective studies evaluating health outcomes, antimicrobial residues, nutrient composition, microbiome changes, and economic aspects are needed to better characterize this feeding strategy.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
Cattle/growth & development
*Anti-Bacterial Agents/administration & dosage/analysis
*Milk/chemistry
*Animal Feed/analysis
Female
Retrospective Studies
Weaning
Dairying
Weight Gain/drug effects
*Milk Substitutes
Diet/veterinary
Male
Animal Nutritional Physiological Phenomena
RevDate: 2026-11-16
Longitudinal oral-gut microbiome remodeling during obesity and following bariatric surgery.
Additional Links: PMID-43037850
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037850,
year = {2026},
author = {Li, S and Zhang, C and Wei, L and Wang, J and Zhang, C and Zhou, J and Zhang, Z and Shuai, S and Sun, G and Zhang, D and Wang, S},
title = {Longitudinal oral-gut microbiome remodeling during obesity and following bariatric surgery.},
journal = {Science China. Life sciences},
volume = {},
number = {},
pages = {},
pmid = {43037850},
issn = {1869-1889},
}
RevDate: 2026-11-16
Small Plastic Particles and the Skin: Microplastics, Nanoplastics, and Issues of Environmental Exposure, Dermatologic Implications, and Global Policy.
American journal of clinical dermatology [Epub ahead of print].
Small plastic particles (microplastics, defined as < 5 mm in size, and nanoplastics, < 1 µm [1000 nm] in size) are now ubiquitous environmental contaminants with increasing relevance to dermatology. These plastics originate from personal care products, synthetic textiles, packaging, and degradation of consumer plastics, resulting in human exposure through air, water, diet, and direct skin contact. These particles are no longer considered environmentally inert, with detection in human tissues and growing evidence linking exposure to inflammatory and cardiometabolic diseases, including atherosclerotic plaque burden and increased cardiovascular risk. For dermatology, concern centers on emerging evidence that small plastic particles and plastic-associated chemicals may have distinct or overlapping effects relevant to inflammatory skin diseases, including atopic dermatitis, psoriasis, hidradenitis suppurativa, and related barrier and immune-mediated disorders. The skin represents a primary interface for environmental exposures, as more than 90% of personal care products are applied directly to the skin, and polymer-based ingredients remain widespread despite partial regulatory bans. This review covers current evidence on cutaneous exposure pathways, biologic mechanisms, clinical relevance, and global policy considerations related to small plastic particles. Experimental studies suggest that micro- and nanoplastics may adhere to the stratum corneum, accumulate within follicular structures, and penetrate epidermal layers under certain conditions, particularly when the skin barrier is disrupted. The extent of penetration across intact human skin and subsequent systemic absorption remains unclear. Plastics may also act as carriers for endocrine-disrupting chemicals, metals, and microbes. Emerging data suggests potential relevance to inflammatory skin conditions, microbiome disruption, and occupational skin disease. Dermatology is uniquely positioned to address this issue through patient education, exposure-aware clinical practice, research, and advocacy. Integrating consideration of small plastic particle exposure into dermatologic care and research represents an important opportunity to advance environmental health, prevention, and health equity within the field.
Additional Links: PMID-43037932
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037932,
year = {2026},
author = {Tan, IJ and Bassir, F and Nelson, CA and Parker, ER and Rosenbach, M},
title = {Small Plastic Particles and the Skin: Microplastics, Nanoplastics, and Issues of Environmental Exposure, Dermatologic Implications, and Global Policy.},
journal = {American journal of clinical dermatology},
volume = {},
number = {},
pages = {},
pmid = {43037932},
issn = {1179-1888},
abstract = {Small plastic particles (microplastics, defined as < 5 mm in size, and nanoplastics, < 1 µm [1000 nm] in size) are now ubiquitous environmental contaminants with increasing relevance to dermatology. These plastics originate from personal care products, synthetic textiles, packaging, and degradation of consumer plastics, resulting in human exposure through air, water, diet, and direct skin contact. These particles are no longer considered environmentally inert, with detection in human tissues and growing evidence linking exposure to inflammatory and cardiometabolic diseases, including atherosclerotic plaque burden and increased cardiovascular risk. For dermatology, concern centers on emerging evidence that small plastic particles and plastic-associated chemicals may have distinct or overlapping effects relevant to inflammatory skin diseases, including atopic dermatitis, psoriasis, hidradenitis suppurativa, and related barrier and immune-mediated disorders. The skin represents a primary interface for environmental exposures, as more than 90% of personal care products are applied directly to the skin, and polymer-based ingredients remain widespread despite partial regulatory bans. This review covers current evidence on cutaneous exposure pathways, biologic mechanisms, clinical relevance, and global policy considerations related to small plastic particles. Experimental studies suggest that micro- and nanoplastics may adhere to the stratum corneum, accumulate within follicular structures, and penetrate epidermal layers under certain conditions, particularly when the skin barrier is disrupted. The extent of penetration across intact human skin and subsequent systemic absorption remains unclear. Plastics may also act as carriers for endocrine-disrupting chemicals, metals, and microbes. Emerging data suggests potential relevance to inflammatory skin conditions, microbiome disruption, and occupational skin disease. Dermatology is uniquely positioned to address this issue through patient education, exposure-aware clinical practice, research, and advocacy. Integrating consideration of small plastic particle exposure into dermatologic care and research represents an important opportunity to advance environmental health, prevention, and health equity within the field.},
}
RevDate: 2026-11-16
Identification of High-Altitude Gut-Bacterial Isolates as New Probiotic Candidates: An In- Vitro and In- Vivo Study on Health-Promoting Effect in Low-Lander Chickens Under Extreme Climatic Conditions.
Probiotics and antimicrobial proteins [Epub ahead of print].
There is no commercially available probiotic suitable for high-altitude animals, as the available probiotics are ineffective. Therefore, this study investigated the identification of new candidate probiotics from high-altitude animals, their in-vitro and in-vivo evaluation for health and production benefits in chicken under high-altitude conditions. This is the first study to integrate in-vitro microbial culturing, cytomic analysis, and in-vivo experimentation, following our laboratory's detailed metagenomic study, wherein only the most abundant beneficial gut bacterial species were selected based on their functional genetic potential. Initially, the dynamics of potential probiotic bacteria from high-altitude animal's fecal samples were examined using culture-based methods, which revealed six promising strains: Enterococcus hirae RC-TJA-P, Arthrobacter citreus z61, Enterococcus lactis EOK2, Staphylococcus hominis Q4, Enterococcus mundtii HF5y, and Enterococcus faecium BRMRS. These gut-bacterial isolates demonstrated significant acid, bile, temperature, and salt tolerance, along with better adhesion and antioxidant properties. Among these, E. hirae RC-TJA-P and A. citreus z61 were most effective in promoting cell viability and suppressing inflammatory cytokines in cell lines and were further selected to explore their health-promoting potential in in-vivo chicken model. In-vivo supplementation of RC-TJA-P and z61 in lowland chicks reared at high altitude demonstrated strain-specific effects on growth parameters, immune responses (IgA and IgG), and antioxidant capacity, with RC-TJA-P significantly improving body weight and weight gain and neither treatment producing adverse effects. In conclusion, the present new indigenous high-altitude animal isolated gut candidate probiotics can enhance poultry health and productivity under extreme conditions. The study advocates for developing region-specific probiotics and their cost-benefit studies with commercially available probiotics to improve poultry farming sustainability in challenging terrains of high altitude.
Additional Links: PMID-43037941
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43037941,
year = {2026},
author = {Bhagat, NR and Bharti, VK and Shukla, G and Rishi, P and Verma, RK and Christyraj, JRSSS},
title = {Identification of High-Altitude Gut-Bacterial Isolates as New Probiotic Candidates: An In- Vitro and In- Vivo Study on Health-Promoting Effect in Low-Lander Chickens Under Extreme Climatic Conditions.},
journal = {Probiotics and antimicrobial proteins},
volume = {},
number = {},
pages = {},
pmid = {43037941},
issn = {1867-1314},
abstract = {There is no commercially available probiotic suitable for high-altitude animals, as the available probiotics are ineffective. Therefore, this study investigated the identification of new candidate probiotics from high-altitude animals, their in-vitro and in-vivo evaluation for health and production benefits in chicken under high-altitude conditions. This is the first study to integrate in-vitro microbial culturing, cytomic analysis, and in-vivo experimentation, following our laboratory's detailed metagenomic study, wherein only the most abundant beneficial gut bacterial species were selected based on their functional genetic potential. Initially, the dynamics of potential probiotic bacteria from high-altitude animal's fecal samples were examined using culture-based methods, which revealed six promising strains: Enterococcus hirae RC-TJA-P, Arthrobacter citreus z61, Enterococcus lactis EOK2, Staphylococcus hominis Q4, Enterococcus mundtii HF5y, and Enterococcus faecium BRMRS. These gut-bacterial isolates demonstrated significant acid, bile, temperature, and salt tolerance, along with better adhesion and antioxidant properties. Among these, E. hirae RC-TJA-P and A. citreus z61 were most effective in promoting cell viability and suppressing inflammatory cytokines in cell lines and were further selected to explore their health-promoting potential in in-vivo chicken model. In-vivo supplementation of RC-TJA-P and z61 in lowland chicks reared at high altitude demonstrated strain-specific effects on growth parameters, immune responses (IgA and IgG), and antioxidant capacity, with RC-TJA-P significantly improving body weight and weight gain and neither treatment producing adverse effects. In conclusion, the present new indigenous high-altitude animal isolated gut candidate probiotics can enhance poultry health and productivity under extreme conditions. The study advocates for developing region-specific probiotics and their cost-benefit studies with commercially available probiotics to improve poultry farming sustainability in challenging terrains of high altitude.},
}
RevDate: 2026-11-17
CmpDate: 2026-11-16
A citywide metagenomic analysis reveals surface-specific microbiome and resistome patterns in outdoor urban environments across Liverpool, UK.
Microbiology (Reading, England), 172(11):.
Urbanization is rapidly increasing worldwide, with increasing attention focused on its consequences for human populations. Despite the importance of outdoor urban environments for biodiversity and human wellbeing, their microbial ecology remains poorly characterized, particularly in relation to emerging microbial threats including antimicrobial resistance (AMR). Where previous studies have targeted individual urban niches, we used shotgun metagenomic sequencing to assess microbial community composition and antimicrobial resistance genes (ARGs) across five outdoor surface types at a citywide level: Touchpoints, Pathways, Soil, Refuse and Watersides. Microbial community composition differed significantly between surface types, with surface identity explaining 33.1% of variation, compared with 15.7% explained by council ward. Soil harboured the most compositionally distinct communities, whereas Touchpoints and Refuse showed greater overlap, with Pathways and Watersides occupying an intermediate position between the Touchpoint/Refuse and Soil communities. Touchpoints had significantly higher ARG abundance than Pathways, Soil and Watersides, with Refuse showing greater variability driven largely by a single high-abundance observation; following sensitivity analysis, Touchpoints were also significantly higher than Refuse. ARGs were rarely detected in Pathways, Watersides and Soil. These findings provide a citywide baseline showing that outdoor urban surfaces support distinct microbial communities and resistance profiles, with the strongest ARG signals observed on frequently contacted surfaces. This highlights the value of surface-specific metagenomic surveillance for characterizing the urban microbial and AMR landscape.
Additional Links: PMID-43038042
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43038042,
year = {2026},
author = {Ackers-Johnson, G and O'Ferrall, AM and Holmes, A and Allman, E and Ambrose, P and Breen, A and Cutcliffe, A and D'Arcy, K and Goodman, R and Kingdon, A and McLeman, A and Moyo, S and Pulmones, R and Rajib, MD and Sharma, P and Shore, E and Clerkin, K and Moore, M and McNeil, H and Roberts, AP},
title = {A citywide metagenomic analysis reveals surface-specific microbiome and resistome patterns in outdoor urban environments across Liverpool, UK.},
journal = {Microbiology (Reading, England)},
volume = {172},
number = {11},
pages = {},
pmid = {43038042},
issn = {1465-2080},
mesh = {*Microbiota/genetics ; Metagenomics ; *Bacteria/genetics/classification/drug effects/isolation & purification ; Humans ; Soil Microbiology ; Cities ; United Kingdom ; *Drug Resistance, Bacterial/genetics ; Metagenome ; Biodiversity ; Anti-Bacterial Agents/pharmacology ; },
abstract = {Urbanization is rapidly increasing worldwide, with increasing attention focused on its consequences for human populations. Despite the importance of outdoor urban environments for biodiversity and human wellbeing, their microbial ecology remains poorly characterized, particularly in relation to emerging microbial threats including antimicrobial resistance (AMR). Where previous studies have targeted individual urban niches, we used shotgun metagenomic sequencing to assess microbial community composition and antimicrobial resistance genes (ARGs) across five outdoor surface types at a citywide level: Touchpoints, Pathways, Soil, Refuse and Watersides. Microbial community composition differed significantly between surface types, with surface identity explaining 33.1% of variation, compared with 15.7% explained by council ward. Soil harboured the most compositionally distinct communities, whereas Touchpoints and Refuse showed greater overlap, with Pathways and Watersides occupying an intermediate position between the Touchpoint/Refuse and Soil communities. Touchpoints had significantly higher ARG abundance than Pathways, Soil and Watersides, with Refuse showing greater variability driven largely by a single high-abundance observation; following sensitivity analysis, Touchpoints were also significantly higher than Refuse. ARGs were rarely detected in Pathways, Watersides and Soil. These findings provide a citywide baseline showing that outdoor urban surfaces support distinct microbial communities and resistance profiles, with the strongest ARG signals observed on frequently contacted surfaces. This highlights the value of surface-specific metagenomic surveillance for characterizing the urban microbial and AMR landscape.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Microbiota/genetics
Metagenomics
*Bacteria/genetics/classification/drug effects/isolation & purification
Humans
Soil Microbiology
Cities
United Kingdom
*Drug Resistance, Bacterial/genetics
Metagenome
Biodiversity
Anti-Bacterial Agents/pharmacology
RevDate: 2026-11-16
Prehabilitation in the surgical patient: current concepts and evolving strategies for perioperative optimization.
Current opinion in critical care pii:00075198-990000000-00400 [Epub ahead of print].
PURPOSE OF REVIEW: More than two decades after its introduction, prehabilitation has evolved from a proof-of-concept strategy into an established component of perioperative care. This review summarizes recent evidence supporting prehabilitation, highlights emerging concepts that may expand its therapeutic scope, and discusses the transition from efficacy studies toward scalable, personalized, and implementation-focused models of care.
RECENT FINDINGS: Recent evidence continues to support prehabilitation for improving functional capacity and postoperative recovery. However, effectiveness appears strongly influenced by adherence, frailty, sarcopenia, treatment exposure, and delivery context. Increasing emphasis on frailty, behavioral support, teleprehabilitation, wearable technologies, and patient-centered outcomes is reshaping the field. Digital health platforms are expanding access and facilitating large-scale implementation, while biological phenotyping, digital biomarkers, immune modulation, and the microbiome offer opportunities for greater personalization. Emerging implementation studies suggest that the key challenge is no longer demonstrating efficacy but achieving sustainable, equitable, and scalable effectiveness in routine practice.
SUMMARY: Prehabilitation is evolving beyond a strategy to improve fitness before surgery into a comprehensive approach aimed at enhancing resilience across the perioperative continuum. Future progress will depend on precision prehabilitation, using tiered delivery models, maximizing patient engagement, and integrating prehabilitation into longitudinal care pathways to close the effectiveness gap between research and real-world practice.
Additional Links: PMID-43038069
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43038069,
year = {2026},
author = {Coca-Martinez, M and Martinez-Palli, G},
title = {Prehabilitation in the surgical patient: current concepts and evolving strategies for perioperative optimization.},
journal = {Current opinion in critical care},
volume = {},
number = {},
pages = {},
doi = {10.1097/MCC.0000000000001445},
pmid = {43038069},
issn = {1531-7072},
abstract = {PURPOSE OF REVIEW: More than two decades after its introduction, prehabilitation has evolved from a proof-of-concept strategy into an established component of perioperative care. This review summarizes recent evidence supporting prehabilitation, highlights emerging concepts that may expand its therapeutic scope, and discusses the transition from efficacy studies toward scalable, personalized, and implementation-focused models of care.
RECENT FINDINGS: Recent evidence continues to support prehabilitation for improving functional capacity and postoperative recovery. However, effectiveness appears strongly influenced by adherence, frailty, sarcopenia, treatment exposure, and delivery context. Increasing emphasis on frailty, behavioral support, teleprehabilitation, wearable technologies, and patient-centered outcomes is reshaping the field. Digital health platforms are expanding access and facilitating large-scale implementation, while biological phenotyping, digital biomarkers, immune modulation, and the microbiome offer opportunities for greater personalization. Emerging implementation studies suggest that the key challenge is no longer demonstrating efficacy but achieving sustainable, equitable, and scalable effectiveness in routine practice.
SUMMARY: Prehabilitation is evolving beyond a strategy to improve fitness before surgery into a comprehensive approach aimed at enhancing resilience across the perioperative continuum. Future progress will depend on precision prehabilitation, using tiered delivery models, maximizing patient engagement, and integrating prehabilitation into longitudinal care pathways to close the effectiveness gap between research and real-world practice.},
}
RevDate: 2026-11-16
Microbiota-derived short-chain fatty acids control cGVHD development by regulating antibody production.
Blood pii:572112 [Epub ahead of print].
Chronic graft-versus-host disease (cGVHD) contributes substantially to morbidity and mortality in allogeneic hematopoietic stem cell transplant recipients. Microbe-derived short-chain fatty acids (SCFA) exert diverse local effects on the intestinal mucosa. We previously reported that a relative deficiency of SCFA in the circulation of transplant patients was associated with an increased incidence of cGVHD. We therefore hypothesized that circulating SCFA were unrecognized immunomodulators, generating protective effects after transplantation. We examined the role of SCFA butyrate and propionate in mouse models of cGVHD and now report that systemic administration of either butyrate or propionate mitigates cGVHD and improves survival. Exogenous SCFA treatment reduced pathogenic hyperexpanded B cells and recipient-specific IgA in the circulation, as well as decreasing the total alloantibody pool, defined using rapid extracellular antigen profiling (REAP). Our findings uncover a mechanism by which the intestinal microbiome plays a role in regulating antibody-dependent cGVHD pathogenesis and has implications for other antibody-mediated pathologies.
Additional Links: PMID-43038184
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43038184,
year = {2026},
author = {Wolfe, AE and Ho, T and Chakka, SR and Yeh, AC and Mirimo-Martinez, M and Bhise, SS and Hsu, Y and Notestine, AA and Pahmeier, F and Jaycox, JR and Wang, H and Stewart, GE and Glabman, R and Turan, A and Ghale, R and Peled, JU and Cao, S and Hill, GR and Ring, AM and van den Brink, MRM and Furlan, SN and Markey, KA},
title = {Microbiota-derived short-chain fatty acids control cGVHD development by regulating antibody production.},
journal = {Blood},
volume = {},
number = {},
pages = {},
doi = {10.1182/blood.2026034453},
pmid = {43038184},
issn = {1528-0020},
abstract = {Chronic graft-versus-host disease (cGVHD) contributes substantially to morbidity and mortality in allogeneic hematopoietic stem cell transplant recipients. Microbe-derived short-chain fatty acids (SCFA) exert diverse local effects on the intestinal mucosa. We previously reported that a relative deficiency of SCFA in the circulation of transplant patients was associated with an increased incidence of cGVHD. We therefore hypothesized that circulating SCFA were unrecognized immunomodulators, generating protective effects after transplantation. We examined the role of SCFA butyrate and propionate in mouse models of cGVHD and now report that systemic administration of either butyrate or propionate mitigates cGVHD and improves survival. Exogenous SCFA treatment reduced pathogenic hyperexpanded B cells and recipient-specific IgA in the circulation, as well as decreasing the total alloantibody pool, defined using rapid extracellular antigen profiling (REAP). Our findings uncover a mechanism by which the intestinal microbiome plays a role in regulating antibody-dependent cGVHD pathogenesis and has implications for other antibody-mediated pathologies.},
}
RevDate: 2026-11-16
Oral Dysbiosis and the Hallmarks of Aging: A Perspective on Mechanisms and Therapeutic Opportunities.
Aging and disease pii:AD.2026.0821 [Epub ahead of print].
Aging is characterized by progressive decline in cellular and tissue functions, markedly increasing susceptibility to age-related diseases (ARDs) such as neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and musculoskeletal disorders. The twelve aging hallmarks proposed in 2022 have clarified the underlying mechanisms linking aging to ARDs. As the second-largest microbiome in the body, oral dysbiosis has been associated with aging-related phenotypes and may influence systemic aging and ARDs. Available evidence, derived largely from observational and preclinical studies, suggests that oral dysbiosis may be associated with selected aging-related processes, including cellular senescence, altered intercellular communication, mitochondrial dysfunction, and loss of proteostasis via virulence factors, metabolites, etc. Here, we summarize epidemiological observations linking oral microbiota to ARDs, and offer a perspective centered on core aging hallmarks to delineate how oral dysbiosis may serve as a plausible modulator of systemic aging and ARD progression. We also introduce promising interventions such as plaque control, targeted antimicrobials, and probiotics as research opportunities. Finally, we discuss current limitations and highlight future directions including microbial biomarkers and machine learning-based aging prediction models to identify whether oral microbiota related biomarkers can improve risk stratification and mechanistic studies of biological aging.
Additional Links: PMID-43038555
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43038555,
year = {2026},
author = {Liao, H and Xie, W and Yang, S and He, C and Chen, Y and Zhao, X and Ren, Q and Su, Y},
title = {Oral Dysbiosis and the Hallmarks of Aging: A Perspective on Mechanisms and Therapeutic Opportunities.},
journal = {Aging and disease},
volume = {},
number = {},
pages = {},
doi = {10.14336/AD.2026.0821},
pmid = {43038555},
issn = {2152-5250},
abstract = {Aging is characterized by progressive decline in cellular and tissue functions, markedly increasing susceptibility to age-related diseases (ARDs) such as neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and musculoskeletal disorders. The twelve aging hallmarks proposed in 2022 have clarified the underlying mechanisms linking aging to ARDs. As the second-largest microbiome in the body, oral dysbiosis has been associated with aging-related phenotypes and may influence systemic aging and ARDs. Available evidence, derived largely from observational and preclinical studies, suggests that oral dysbiosis may be associated with selected aging-related processes, including cellular senescence, altered intercellular communication, mitochondrial dysfunction, and loss of proteostasis via virulence factors, metabolites, etc. Here, we summarize epidemiological observations linking oral microbiota to ARDs, and offer a perspective centered on core aging hallmarks to delineate how oral dysbiosis may serve as a plausible modulator of systemic aging and ARD progression. We also introduce promising interventions such as plaque control, targeted antimicrobials, and probiotics as research opportunities. Finally, we discuss current limitations and highlight future directions including microbial biomarkers and machine learning-based aging prediction models to identify whether oral microbiota related biomarkers can improve risk stratification and mechanistic studies of biological aging.},
}
RevDate: 2026-11-16
Prophages at the interface of antibiotic tolerance, persistence and antibiotic resistance: Evidence, mechanisms and therapeutic limits.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 90:101505 pii:S1368-7646(26)00157-3 [Epub ahead of print].
Prophages are widespread in bacterial genomes, and several experimental systems show that they change how bacteria survive antibiotics. Using the consensus definitions of Balaban and colleagues, this review sorts the primary evidence by the endpoint actually measured: resistance defined by the minimum inhibitory concentration (MIC), tolerance (killing kinetics), persistence (biphasic killing), resuscitation (single-cell regrowth), and stress or biofilm survival. These endpoints are not treated as interchangeable. Effects depend on strain, prophage, antibiotic, and endpoint. In Escherichia coli, deleting nine cryptic prophages leaves persister formation unchanged but accelerates resuscitation. In Salmonella enterica serovar Typhimurium, ciprofloxacin-induced Gifsy-1 lysis lowers persister survival, and TisB raises persister numbers largely by limiting that induction. In methicillin-resistant Staphylococcus aureus, φSA169 increases survival at a single 24 h vancomycin time point without changing the MIC, which is a survival difference at one time point and does not demonstrate tolerance or persistence. Unverified prophages can confound persistence assays. Prophage genomes rarely encode resistance genes; a Pseudomonas aeruginosa clinical collection showed only infrequent prophage-resistance associations, and transduction can nonetheless move resistance determinants. Whether prophage-associated survival under antibiotic exposure promotes or restricts the evolution of resistance is an open hypothesis, supported by one species, one antibiotic, and a preprint, and a serial-passaging design to test it is outlined. Gut and probiotic prophages are abundant and inducible, but persistence data for them are lacking. Therapeutic approaches are separated into those acting on resident prophages, temperate phage-antibiotic synergy, and related but distinct strategies. Evidence that any prophage-directed intervention eliminates persisters in infection models is currently lacking. A minimum reporting checklist for future studies is provided.
Additional Links: PMID-43038727
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43038727,
year = {2026},
author = {Khan, F and Tabassum, N and Javaid, A and Kim, TH and Kim, YM},
title = {Prophages at the interface of antibiotic tolerance, persistence and antibiotic resistance: Evidence, mechanisms and therapeutic limits.},
journal = {Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy},
volume = {90},
number = {},
pages = {101505},
doi = {10.1016/j.drup.2026.101505},
pmid = {43038727},
issn = {1532-2084},
abstract = {Prophages are widespread in bacterial genomes, and several experimental systems show that they change how bacteria survive antibiotics. Using the consensus definitions of Balaban and colleagues, this review sorts the primary evidence by the endpoint actually measured: resistance defined by the minimum inhibitory concentration (MIC), tolerance (killing kinetics), persistence (biphasic killing), resuscitation (single-cell regrowth), and stress or biofilm survival. These endpoints are not treated as interchangeable. Effects depend on strain, prophage, antibiotic, and endpoint. In Escherichia coli, deleting nine cryptic prophages leaves persister formation unchanged but accelerates resuscitation. In Salmonella enterica serovar Typhimurium, ciprofloxacin-induced Gifsy-1 lysis lowers persister survival, and TisB raises persister numbers largely by limiting that induction. In methicillin-resistant Staphylococcus aureus, φSA169 increases survival at a single 24 h vancomycin time point without changing the MIC, which is a survival difference at one time point and does not demonstrate tolerance or persistence. Unverified prophages can confound persistence assays. Prophage genomes rarely encode resistance genes; a Pseudomonas aeruginosa clinical collection showed only infrequent prophage-resistance associations, and transduction can nonetheless move resistance determinants. Whether prophage-associated survival under antibiotic exposure promotes or restricts the evolution of resistance is an open hypothesis, supported by one species, one antibiotic, and a preprint, and a serial-passaging design to test it is outlined. Gut and probiotic prophages are abundant and inducible, but persistence data for them are lacking. Therapeutic approaches are separated into those acting on resident prophages, temperate phage-antibiotic synergy, and related but distinct strategies. Evidence that any prophage-directed intervention eliminates persisters in infection models is currently lacking. A minimum reporting checklist for future studies is provided.},
}
RevDate: 2026-11-16
Microbiome-sparing antimicrobial stewardship in food animals: a conceptual farm-level decision framework.
Research in veterinary science, 214:106481 pii:S0034-5288(26)00435-2 [Epub ahead of print].
Antimicrobial stewardship in food animals must reduce unnecessary antimicrobial exposure while preserving therapeutic success, animal welfare, and productivity; when animals or animal products enter the food chain, applicable withdrawal periods and residue limits must be observed under the rules in the relevant jurisdiction. However, stewardship often remains framed as a reduction target rather than a decision-quality problem. Under field conditions, variable delivery during group medication and diagnostic uncertainty can result in ineffective or unnecessary exposure; antimicrobial-associated microbiome changes are an additional ecological concern, but their contribution to relapse, retreatment, or productivity loss remains incompletely established. This review proposes a microbiome-sparing antimicrobial stewardship framework for food-animal systems. The framework integrates four practical decision layers: exposure integrity, diagnostic confidence, pharmacokinetic/pharmacodynamic (PK/PD) adequacy, and microbiome-risk assessment. It emphasizes reliable route and dose delivery, avoidance of prolonged suboptimal exposure, decision-changing diagnostics, severity-based treat-versus-observe thresholds, and explicit de-escalation and stop criteria. These principles are illustrated through syndrome-specific decision pathways for poultry enteric syndromes, calf diarrhea complexes, bovine respiratory disease, and mastitis, with emphasis on supportive care, preventive management, treatment permitted under applicable local rules, and withdrawal compliance. The review also advances a proposed six-domain reporting framework for stewardship studies, including clinical cure and relapse, productivity, exposure reliability, antimicrobial resistance (AMR) endpoints, microbiome disruption and recovery, and residue compliance. Overall, microbiome-sparing stewardship shifts food-animal antimicrobial use from quantity-focused reduction toward therapeutically reliable, ecologically informed, and farm-implementable decision pathways; its clinical and ecological effects require prospective evaluation across production systems.
Additional Links: PMID-43038733
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43038733,
year = {2026},
author = {Amin, A and Zaman, W},
title = {Microbiome-sparing antimicrobial stewardship in food animals: a conceptual farm-level decision framework.},
journal = {Research in veterinary science},
volume = {214},
number = {},
pages = {106481},
doi = {10.1016/j.rvsc.2026.106481},
pmid = {43038733},
issn = {1532-2661},
abstract = {Antimicrobial stewardship in food animals must reduce unnecessary antimicrobial exposure while preserving therapeutic success, animal welfare, and productivity; when animals or animal products enter the food chain, applicable withdrawal periods and residue limits must be observed under the rules in the relevant jurisdiction. However, stewardship often remains framed as a reduction target rather than a decision-quality problem. Under field conditions, variable delivery during group medication and diagnostic uncertainty can result in ineffective or unnecessary exposure; antimicrobial-associated microbiome changes are an additional ecological concern, but their contribution to relapse, retreatment, or productivity loss remains incompletely established. This review proposes a microbiome-sparing antimicrobial stewardship framework for food-animal systems. The framework integrates four practical decision layers: exposure integrity, diagnostic confidence, pharmacokinetic/pharmacodynamic (PK/PD) adequacy, and microbiome-risk assessment. It emphasizes reliable route and dose delivery, avoidance of prolonged suboptimal exposure, decision-changing diagnostics, severity-based treat-versus-observe thresholds, and explicit de-escalation and stop criteria. These principles are illustrated through syndrome-specific decision pathways for poultry enteric syndromes, calf diarrhea complexes, bovine respiratory disease, and mastitis, with emphasis on supportive care, preventive management, treatment permitted under applicable local rules, and withdrawal compliance. The review also advances a proposed six-domain reporting framework for stewardship studies, including clinical cure and relapse, productivity, exposure reliability, antimicrobial resistance (AMR) endpoints, microbiome disruption and recovery, and residue compliance. Overall, microbiome-sparing stewardship shifts food-animal antimicrobial use from quantity-focused reduction toward therapeutically reliable, ecologically informed, and farm-implementable decision pathways; its clinical and ecological effects require prospective evaluation across production systems.},
}
▼ ▼ LOAD NEXT 100 CITATIONS
RJR Experience and Expertise
Researcher
Robbins holds BS, MS, and PhD degrees in the life sciences. He served as a tenured faculty member in the Zoology and Biological Science departments at Michigan State University. He is currently exploring the intersection between genomics, microbial ecology, and biodiversity — an area that promises to transform our understanding of the biosphere.
Educator
Robbins has extensive experience in college-level education: At MSU he taught introductory biology, genetics, and population genetics. At JHU, he was an instructor for a special course on biological database design. At FHCRC, he team-taught a graduate-level course on the history of genetics. At Bellevue College he taught medical informatics.
Administrator
Robbins has been involved in science administration at both the federal and the institutional levels. At NSF he was a program officer for database activities in the life sciences, at DOE he was a program officer for information infrastructure in the human genome project. At the Fred Hutchinson Cancer Research Center, he served as a vice president for fifteen years.
Technologist
Robbins has been involved with information technology since writing his first Fortran program as a college student. At NSF he was the first program officer for database activities in the life sciences. At JHU he held an appointment in the CS department and served as director of the informatics core for the Genome Data Base. At the FHCRC he was VP for Information Technology.
Publisher
While still at Michigan State, Robbins started his first publishing venture, founding a small company that addressed the short-run publishing needs of instructors in very large undergraduate classes. For more than 20 years, Robbins has been operating The Electronic Scholarly Publishing Project, a web site dedicated to the digital publishing of critical works in science, especially classical genetics.
Speaker
Robbins is well-known for his speaking abilities and is often called upon to provide keynote or plenary addresses at international meetings. For example, in July, 2012, he gave a well-received keynote address at the Global Biodiversity Informatics Congress, sponsored by GBIF and held in Copenhagen. The slides from that talk can be seen HERE.
Facilitator
Robbins is a skilled meeting facilitator. He prefers a participatory approach, with part of the meeting involving dynamic breakout groups, created by the participants in real time: (1) individuals propose breakout groups; (2) everyone signs up for one (or more) groups; (3) the groups with the most interested parties then meet, with reports from each group presented and discussed in a subsequent plenary session.
Designer
Robbins has been engaged with photography and design since the 1960s, when he worked for a professional photography laboratory. He now prefers digital photography and tools for their precision and reproducibility. He designed his first web site more than 20 years ago and he personally designed and implemented this web site. He engages in graphic design as a hobby.
RJR Picks from Around the Web (updated 11 MAY 2018 )
Old Science
Weird Science
Treating Disease with Fecal Transplantation
Fossils of miniature humans (hobbits) discovered in Indonesia
Paleontology
Dinosaur tail, complete with feathers, found preserved in amber.
Astronomy
Mysterious fast radio burst (FRB) detected in the distant universe.
Big Data & Informatics
Big Data: Buzzword or Big Deal?
Hacking the genome: Identifying anonymized human subjects using publicly available data.